image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
fb22851cfd72b0c2cf5119cd07624f8199425b0e25784a9665b9dbf7595eaddf.png | simple | <table><tr><td>Comparison (5-Aza)</td><td>Methods</td><td>Cuffdiff</td><td>SAMSeq</td><td>baySeq</td><td>DESeq</td><td>Noiseq</td></tr><tr><td>5 μM vs 0 μM</td><td>T-test</td><td>25.8%</td><td>22.5%</td><td>24.5%</td><td>25.8%</td><td>29.7%</td></tr><tr><td></td><td>SAM</td><td>39.9%</td><td>39.9%</td><td>42.7%</td><td>44.5%</td><td>33.5%</td></tr><tr><td></td><td>Ebayes</td><td>39.5%</td><td>39.5%</td><td>42.2%</td><td>44.0%</td><td>33.3%</td></tr><tr><td>10 μM vs 5 μM</td><td>T-test</td><td>0.5%</td><td>0.5%</td><td>0.6%</td><td>0.6%</td><td>0.0%</td></tr><tr><td></td><td>SAM</td><td>31.1%</td><td>30.2%</td><td>32.6%</td><td>34.2%</td><td>19.4%</td></tr><tr><td></td><td>Ebayes</td><td>30.3%</td><td>28.3%</td><td>31.9%</td><td>33.5%</td><td>19.1%</td></tr></table> |
6250b1f85974b989a6b9fac0b30e921f047441caa57399245c12ca92083030b4.png | simple | <table><tr><td></td><td><i>Local density</i></td><td><i>Coeff. variation nearest distances</i></td><td><i>Area</i></td></tr><tr><td><i>Local density</i></td><td>1.00</td><td>---</td><td>---</td></tr><tr><td><i>Coeff. Variation nearest distances</i></td><td>0.22*</td><td>1.00</td><td>---</td></tr><tr><td><i>Area</i></td><td>-0.10</td><td>0.11</td><td>1.00</td></tr></table> |
d537e6bfb5728ac33a68d702cc71cd0bdcc8be5c13baf1a0d4ef1ff21d40f079.png | simple | <table><tr><td>Variable</td><td>Factor</td><td><i>P</i> value</td><td>HR</td><td>95.0% CI</td></tr><tr><td>Age</td><td>Continuous</td><td>0.367</td><td>1.02</td><td>0.98–1.05</td></tr><tr><td>Sex</td><td>Male</td><td>0.001</td><td>0.36</td><td>0.20–0.66</td></tr><tr><td>ECOG-PS</td><td>>1</td><td>0.034</td><td>2.13</td><td>1.06–3.39</td></tr><tr><td>Comorbidities (CVD or DM)</td><td>Positive</td><td>0.084</td><td>0.53</td><td>0.25–1.07</td></tr><tr><td>Metastatic disease</td><td>Positive</td><td><0.001</td><td>9.34</td><td>5.12–17.1</td></tr><tr><td>Frailty discriminant score</td><td>>2.30</td><td>0.005</td><td>3.03</td><td>1.41–5.51</td></tr></table> |
2d98da39147020b154e4f7f8ed9454d29e5cfccec634723eef6725e75f2ba4bb.png | simple | <table><tr><td>miRNA</td><td>Target</td><td>Effector cell</td><td>Affected chemokine</td><td>Role in atherosclerosis</td><td>References</td></tr><tr><td>miR-181b</td><td>Importin-α3</td><td>ECs</td><td>CXCL1</td><td>Protective</td><td>[58]</td></tr><tr><td>miR-103</td><td>KLF4</td><td>ECs</td><td>CXCL1CCL2</td><td>Damaging</td><td>Unpublished</td></tr><tr><td>miR-126-3p</td><td>RGS16</td><td>ECs</td><td>CXCL12</td><td>Protective</td><td>[64]</td></tr><tr><td>miR-10a</td><td>TAK1, β‐TRC</td><td>ECs</td><td>CCL2</td><td>Protective</td><td>[87]</td></tr><tr><td>miR-92a</td><td>KLF2, KLF4, SOCS5</td><td>ECs</td><td>CCL2CXCL1?</td><td>Damaging</td><td>[88]</td></tr><tr><td>miR-21</td><td>PPARα</td><td>ECs</td><td>CCL2</td><td>Damaging</td><td>[79]</td></tr><tr><td>let-7g</td><td>THBS1, TGFBR1, SMAD2</td><td>ECs</td><td>CCL2</td><td>Protective</td><td>[97]</td></tr><tr><td>miR-155</td><td>BCL6</td><td>Macrophages</td><td>CCL2</td><td>Damaging</td><td>[43]</td></tr><tr><td>miR-342-5p</td><td>AKT1</td><td>Macrophages</td><td>CCL2 (via miR-155)</td><td>Damaging</td><td>[102]</td></tr><tr><td>miR-467b</td><td>LPL</td><td>Macrophages</td><td>CCL2</td><td>Protective</td><td>[105]</td></tr><tr><td>miR-24</td><td>CHI3L1</td><td>Macrophages</td><td>CCL2</td><td>Protective</td><td>[108]</td></tr></table> |
c063090c45c98a7e74b27088f907ad1dbb0f9004e399a5961ef0d74f20bc1b5d.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">STIB900-M vs. STIB900</td><td colspan="3">STIB900-P vs. STIB900</td></tr><tr><td>Overall</td><td>CDS</td><td>NS</td><td>Overall</td><td>CDS</td><td>NS</td></tr><tr><td>Chr1</td><td>0</td><td>0</td><td>0</td><td>2</td><td>0</td><td>0</td></tr><tr><td>Chr2</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Chr3</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td></tr><tr><td>Chr4</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Chr5</td><td>2</td><td>0</td><td>0</td><td>1</td><td>Tb927.5.286b</td><td>G430R</td></tr><tr><td>Chr6</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Chr7</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td></tr><tr><td>Chr8</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Chr9</td><td>6</td><td>0</td><td>0</td><td>5</td><td>Tb927.9.8310*</td><td>D31G</td></tr><tr><td>Chr10</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Chr11</td><td>2</td><td>Tb927.11.500</td><td>R131L</td><td>4</td><td>Tb927.11.500</td><td>R131L</td></tr><tr><td>Total</td><td>12</td><td>1</td><td>1</td><td>14</td><td>3</td><td>3</td></tr></table> |
55f6c1b2e6563ffed7cddf95063e24944177a66ac6cfadb0bfc0d26ae5182229.png | complex | <table><tr><td></td><td colspan="6">Groups</td></tr><tr><td></td><td colspan="3">NH</td><td colspan="3">CI</td></tr><tr><td></td><td>Long, complex sentences</td><td>Highly meaningful sentences</td><td>Nonsense sentences</td><td>Long, complex sentences</td><td>Highly meaningful sentences</td><td>Nonsense sentences</td></tr><tr><td>Verbal Working Memory</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>LSpan (total letters correctly recalled)</td><td>.10</td><td>.05</td><td>.07</td><td>.64**</td><td>.57**</td><td>.68**</td></tr><tr><td>Rspan (total letters correctly recalled)</td><td>‐.01</td><td>.06</td><td>.13</td><td>‐.03</td><td>.01</td><td>‐.02</td></tr><tr><td>Modality‐General Neurocognitive Scores</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Attention Sustained (scaled score)</td><td>.14</td><td>.07</td><td>‐.08</td><td>.14</td><td>.19</td><td>.29</td></tr><tr><td>Forward Memory (scaled score)</td><td>‐.10</td><td>‐.35</td><td>.17</td><td>.23</td><td>.23</td><td>.14</td></tr><tr><td>Reverse Memory (scaled score)</td><td>.06</td><td>‐.11</td><td>.08</td><td>.20</td><td>.20</td><td>.04</td></tr><tr><td>Verbal Stroop–Congruent (response time)</td><td>‐.04</td><td>.20</td><td>.07</td><td>‐.28</td><td>‐.29</td><td>‐.36</td></tr><tr><td>Verbal Stroop–Incongruent (response time)</td><td>‐.14</td><td>‐.05</td><td>‐.03</td><td>‐.41*</td><td>‐.43*</td><td>‐.43*</td></tr><tr><td>* <i>p</i>‐value < 0.05</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>** <i>p</i>‐value < 0.01CI = cochlear impant; LSpan = Listening Span; NH = normal hearing; RSpan = Reading Span</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> |
79b13f563212c54a3431e49491e8f3e7e71995cc10bc59814848272eae82d655.png | simple | <table><tr><td>Parameters</td><td>No of patients with ≥ G2 RP (%)</td><td>No of patients with G0-1 RP (%)</td><td><i>p</i> value</td></tr><tr><td>Age</td><td></td><td></td><td>0.074</td></tr><tr><td> < 75 years old</td><td>1 (11)</td><td>25 (45)</td><td></td></tr><tr><td> ≥ 75</td><td>8 (89)</td><td>31 (55)</td><td></td></tr><tr><td>Sex</td><td></td><td></td><td>0.392</td></tr><tr><td> Man</td><td>6 (67)</td><td>45 (80)</td><td></td></tr><tr><td> Female</td><td>3 (33)</td><td>11 (20)</td><td></td></tr><tr><td>PS</td><td></td><td></td><td>0.458</td></tr><tr><td> 0 or 1</td><td>8 (89)</td><td>53 (95)</td><td></td></tr><tr><td> 2</td><td>1 (11)</td><td>3 (5)</td><td></td></tr><tr><td>Location of primary tumor</td><td></td><td></td><td>0.706</td></tr><tr><td> Upper or Middle lobe</td><td>7 (78)</td><td>36 (64)</td><td></td></tr><tr><td> Lower lobe</td><td>2 (22)</td><td>20 (36)</td><td></td></tr><tr><td>Clinical Stage</td><td></td><td></td><td>1.000</td></tr><tr><td> II</td><td>5 (56)</td><td>32 (57)</td><td></td></tr><tr><td> III</td><td>4 (44)</td><td>24 (43)</td><td></td></tr><tr><td>Total dose</td><td></td><td></td><td>1.000</td></tr><tr><td> ≤ 72 Gy RBE</td><td>8 (89)</td><td>46 (82)</td><td></td></tr><tr><td> > 72 Gy RBE</td><td>1 (11)</td><td>10 (18)</td><td></td></tr><tr><td>Chemotherapy</td><td></td><td></td><td>0.187</td></tr><tr><td> Yes</td><td>0</td><td>14 (25)</td><td></td></tr><tr><td> No</td><td>9 (100)</td><td>42 (75)</td><td></td></tr><tr><td>Brinkman Index</td><td></td><td></td><td>1.000</td></tr><tr><td> < 600</td><td>3 (33)</td><td>19 (34)</td><td></td></tr><tr><td> ≥ 600</td><td>6 (67)</td><td>37 (66)</td><td></td></tr><tr><td>Pulmonary emphysema</td><td></td><td></td><td>0.191</td></tr><tr><td> Yes</td><td>0</td><td>12 (21)</td><td></td></tr><tr><td> No</td><td>9 (100)</td><td>44 (79)</td><td></td></tr></table> |
c7c8b07f56bc36ac1de352ec1407cc9c32708b3694a0f96011265927b2c0b0ac.png | complex | <table><tr><td>Dose (mg/cm<sup>2</sup>)</td><td>#</td><td colspan="4">Mortality record for applied pests</td></tr><tr><td></td><td></td><td>Record after 24 hours</td><td>Average ± SD record after 24 hours</td><td>Record after 48 hours</td><td>Average ± SD record after 48 hours</td></tr><tr><td>1.77</td><td>10</td><td>10</td><td rowspan="3">9.66 ± 0.57</td><td>10</td><td rowspan="3">9.66 ± 0.57</td></tr><tr><td>1.77</td><td>10</td><td>10</td><td>10</td></tr><tr><td>1.77</td><td>10</td><td>9</td><td>9</td></tr><tr><td>0.88</td><td>10</td><td>10</td><td rowspan="3">9.00 ± 1.00</td><td>10</td><td rowspan="3">9.00 ± 1.00</td></tr><tr><td>0.88</td><td>10</td><td>9</td><td>9</td></tr><tr><td>0.88</td><td>10</td><td>8</td><td>8</td></tr><tr><td>0.44</td><td>10</td><td>5</td><td rowspan="3">5.33 ± 0.57</td><td>6</td><td rowspan="3">5.66 ± 0.57</td></tr><tr><td>0.44</td><td>10</td><td>6</td><td>6</td></tr><tr><td>0.44</td><td>10</td><td>5</td><td>5</td></tr><tr><td>0.22</td><td>10</td><td>2</td><td rowspan="3">2.00 ± 1.00</td><td>2</td><td rowspan="3">2.33 ± 0.57</td></tr><tr><td>0.22</td><td>10</td><td>1</td><td>2</td></tr><tr><td>0.22</td><td>10</td><td>3</td><td>3</td></tr><tr><td>Control</td><td>10</td><td>0</td><td>0.00</td><td>0</td><td>0.00</td></tr></table> |
35ef44738842c10a84d539744e9b43a58c1edb57b415cc7ce9d21c8a20b83bc5.png | simple | <table><tr><td>Variables</td><td>Unstandardised coefficients (B)</td><td>S.E</td><td>Standardised coefficients (Beta)</td><td>P value</td></tr><tr><td>Age</td><td>− 0.020</td><td>0.017</td><td>− 0.066</td><td>0.241</td></tr><tr><td>Marital status</td><td>0.052</td><td>0.041</td><td>0.077</td><td>0.205</td></tr><tr><td>Income level</td><td>0.064</td><td>0.023</td><td>0.163</td><td><i>0.006</i></td></tr><tr><td>The current condition</td><td>− 0.023</td><td>0.019</td><td>− 0.074</td><td>0.222</td></tr><tr><td>Pain severity score</td><td>− 0.011</td><td>0.002</td><td>− 0.353</td><td><i><</i> <i>0.001</i></td></tr><tr><td>Pain interference score</td><td>− 0.007</td><td>0.001</td><td>− 0.350</td><td><i><</i> <i>0.001</i></td></tr><tr><td>Post-treatment pain</td><td>− 0.010</td><td>0.051</td><td>− 0.012</td><td>0.842</td></tr></table> |
7b849647d4a58575ee84dcb0e4afa9e9d8b64cda07823fb0461a9a26417a0ca9.png | complex | <table><tr><td></td><td></td><td colspan="2">Selection</td><td></td><td>Comparability</td><td></td><td>Outcome assessment</td><td></td><td></td></tr><tr><td>Author</td><td>Year</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>Score</td></tr><tr><td>Kon</td><td>2007</td><td>*</td><td>*</td><td>*</td><td>*</td><td>**</td><td>*</td><td>-</td><td>*******</td></tr><tr><td>Zhao</td><td>2008</td><td>-</td><td>*</td><td>*</td><td>**</td><td>*</td><td>*</td><td>-</td><td>******</td></tr><tr><td>Reicher</td><td>2007</td><td>*</td><td>*</td><td>*</td><td>**</td><td>**</td><td>*</td><td>-</td><td>********</td></tr><tr><td>Vassiliades</td><td>2009</td><td>*</td><td>*</td><td>*</td><td>**</td><td>*</td><td>*</td><td>*</td><td>********</td></tr><tr><td>Delhaye</td><td>2010</td><td>*</td><td>*</td><td>*</td><td>**</td><td>*</td><td>*</td><td>-</td><td>*******</td></tr><tr><td>Hu</td><td>2010</td><td>*</td><td>*</td><td>*</td><td>**</td><td>**</td><td>*</td><td>*</td><td>*********</td></tr><tr><td>Halkos</td><td>2011</td><td>*</td><td>*</td><td>*</td><td>*</td><td>*</td><td>*</td><td>-</td><td>******</td></tr><tr><td>Bachinsky</td><td>2012</td><td>-</td><td>*</td><td>*</td><td>**</td><td>**</td><td>*</td><td>-</td><td>*******</td></tr><tr><td>Leacche</td><td>2012</td><td>-</td><td>*</td><td>*</td><td>**</td><td>*</td><td>*</td><td>-</td><td>******</td></tr></table> |
4686cc8e1b3bd8ce58b9ce0e462f1858102fc0c13c8baf99f31f360359eb7514.png | simple | <table><tr><td>Items</td><td>Normal controls</td><td>IPF</td><td>NSIP</td><td>HP</td><td>Sarcoidosis</td></tr><tr><td>No.</td><td>41</td><td>86</td><td>22</td><td>20</td><td>19</td></tr><tr><td>Age (year)</td><td>55(35–72)</td><td>67(59–75)*</td><td>60.1(39–70)</td><td>51.3(28–70)<sup>†</sup></td><td>43.3 (28–69)<sup>†</sup></td></tr><tr><td>Sex (male/female)</td><td>24/17</td><td>51/ 35</td><td>9/13</td><td>10/10</td><td>10/9</td></tr><tr><td>Smoke (CS/ES/NS)</td><td>9/11/14</td><td>19/25/36</td><td>2/5/12</td><td>3/3/12</td><td>5/2/9</td></tr><tr><td>Survival/Death</td><td>ND</td><td>57/21</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>Follow up duration (years)</td><td>ND</td><td>3.6(1.6–6.5)</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>FVC (% pred.)</td><td>106.1(87.0–119.0)</td><td>67.0(52.0–80.0)*</td><td>78.0(66.0–91.8)*</td><td>64.5(57.0–82.5)*</td><td>77.0(65.0–86.0)*</td></tr><tr><td>FEV1 (% pred.)</td><td>102.1(88.2–117.0)</td><td>83.0(59.0–93.0)*</td><td>85.0(73.8–101.3)*</td><td>74.5(64.3–92.0)*</td><td>85.0(64.0–101.0)*</td></tr><tr><td>DLCO (% pred.)</td><td>85.6(77.5–108.0)</td><td>57.0(46.0–71.0)*</td><td>76.0(59.0–92.0)*</td><td>67.0(55.0–90.0)*</td><td>75.5(57.8–84.5)*</td></tr><tr><td>dFVC (%/year)</td><td>NA</td><td>–7.1(–15.8–2.8)</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>BAL total cell count (×10<sup>4</sup>/mL)</td><td>3.46 ± 0.82</td><td>7.58 ± 2.24*</td><td>17.64 ± 3.86*</td><td>13.03 ± 3.78*</td><td>8.45 ± 3.78*</td></tr><tr><td>Macrophages (×10<sup>4</sup>/mL)</td><td>3.02 ± 0.41</td><td>5.12 ± 1.71*</td><td>11.51 ± 3.07*</td><td>8.25 ± 2.38*</td><td>6.76 ± 3.79*</td></tr><tr><td>Neutrophils (×10<sup>4</sup>/mL)</td><td>0.21 ± 0.047</td><td>1.45 ± 0.38*</td><td>2.31 ± 1.01*</td><td>3.14 ± 2.36*</td><td>0.45 ± 0.16*</td></tr><tr><td>Eosinophils (×10<sup>4</sup>/mL)</td><td>0.02 ± 0.01</td><td>0.29 ± 0.07*</td><td>0.45 ± 0.14*</td><td>0.41 ± 0.19*</td><td>0.11 ± 0.07</td></tr><tr><td>Lymphocytes (×10<sup>4</sup>/mL)</td><td>0.04 ± 0.01</td><td>0.14 ± 0.05</td><td>2.68 ± 0.18*<sup>†</sup></td><td>2.20 ± 0.19*<sup>†</sup></td><td>2.17 ± 0.24*<sup>†</sup></td></tr></table> |
335ef491bd792128d8416aedc0a6114433507e40e70d94596c06bec8fd8914ff.png | simple | <table><tr><td>Kinases</td><td>Phosphatases</td><td>Growth factors</td><td>Cytokines</td><td>Transcription factors</td></tr><tr><td><i>Fgfr1</i></td><td><i>Acpp</i></td><td><i>Clec11a</i></td><td><i>Il10</i></td><td><i>Gata6</i></td></tr><tr><td><i>Pdk4</i></td><td><i>Dusp23</i></td><td><i>Gas6</i></td><td><i>Pf4</i></td><td><i>Lass4</i></td></tr><tr><td><i>Srms</i></td><td><i>Nt5e</i></td><td><i>Gdf6</i></td><td><i>Thpo</i></td><td><i>Lhx4</i></td></tr><tr><td><i>Srk3</i></td><td><i>Pon1</i></td><td><i>Igf1</i></td><td><i>Wnt5a</i></td><td><i>Nfatc2</i></td></tr><tr><td></td><td><i>Ppap2b</i></td><td><i>Igf2</i></td><td></td><td><i>Per2</i></td></tr><tr><td></td><td></td><td><i>Inhbe</i></td><td></td><td><i>Tal1</i></td></tr><tr><td></td><td></td><td><i>Mst1</i></td><td></td><td><i>Tcf7l2</i></td></tr><tr><td></td><td></td><td></td><td></td><td><i>Sox9</i></td></tr></table> |
29a93c96c76b9190f222bad3606f537f172ae4bbbd90a74b19920161781e768d.png | simple | <table><tr><td>Variables<sup>a</sup></td><td>Preoperative</td><td>Discharge</td><td>6 months</td><td>1 year</td></tr><tr><td>Size 19 mm (n)</td><td>31</td><td>29</td><td>29</td><td>25</td></tr><tr><td> Peak gr, (mmHg)<sup>b</sup></td><td>76.1 ± 28.7</td><td>25.3 ± 9.5</td><td>24.1 ± 8.2</td><td>29.5 ± 11.0</td></tr><tr><td> Mean gr (mmHg)<sup>b</sup></td><td>45.7 ± 18.3</td><td>13.5 ± 5.7</td><td>13.2 ± 4.4</td><td>16.6 ± 5.8</td></tr><tr><td> EOA (cm2)<sup>b</sup></td><td>1.0 ± 0.5</td><td>1.6 ± 0.4</td><td>1.4 ± 0.4</td><td>1.4 ± 0.1</td></tr><tr><td> EOAI (cm2/m2)<sup>b</sup></td><td>0.2 ± 0.4</td><td>1.1 ± 0.7</td><td>1.0 ± 0.1</td><td>1.0 ± 0.1</td></tr><tr><td> LVMI (g/m2)<sup>b</sup></td><td>136.2 ± 8.2</td><td>124.2 ± 23.3</td><td>118.1 ± 44.6</td><td>123.4 ± 40.4</td></tr><tr><td> EF (%)</td><td>58.7 ± 9.4</td><td>55.5 ± 8.2</td><td>57.3 ± 5.9</td><td>58.4 ± 6.1</td></tr><tr><td>Size 21 mm (n)</td><td>58</td><td>57</td><td>56</td><td>51</td></tr><tr><td> Peak gr (mmHg)<sup>b</sup></td><td>87.7 ± 25.6</td><td>18.2 ± 5.2</td><td>17.9 ± 5.2</td><td>18.3 ± 5.2</td></tr><tr><td> Mean gr (mmHg)<sup>b</sup></td><td>54.7 ± 17.3</td><td>9.8 ± 2.9</td><td>9.4 ± 2.7</td><td>9.9 ± 3.0</td></tr><tr><td> EOA (cm2)<sup>b</sup></td><td>0.7 ± 0.2</td><td>1.9 ± 0.9</td><td>2.0 ± 0.3</td><td>2.1 ± 0.5</td></tr><tr><td> EOAI (cm2/m2)<sup>b</sup></td><td>0.5 ± 0.1</td><td>1.1 ± 0.3</td><td>1.2 ± 0.3</td><td>1.4 ± 0.4</td></tr><tr><td> LVMI (g/m2)<sup>b</sup></td><td>146.1 ± 22.8</td><td>142.2 ± 52.3</td><td>120.5 ± 48.7</td><td>127.7 ± 57.1</td></tr><tr><td> EF (%)</td><td>58.4 ± 7.9</td><td>56.4 ± 8.4</td><td>56.8 ± 8.2</td><td>55.9 ± 8.4</td></tr><tr><td>Size 23 mm (n)</td><td>58</td><td>56</td><td>56</td><td>53</td></tr><tr><td> Peak gr (mmHg)<sup>b</sup></td><td>77.6 ± 29.9</td><td>14.4 ± 5.0</td><td>15.1 ± 4.8</td><td>16.6 ± 5.4</td></tr><tr><td> Mean gr (mmHg)<sup>b</sup></td><td>47.8 ± 20.3</td><td>7.6 ± 2.3</td><td>8.2 ± 3.1</td><td>9.1 ± 3.2</td></tr><tr><td> EOA (cm2)<sup>b</sup></td><td>1.1 ± 0.6</td><td>2.1 ± 0.3</td><td>1.9 ± 0.3</td><td>1.8 ± 0.2</td></tr><tr><td> EOAI (cm2/m2)<sup>b</sup></td><td>0.6 ± 0.8</td><td>1.1 ± 0.3</td><td>1.0 ± 0.1</td><td>1.2 ± 0.1</td></tr><tr><td> LVMI (g/m2)<sup>b</sup></td><td>140.8 ± 25.8</td><td>135.2 ± 37.3</td><td>123.4 ± 33.2</td><td>125.9 ± 30.8</td></tr><tr><td> EF (%)</td><td>55.7 ± 8.9</td><td>52.4 ± 8.9</td><td>54.5 ± 9.5</td><td>53.4 ± 8.6</td></tr><tr><td>Size 25/27 mm (n)</td><td>31</td><td>31</td><td>31</td><td>27</td></tr><tr><td> Peak gr (mmHg)<sup>b</sup></td><td>62.7 ± 28.9</td><td>13.6 ± 5.2</td><td>14.4 ± 4.6</td><td>14.1 ± 4.7</td></tr><tr><td> Mean gr (mmHg)<sup>b</sup></td><td>36.7 ± 18.0</td><td>7.4 ± 2.8</td><td>8.2 ± 2.5</td><td>7.7 ± 2.4</td></tr><tr><td> EOA (cm2)<sup>b</sup></td><td>1.2 ± 0.5</td><td>2.2 ± 0.8</td><td>2.0 ± 0.8</td><td>2.5 ± 1.3</td></tr><tr><td> EOAI (cm2/m2)<sup>b</sup></td><td>0.9 ± 0.4</td><td>1.2 ± 0.4</td><td>1.2 ± 0.5</td><td>1.5 ± 0.5</td></tr><tr><td> LVMI (g/m2)<sup>b</sup></td><td>157.0 ± 53.1</td><td>126.2 ± 42.9</td><td>118.4 ± 24.3</td><td>100.9 ± 41.0</td></tr><tr><td> EF (%)</td><td>54.5 ± 11.1</td><td>50.8 ± 9.7</td><td>55.5 ± 8.9</td><td>56.2 ± 9.5</td></tr></table> |
98e20c93834804c50058e05ff439ffef7ab9d060d27b5374ba04aca88611a2f3.png | complex | <table><tr><td>Gene ID</td><td>I_CN</td><td>I_0</td><td>Annotation</td></tr><tr><td colspan="4">Kinase</td></tr><tr><td> Unigene43155_xckb</td><td>D_U</td><td>F_F</td><td>Proline-rich receptor-like protein kinase PERK2</td></tr><tr><td> Unigene66089_xckb</td><td>U_D</td><td>F_F</td><td>G-type lectin S-receptor-like serine/threonine-protein kinase SD1-13</td></tr><tr><td> Unigene13595_xckb</td><td>U_D</td><td>F_F</td><td>Protein kinase domain containing protein</td></tr><tr><td> CL3347.Contig1_xckb</td><td>U_D</td><td>F_F</td><td>Cysteine-rich receptor-like protein kinase 8</td></tr><tr><td> Unigene60834_xckb</td><td>U_D</td><td>F_F</td><td>Probable LRR receptor-like serine/threonine-protein kinase At4g29180</td></tr><tr><td> Unigene68690_xckb</td><td>U_D</td><td>F_F</td><td>Proline-rich receptor-like protein kinase PERK10</td></tr><tr><td> Unigene35121_xckb</td><td>U_D</td><td>F_F</td><td>Proline-rich receptor-like protein kinase PERK2</td></tr><tr><td colspan="4">TF</td></tr><tr><td> Unigene65053_xckb</td><td>U_D</td><td>F_F</td><td>MADS-box transcription factor 15</td></tr><tr><td> Unigene34602_xckb</td><td>U_F</td><td>F_F</td><td>Ethylene-responsive transcription factor ABI4</td></tr><tr><td> Unigene69673_xckb</td><td>U_F</td><td>F_F</td><td>Ethylene-responsive transcription factor ERF109</td></tr><tr><td colspan="4">Resistance</td></tr><tr><td> Unigene68271_xckb</td><td>U_D</td><td>F_F</td><td>Leucine-rich repeat extensin-like protein 3</td></tr><tr><td> CL2708.Contig2_xckb</td><td>U_D</td><td>F_F</td><td>Pollen-specific leucine-rich repeat extensin-like protein 1</td></tr><tr><td> Unigene72805_xckb</td><td>U_D</td><td>F_F</td><td>Resistance protein RGA2</td></tr><tr><td> CL6805.Contig1_xckb</td><td>F_U</td><td>F_F</td><td>Hydroxyproline-rich glycoprotein gp1</td></tr><tr><td> Unigene48841_xckb</td><td>F_U</td><td>F_F</td><td>Hydroxyproline-rich glycoprotein gp1</td></tr><tr><td> Unigene46836_xckb</td><td>U_D</td><td>F_F</td><td>Hydroxyproline-rich glycoprotein gp1</td></tr><tr><td> Unigene72060_xckb</td><td>U_D</td><td>F_F</td><td>Hydroxyproline-rich glycoprotein gp1</td></tr></table> |
54e070f1480b59746d56af6f1c8d981409666238f4054b7239c4c1faec8f447a.png | simple | <table><tr><td>Diagnosis</td><td>Cases</td></tr><tr><td>Head injury</td><td>7</td></tr><tr><td>Skin lesions</td><td>5</td></tr><tr><td>Poisoning</td><td>4</td></tr><tr><td>Polytrauma</td><td>3</td></tr><tr><td>Others</td><td>2</td></tr></table> |
3f252318011550c532575ace12b56de6b44ff0f67826b130d7cc40a2d6bea4c2.png | complex | <table><tr><td>Measure</td><td colspan="3">Early</td><td colspan="3">Late</td></tr><tr><td></td><td>Negative</td><td>Neutral</td><td>Positive</td><td>Negative</td><td>Neutral</td><td>Positive</td></tr><tr><td colspan="7">BEHAVIORAL</td></tr><tr><td>RT (ms)</td><td>666.06 (139.98)</td><td>668.84 (138.55)</td><td>667.24 (150.35)</td><td>631.73 (128.06)</td><td>647.42 (131.51)</td><td>641.09 (120.62)</td></tr><tr><td>ACC</td><td>0.94 (0.04)</td><td>0.96 (0.03)</td><td>0.95 (0.04)</td><td>0.96 (0.04)</td><td>0.95 (0.05)</td><td>0.95 (0.05)</td></tr><tr><td colspan="7">FACE-LOCKED ERPs</td></tr><tr><td>N170 (μV)</td><td>−8.36 (5.21)</td><td>−9.35 (5.24)</td><td>−8.74 (5.45)</td><td>−11.10 (5.81)</td><td>-12.03 (5.97)</td><td>−11.44 (5.70)</td></tr><tr><td>P3 (μV)</td><td>19.26 (5.55)</td><td>17.46 (5.64)</td><td>18.99 (6.49)</td><td>15.99 (6.98)</td><td>14.89 (7.31)</td><td>16.07 (8.00)</td></tr><tr><td colspan="7">IAPS-LOCKED ERPs</td></tr><tr><td>LPP (μV <sup>*</sup> ms)</td><td>2843.84 (4114.14)</td><td>1611.45 (3200.67)</td><td>535.69 (2636.49)</td><td>3259.33 (3327.15)</td><td>1808.66 (3186.92)</td><td>1248.49 (3779.14)</td></tr></table> |
97e20107cedcf3282aa86b9364c471ff1af528c1e0f7d2b539aea11bb502d559.png | complex | <table><tr><td>Plasmid</td><td colspan="5">Transfer frequency (transconjugant/recipient) (%)<sup>*</sup></td></tr><tr><td></td><td>1</td><td>2</td><td>3</td><td>4</td><td>Mean ± <i>SD</i></td></tr><tr><td>pIJ303</td><td>93.83</td><td>103.18</td><td>101.03</td><td>95.90</td><td>95.83 ± 1.57</td></tr><tr><td>pIJ303ΔspdA2</td><td>97.49</td><td>96.48</td><td>95.77</td><td>92.92</td><td>100.20 ± 4.04</td></tr><tr><td>pIJ303-sps</td><td>95.43</td><td>96.95</td><td>92.74</td><td>98.16</td><td>96.35 ± 3.44</td></tr><tr><td>pIJ303spdA2c</td><td>96.55</td><td>104.19</td><td>95.87</td><td>106.21</td><td>98.30 ± 5.69</td></tr></table> |
f4c3a42226b868e280dcc19d78a0b6bb909a2d756cdf996eba86840d8584e1e5.png | simple | <table><tr><td>Kind of complications</td><td><i>n</i> = 20 (23.2 %)</td><td>Need for reoperation <i>n</i> = 19 (22.0 %)</td><td>Way the complication was handled</td></tr><tr><td>- Femoral shaft fracture</td><td>4 (4.6 %)</td><td>4 (4.6 %)</td><td>cerclage, cemented stem</td></tr><tr><td>- Calcar fracture</td><td>1 (1.2 %)</td><td>1 (1.2 %)</td><td>change of approach</td></tr><tr><td>- Dislocation</td><td>2 (2.3 %)</td><td>2 (2.3 %)</td><td>closed reduction</td></tr><tr><td>- Sintering</td><td>1 (1.2 %)</td><td>1 (1.2 %)</td><td>larger neck size</td></tr><tr><td>- Periprosthetic fracture</td><td>6 (6.9 %)</td><td>6 (6.9 %)</td><td>plate osteosynthesis, cerclage, cemented stem, augmentation, total exchange</td></tr><tr><td>- Cup displacement</td><td>1 (1.2 %)</td><td>1 (1.2 %)</td><td>cemented cup</td></tr><tr><td>- Infection</td><td>2 (2.3 %)</td><td>2 (2.3 %)</td><td>exchange of head & inlay</td></tr><tr><td>- Hematoma</td><td>3 (3.5 %)</td><td>2 (2.3 %)</td><td>lavage, punction</td></tr><tr><td>- Thrombosis (%)</td><td>0 (0.0 %)</td><td>0 (0.0 %)</td><td>-</td></tr><tr><td>- Pulmonary embolism (%)</td><td>0 (0.0 %)</td><td>0 (0.0 %)</td><td>-</td></tr></table> |
e095678724d2022e64d896eee392d8b5c1d5324b8dd5e4614c2b3fe7cd2411f4.png | complex | <table><tr><td></td><td></td><td colspan="4">Cortisol</td><td colspan="4">DHEA</td></tr><tr><td></td><td></td><td colspan="2">IBS</td><td colspan="2">Control</td><td colspan="2">IBS</td><td colspan="2">Control</td></tr><tr><td>Day 1</td><td>Time 1</td><td>2.93</td><td>(0.29)</td><td>2.68</td><td>(0.24)</td><td>1.09</td><td>(0.08)</td><td>1.04</td><td>(0.06)</td></tr><tr><td></td><td>Time 2</td><td>3.82</td><td>(0.30)</td><td>3.87</td><td>(0.24)</td><td>1.08</td><td>(0.08)</td><td>1.14</td><td>(0.06)</td></tr><tr><td></td><td>Time 3</td><td>1.44</td><td>(0.29)</td><td>1.08</td><td>(0.25)</td><td>0.74</td><td>(0.08)</td><td>0.81</td><td>(0.06)</td></tr><tr><td>Day 2</td><td>Time 1</td><td>3.24</td><td>(0.30)</td><td>3.50</td><td>(0.24)</td><td>1.19</td><td>(0.08)</td><td>1.09</td><td>(0.07)</td></tr><tr><td></td><td>Time 2</td><td>4.64</td><td>(0.30)</td><td>3.65</td><td>(0.24)</td><td>1.10</td><td>(0.08)</td><td>1.12</td><td>(0.06)</td></tr><tr><td></td><td>Time 3</td><td>1.85</td><td>(0.30)</td><td>2.06</td><td>(0.25)</td><td>0.80</td><td>(0.08)</td><td>0.77</td><td>(0.06)</td></tr><tr><td>Day 3</td><td>Time 1</td><td>3.19</td><td>(0.32)</td><td>3.33</td><td>(0.23)</td><td>1.16</td><td>(0.08)</td><td>1.25</td><td>(0.06)</td></tr><tr><td></td><td>Time 2</td><td>4.52</td><td>(0.32)</td><td>4.22</td><td>(0.23)</td><td>1.11</td><td>(0.08)</td><td>1.26</td><td>(0.06)</td></tr><tr><td></td><td>Time 3</td><td>1.66</td><td>(0.33)</td><td>1.94</td><td>(0.26)</td><td>0.73</td><td>(0.08)</td><td>0.80</td><td>(0.06)</td></tr><tr><td>Day 4</td><td>Time 1</td><td>2.56</td><td>(0.31)</td><td>3.13</td><td>(0.25)</td><td>0.94</td><td>(0.09)</td><td>1.00</td><td>(0.07)</td></tr><tr><td></td><td>Time 2</td><td>3.28</td><td>(0.31)</td><td>3.19</td><td>(0.25)</td><td>0.95</td><td>(0.08)</td><td>1.04</td><td>(0.06)</td></tr><tr><td></td><td>Time 3</td><td>1.15</td><td>(0.33)</td><td>1.64</td><td>(0.25)</td><td>0.65</td><td>(0.08)</td><td>0.70</td><td>(0.06)</td></tr><tr><td></td><td></td><td colspan="4">DHEA-S</td><td colspan="4">DHEA-S/DHEA</td></tr><tr><td></td><td></td><td colspan="2">IBS</td><td colspan="2">Control</td><td colspan="2">IBS</td><td colspan="2">Control</td></tr><tr><td>Day 1</td><td>Time 1</td><td>3.85</td><td>(0.44)</td><td>3.48</td><td>(0.36)</td><td>3.85</td><td>(0.53)</td><td>3.38</td><td>(0.44)</td></tr><tr><td></td><td>Time 2</td><td>2.23</td><td>(0.45)</td><td>2.93</td><td>(0.36)</td><td>2.23</td><td>(0.55)</td><td>2.55</td><td>(0.44)</td></tr><tr><td></td><td>Time 3</td><td>2.80</td><td>(0.45)</td><td>2.43</td><td>(0.36)</td><td>4.07</td><td>(0.55)</td><td>3.07</td><td>(0.44)</td></tr><tr><td>Day 2</td><td>Time 1</td><td>3.13</td><td>(0.45)</td><td>3.52</td><td>(0.36)</td><td>2.58</td><td>(0.55)</td><td>3.10</td><td>(0.49)</td></tr><tr><td></td><td>Time 2</td><td>2.26</td><td>(0.45)</td><td>2.56</td><td>(0.36)</td><td>2.04</td><td>(0.55)</td><td>2.44</td><td>(0.44)</td></tr><tr><td></td><td>Time 3</td><td>1.76</td><td>(0.45)</td><td>2.26</td><td>(0.36)</td><td>2.32</td><td>(0.55)</td><td>3.16</td><td>(0.44)</td></tr><tr><td>Day 3</td><td>Time 1</td><td>3.77</td><td>(0.47)</td><td>3.86</td><td>(0.36)</td><td>3.52</td><td>(0.58)</td><td>3.25</td><td>(0.44)</td></tr><tr><td></td><td>Time 2</td><td>1.70</td><td>(0.47)</td><td>2.23</td><td>(0.36)</td><td>1.52</td><td>(0.58)</td><td>1.84</td><td>(0.43)</td></tr><tr><td></td><td>Time 3</td><td>2.01</td><td>(0.45)</td><td>2.59</td><td>(0.36)</td><td>3.00</td><td>(0.55)</td><td>3.42</td><td>(0.44)</td></tr><tr><td>Day 4</td><td>Time 1</td><td>2.62</td><td>(0.48)</td><td>3.29</td><td>(0.37)</td><td>2.61</td><td>(0.62)</td><td>3.50</td><td>(0.46)</td></tr><tr><td></td><td>Time 2</td><td>1.95</td><td>(0.46)</td><td>3.20</td><td>(0.37)</td><td>2.22</td><td>(0.57)</td><td>3.20</td><td>(0.45)</td></tr><tr><td></td><td>Time 3</td><td>2.14</td><td>(0.45)</td><td>2.47</td><td>(0.37)</td><td>3.51</td><td>(0.55)</td><td>3.67</td><td>(0.45)</td></tr></table> |
19e7036c12d9859476ea915f6cec67018e4166890fbfc74f4c73c291f57b9069.png | complex | <table><tr><td colspan="2">Demographic Data</td><td>Diabetes Medication</td><td>Frequency</td></tr><tr><td>Male (%)</td><td>44 (61)</td><td>OHA</td><td>39</td></tr><tr><td>Female (%)</td><td>28 (39)</td><td>Insulin</td><td>7</td></tr><tr><td>Mean age</td><td>56</td><td>OHA + Insulin</td><td>18</td></tr><tr><td>Median age</td><td>59</td><td>Nil</td><td>8</td></tr><tr><td>Mean BMI</td><td>39</td><td>HbA1c</td><td>(mmol/mol)</td></tr><tr><td>Median BMI</td><td>39</td><td>Mean HbA1c</td><td>67</td></tr><tr><td></td><td></td><td>Median Hb A1c</td><td>57</td></tr></table> |
ecf29b7ed3fa6c9cb5b354ddd8ab003945960126cde14fe57ca3718319c922ae.png | simple | <table><tr><td></td><td>National average</td><td>Less than $25,000</td><td>$25,000 to $34,999</td><td>$35,000 to $49,999</td><td>$50,000 to $74,999</td><td>$75,000 to $99,999</td><td>$100,000 or more</td></tr><tr><td><i>They are being harmed now</i></td><td>38</td><td>46</td><td>45</td><td>34</td><td>38</td><td>32</td><td>33</td></tr><tr><td><i>In 10 years</i></td><td>13</td><td>10</td><td>13</td><td>12</td><td>13</td><td>13</td><td>16</td></tr><tr><td><i>In 25 years</i></td><td>12</td><td>12</td><td>12</td><td>10</td><td>16</td><td>12</td><td>10</td></tr><tr><td><i>In 50 years</i></td><td>12</td><td>10</td><td>11</td><td>14</td><td>12</td><td>12</td><td>12</td></tr><tr><td><i>In 100 years</i></td><td>11</td><td>9</td><td>7</td><td>14</td><td>9</td><td>14</td><td>12</td></tr><tr><td><i>Never</i></td><td>14</td><td>12</td><td>11</td><td>16</td><td>11</td><td>17</td><td>17</td></tr><tr><td><i>χ2, p < 0.01; n = 2,073</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> |
4c0f3bb50b42e6ea4feb5cdf51637ff452f2d826e0cda1bb69407ee4df8a8fdf.png | complex | <table><tr><td rowspan="2">Natural populations</td><td rowspan="2">Year (number of accessions)</td><td colspan="2"><i>TaFlo2-A1a</i>Mean ± SE<sup>a</sup> (number of accessions)</td><td colspan="2"><i>TaFlo2-A1b</i>Mean ± SE (number of accessions)</td><td colspan="2">Mean difference ± SE</td><td rowspan="2">PVE (%)<sup>b</sup> TGW</td></tr><tr><td>TGW</td><td>GpS</td><td>TGW</td><td>GpS</td><td>TGW</td><td>GpS</td></tr><tr><td rowspan="3">Chinese Micro Core Collection</td><td>2002 (137)</td><td>33.6 ± 0.54(98)</td><td>50.8 ± 1.2(98)</td><td>40.6 ± 1.2(39)</td><td>49.7 ± 1.5(39)</td><td>7.0 ± 1.1**</td><td>1.06 ± 2.1<sup>ns</sup></td><td>6.19</td></tr><tr><td>2005 (169)</td><td>30.7 ± 0.52(128)</td><td>43.1 ± 0.8(128)</td><td>38.5 ± 1.1(41)</td><td>40.5 ± 1.1(41)</td><td>7.8 ± 1.1**</td><td>2.6 ± 1.5 <sup>ns</sup></td><td>7.76</td></tr><tr><td>2006 (185)</td><td>32.8 ± 0.43(141)</td><td>51.4 ± 0.7(141)</td><td>41.2 ± 0.9(44)</td><td>48.6 ± 1.2(43)</td><td>8.4 ± 0.9**</td><td>2.7 ± 1.5 <sup>ns</sup></td><td>8.37</td></tr><tr><td rowspan="2">Pakistani collection</td><td>2009 (130)</td><td>40.6 ± 0.43(85)</td><td>46.6 ± 1.1(85)</td><td>45.1 ± 0.55(45)</td><td>44.4–1.8(45)</td><td>4.5 + 0.71**</td><td>2.2 ± 1.9 <sup>ns</sup></td><td>4.42</td></tr><tr><td>2010 (130)</td><td>40.5 ± 0.47(85)</td><td>47.8 ± 1.2(85)</td><td>45.7 ± 0.46(45)</td><td>44.9 + 1.6(45)</td><td>5.2 ± 0.72**</td><td>2.9 ± 2.0 <sup>ns</sup></td><td>5.11</td></tr></table> |
c6811e52ba867e8638f30432767873efda85b1a793989d6bef409b4d8fe03bad.png | simple | <table><tr><td>Test</td><td>Occlusive patch (means)</td><td>Scotogenic lens (means)</td><td>Significance (K–S test), p value</td></tr><tr><td>Symptom control</td><td>9.73</td><td>9.27</td><td>0.985</td></tr><tr><td>Comfort</td><td>4.36</td><td>7.45</td><td>0.047</td></tr><tr><td>Aesthetics</td><td>2.00</td><td>9.45</td><td><0.001</td></tr><tr><td>Overall assessment</td><td>4.18</td><td>8.54</td><td><0.001</td></tr></table> |
4b9d27283901f65ba377d0682b6fc72d39501679f680807c7d60f4b2d9602c08.png | complex | <table><tr><td></td><td colspan="5">% of <i>|P</i>|</td></tr><tr><td># of ops as% of <i>n</i></td><td>Method</td><td>0</td><td>≤ 15%</td><td>≤ 20%</td><td>≤ 50%</td></tr><tr><td></td><td>1</td><td>97</td><td>97</td><td>97</td><td>100</td></tr><tr><td>10</td><td>2</td><td>97</td><td>97</td><td>97</td><td>100</td></tr><tr><td></td><td>3</td><td>96</td><td>96</td><td>96</td><td>99</td></tr><tr><td></td><td>1</td><td>93</td><td>93</td><td>93</td><td>100</td></tr><tr><td>15</td><td>2</td><td>93</td><td>93</td><td>93</td><td>100</td></tr><tr><td></td><td>3</td><td>89</td><td>89</td><td>89</td><td>100</td></tr><tr><td></td><td>1</td><td>84</td><td>84</td><td>93</td><td>100</td></tr><tr><td>20</td><td>2</td><td>83</td><td>83</td><td>92</td><td>100</td></tr><tr><td></td><td>3</td><td>76</td><td>76</td><td>85</td><td>100</td></tr><tr><td></td><td>1</td><td>78</td><td>88</td><td>88</td><td>100</td></tr><tr><td>25</td><td>2</td><td>76</td><td>86</td><td>86</td><td>100</td></tr><tr><td></td><td>3</td><td>67</td><td>77</td><td>77</td><td>100</td></tr><tr><td></td><td>1</td><td>68</td><td>83</td><td>93</td><td>100</td></tr><tr><td>29</td><td>2</td><td>66</td><td>81</td><td>89</td><td>100</td></tr><tr><td></td><td>3</td><td>57</td><td>69</td><td>76</td><td>100</td></tr></table> |
77a3b180132c795cce75623505886ee1e1f3d80f6b6eecbb98829a43608d8dbd.png | complex | <table><tr><td>Assays</td><td>Treatment Group</td><td>MeanCFU Counts</td><td colspan="4">Treatment Effect Group</td></tr><tr><td>CFU-GM</td><td>N</td><td>79.3</td><td>A</td><td></td><td></td><td></td></tr><tr><td></td><td>APS</td><td>52.3</td><td></td><td>B</td><td></td><td></td></tr><tr><td></td><td>TPO</td><td>50.0</td><td></td><td>B</td><td></td><td></td></tr><tr><td></td><td>C</td><td>34.5</td><td></td><td></td><td>C</td><td></td></tr><tr><td>BFU-E</td><td>N</td><td>55.3</td><td>A</td><td></td><td></td><td></td></tr><tr><td></td><td>TPO</td><td>31.2</td><td></td><td>B</td><td></td><td></td></tr><tr><td></td><td>APS</td><td>22.3</td><td></td><td></td><td>C</td><td></td></tr><tr><td></td><td>C</td><td>8.3</td><td></td><td></td><td></td><td>D</td></tr><tr><td>CFU-GEMM</td><td>N</td><td>27.7</td><td>A</td><td></td><td></td><td></td></tr><tr><td></td><td>APS</td><td>19.7</td><td></td><td>B</td><td></td><td></td></tr><tr><td></td><td>TPO</td><td>18.0</td><td></td><td>B</td><td></td><td></td></tr><tr><td></td><td>C</td><td>8.3</td><td></td><td></td><td>C</td><td></td></tr><tr><td>CFU-MK</td><td>N</td><td>51.8</td><td>A</td><td></td><td></td><td></td></tr><tr><td></td><td>APS</td><td>32.5</td><td></td><td>B</td><td></td><td></td></tr><tr><td></td><td>TPO</td><td>37.5</td><td></td><td>B</td><td></td><td></td></tr><tr><td></td><td>C</td><td>15.3</td><td></td><td></td><td>C</td><td></td></tr><tr><td>CFU-F</td><td>N</td><td>29.8</td><td>A</td><td></td><td></td><td></td></tr><tr><td></td><td>APS</td><td>27.6</td><td>A</td><td></td><td></td><td></td></tr><tr><td></td><td>TPO</td><td>19.3</td><td></td><td>B</td><td></td><td></td></tr><tr><td></td><td>C</td><td>8.8</td><td></td><td></td><td>C</td><td></td></tr></table> |
c682ab8df4df694ff1dda0518eb27b3ae4004519f15e44061a97896be062d493.png | complex | <table><tr><td>Diets<sup>1</sup></td><td>Normal (%)</td><td colspan="4">Degree of Steatosis<sup>2</sup></td></tr><tr><td></td><td></td><td>< 5%</td><td>5-33%</td><td>33-6%</td><td>> 66%</td></tr><tr><td>CNC</td><td>100</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CC</td><td></td><td>40</td><td>-</td><td>20</td><td>40</td></tr><tr><td>LWS50</td><td>100</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CS50</td><td>20</td><td>-</td><td>-</td><td>-</td><td>80</td></tr><tr><td>OS50</td><td>60</td><td>20</td><td>-</td><td>-</td><td>20</td></tr></table> |
210214df48f1f95bda3f5dad79c0c9e7c8e852887f574d51dfd9f9fc2bc000a4.png | simple | <table><tr><td>Case</td><td>Age</td><td>Disease recurrence</td><td>Presence of metastasis*</td><td>Follow-up (months)</td><td>Life status</td></tr><tr><td>1</td><td>41</td><td>No</td><td>No</td><td>64</td><td>Alive</td></tr><tr><td>2</td><td>37</td><td>No</td><td>Yes</td><td>22</td><td>Alive</td></tr><tr><td>3</td><td>55</td><td>NI</td><td>NI</td><td>NI</td><td>NI</td></tr><tr><td>4</td><td>59</td><td>No</td><td>Yes</td><td>16</td><td>Dead</td></tr><tr><td>5</td><td>46</td><td>No</td><td>No</td><td>107</td><td>Alive</td></tr><tr><td>6</td><td>27</td><td>No</td><td>No</td><td>28</td><td>Alive</td></tr><tr><td>7</td><td>33</td><td>Yes</td><td>No</td><td>36</td><td>Alive</td></tr><tr><td>8</td><td>67</td><td>No</td><td>No</td><td>34</td><td>Alive</td></tr><tr><td>9</td><td>40</td><td>No</td><td>No</td><td>35</td><td>Alive</td></tr><tr><td>10</td><td>54</td><td>No</td><td>Yes</td><td>48</td><td>Dead</td></tr><tr><td>11</td><td>57</td><td>Yes</td><td>No</td><td>30</td><td>Alive</td></tr><tr><td>12</td><td>61</td><td>No</td><td>No</td><td>9</td><td>Alive</td></tr><tr><td>13</td><td>67</td><td>No</td><td>No</td><td>32</td><td>Alive</td></tr><tr><td>14</td><td>38</td><td>No</td><td>No</td><td>17</td><td>Alive</td></tr><tr><td>15</td><td>71</td><td>No</td><td>No</td><td>5</td><td>Alive</td></tr><tr><td>16</td><td>40</td><td>No</td><td>No</td><td>87</td><td>Alive</td></tr><tr><td>17</td><td>40</td><td>No</td><td>No</td><td>10</td><td>Alive</td></tr><tr><td>18</td><td>58</td><td>No</td><td>Yes</td><td>47</td><td>Dead</td></tr><tr><td>19</td><td>47</td><td>No</td><td>No</td><td>22</td><td>Alive</td></tr><tr><td>20</td><td>41</td><td>No</td><td>No</td><td>14</td><td>Alive</td></tr><tr><td>21</td><td>39</td><td>No</td><td>Yes</td><td>9</td><td>Dead</td></tr><tr><td>22</td><td>40</td><td>No</td><td>Yes</td><td>48</td><td>Alive</td></tr><tr><td>23</td><td>45</td><td>No</td><td>No</td><td>35</td><td>Alive</td></tr><tr><td>24</td><td>53</td><td>No</td><td>Yes</td><td>13</td><td>Alive</td></tr><tr><td>25</td><td>29</td><td>No</td><td>Yes</td><td>14</td><td>Dead</td></tr><tr><td>26</td><td>36</td><td>No</td><td>Yes</td><td>19</td><td>Dead</td></tr><tr><td>27</td><td>24</td><td>No</td><td>Yes</td><td>6</td><td>Alive</td></tr><tr><td>28</td><td>48</td><td>No</td><td>Yes</td><td>NI</td><td>Dead</td></tr><tr><td>29</td><td>56</td><td>No</td><td>No</td><td>22</td><td>Alive</td></tr><tr><td>30</td><td>77</td><td>No</td><td>Yes</td><td>17</td><td>Alive</td></tr></table> |
2d125cf7f0aa01bcc31a55fd90c327dabe0ecd53f72b8f083eec8d39a7547202.png | simple | <table><tr><td></td><td>Prior to replacement (RR*, 95% CI)</td><td>Subsequent to replacement(RR, 95% CI)</td></tr><tr><td>All Outdoor Injuries</td><td>1.65 (1.50-1.82)</td><td>2.07 (1.91-2.24)</td></tr><tr><td>Non-equipment injuries</td><td>1.68 (1.50-1.89)</td><td>2.41 (2.20-2.64)</td></tr><tr><td>Equipment-related injuries</td><td>1.52 (1.24-1.86)</td><td>1.13 (0.95-1.32)</td></tr></table> |
5e85705dbbeef4ab6b39cf159b16e0d4d427ef630803e7b3ed21d9a66646f9c1.png | complex | <table><tr><td></td><td colspan="3">KwaZulu-Natal (KZN)</td><td colspan="3">Other South Africa (Other SA)</td></tr><tr><td></td><td>Initial, 2002</td><td colspan="2">Annual growth (%)</td><td>Initial, 2002</td><td colspan="2">Annual growth (%)</td></tr><tr><td></td><td></td><td>AIDS</td><td>No AIDS</td><td></td><td>AIDS</td><td>No AIDS</td></tr><tr><td>Employment (1000s)</td><td>1,902</td><td>0.63</td><td>1.75</td><td>7,988</td><td>0.81</td><td>1.64</td></tr><tr><td> African</td><td>1,436</td><td>0.90</td><td>2.24</td><td>5,677</td><td>1.05</td><td>2.11</td></tr><tr><td>Skilled</td><td>184</td><td>0.87</td><td>1.73</td><td>679</td><td>1.01</td><td>1.67</td></tr><tr><td>Semi-skilled</td><td>718</td><td>0.99</td><td>2.23</td><td>2,844</td><td>1.06</td><td>2.04</td></tr><tr><td>Low skilled</td><td>534</td><td>0.78</td><td>2.43</td><td>2,154</td><td>1.05</td><td>2.33</td></tr><tr><td> Other</td><td>466</td><td>-0.31</td><td>-0.24</td><td>2,311</td><td>0.15</td><td>0.24</td></tr><tr><td>Labour productivity</td><td>-</td><td>1.80</td><td>1.92</td><td>-</td><td>1.80</td><td>1.88</td></tr><tr><td> African</td><td>-</td><td>1.80</td><td>2.02</td><td>-</td><td>1.80</td><td>1.95</td></tr><tr><td>Skilled</td><td>-</td><td>1.80</td><td>1.93</td><td>-</td><td>1.80</td><td>1.89</td></tr><tr><td>Semi-skilled</td><td>-</td><td>1.80</td><td>2.02</td><td>-</td><td>1.80</td><td>1.96</td></tr><tr><td>Low skilled</td><td>-</td><td>1.80</td><td>2.10</td><td>-</td><td>1.80</td><td>2.00</td></tr><tr><td> Other</td><td>-</td><td>1.80</td><td>1.82</td><td>-</td><td>1.80</td><td>1.82</td></tr><tr><td>Wages (Rands)</td><td>75,511</td><td>3.09</td><td>4.05</td><td>96,054</td><td>2.94</td><td>3.93</td></tr><tr><td> African</td><td>59,219</td><td>2.48</td><td>2.88</td><td>91,944</td><td>2.67</td><td>3.33</td></tr><tr><td>Skilled</td><td>64,824</td><td>2.53</td><td>3.24</td><td>120,083</td><td>2.76</td><td>3.63</td></tr><tr><td>Semi-skilled</td><td>33,516</td><td>2.30</td><td>2.69</td><td>41,826</td><td>2.33</td><td>2.89</td></tr><tr><td>Low skilled</td><td>20,098</td><td>2.63</td><td>1.86</td><td>21,979</td><td>2.74</td><td>2.33</td></tr><tr><td> Other</td><td>91,803</td><td>3.44</td><td>4.68</td><td>100,163</td><td>3.19</td><td>4.41</td></tr></table> |
19819d8b6b115a6ab508c6ebb67aa2f9e8d85940bf4a44ecfe0fba0b69701958.png | simple | <table><tr><td>Polar Bear Scaffolds</td><td>5′ LTR Location</td><td>3′ LTR Location</td><td>Overall Mean K2P Distance</td><td>Age Estimation Mya</td></tr><tr><td>Scaffold 1</td><td>66,674,296–66,674,797</td><td>66,681,308–66,681,790</td><td>0.002</td><td>0.625</td></tr><tr><td>Scaffold 7</td><td>30,626,500–30,627,187</td><td>30,633,692–30,634,278</td><td>0.007</td><td>2.1875</td></tr><tr><td>Scaffold 162</td><td>7152–7643</td><td>13,824–14,441</td><td>ND</td><td>ND</td></tr><tr><td>Scaffold 200</td><td>145,219–145,715</td><td>152,850–153,350</td><td>0</td><td>0</td></tr></table> |
f64c325b3035d88ad2adecef7edb51f4b608a7cd1348138a50473927918d3e73.png | complex | <table><tr><td> </td><td> </td><td> </td><td> </td><td colspan="2">Cardiac infarction</td><td>Crude estimate</td><td>Age-adjusted estimate</td></tr><tr><td> </td><td>Age (years)</td><td>Gender</td><td>Total</td><td>Yes</td><td>No</td><td>OR (95% CI), <i>p</i>-value</td><td>OR (95% CI), <i>p</i>-value</td></tr><tr><td>iNPH</td><td>≥ 35 - 70</td><td>Female</td><td>95</td><td>2 (2.1%)</td><td>93 (97.9%)</td><td>2.8 (0.7 – 11.6), NS</td><td>1.5 (0.4 – 6.4), NS</td></tr><tr><td>HUNT3</td><td>≥ 35 - 70</td><td>Female</td><td>18,988</td><td>143 (0.8%)</td><td>18,845 (99.2%)</td><td> </td><td> </td></tr><tr><td>iNPH</td><td>≥ 35 - 70</td><td>Male</td><td>81</td><td>13 (16.0%)</td><td>68 (84.0%)</td><td>5.0 (2.8 – 9.1), <0.001</td><td>2.6 (1.4 – 4.7), 0.002</td></tr><tr><td>HUNT3</td><td>≥ 35 - 70</td><td>Male</td><td>16,425</td><td>604 (3.7%)</td><td>15,821 (96.3%)</td><td> </td><td> </td></tr><tr><td>iNPH</td><td>≥70 - 90</td><td>Female</td><td>125</td><td>7 (5.6%)</td><td>118 (94.4%)</td><td>0.8 (0.64 – 1.8), .NS</td><td>0.8 (0.4 – 1.8), NS</td></tr><tr><td>HUNT3</td><td>≥70 - 90</td><td>Female</td><td>4,384</td><td>298 (6.8%)</td><td>4,086 (93.2%)</td><td> </td><td> </td></tr><tr><td>iNPH</td><td>≥70 - 90</td><td>Male</td><td>139</td><td>19 (13.7%)</td><td>120 (86.3%)</td><td>0.8 (0.5 – 1.3), NS</td><td>0.8 (0.5 – 1.3), NS</td></tr><tr><td>HUNT3</td><td>≥70 - 90</td><td>Male</td><td>3,590</td><td>580 (16.2%)</td><td>3,010 (83.8%)</td><td> </td><td> </td></tr></table> |
01c0065d64387e586044d08fc5a615ed1006fc0849a0e14d59a76110bcc61af6.png | complex | <table><tr><td>S-RAMM items</td><td>AUC</td><td colspan="2">95% confidence interval of AUC</td><td>p</td><td>Odds ratio</td><td colspan="2">95% confidence interval of OR</td><td>p</td></tr><tr><td> </td><td> </td><td>Lower</td><td>Upper</td><td> </td><td> </td><td>Lower</td><td>Upper</td><td> </td></tr><tr><td>B1 History of deliberate self harm</td><td>0.474</td><td>0.275</td><td>0.672</td><td>0.783</td><td>1.186</td><td>0.582</td><td>2.416</td><td>0.639</td></tr><tr><td>B2 Seriousness of previous suicidality</td><td>0.411</td><td>0.215</td><td>0.607</td><td>0.349</td><td>1.513</td><td>0.724</td><td>3.159</td><td>0.271</td></tr><tr><td>B3 Previous hospitalisation</td><td>0.630</td><td>0.463</td><td>0.796</td><td>0.172</td><td>0.540</td><td>0.225</td><td>1.298</td><td>0.168</td></tr><tr><td>B4 Mental disorder</td><td>0.488</td><td>0.304</td><td>0.672</td><td>0.903</td><td>1.286</td><td>1.115</td><td>1.483</td><td>1.000</td></tr><tr><td>B5 Substance abuse disorder</td><td>0.554</td><td>0.372</td><td>0.737</td><td>0.568</td><td>0.792</td><td>0.368</td><td>1.703</td><td>0.550</td></tr><tr><td>B6 Personality</td><td>0.512</td><td>0.328</td><td>0.696</td><td>0.903</td><td>0.862</td><td>0.243</td><td>3.055</td><td>0.819</td></tr><tr><td>B7 Childhood adversity</td><td>0.529</td><td>0.370</td><td>0.688</td><td>0.760</td><td>0.906</td><td>0.423</td><td>1.939</td><td>0.799</td></tr><tr><td>B8 Suicide in the family</td><td>0.437</td><td>0.245</td><td>0.629</td><td>0.508</td><td>1.504</td><td>0.546</td><td>4.143</td><td>0.430</td></tr><tr><td>B9 Age, Gender and marital status</td><td>0.628</td><td>0.430</td><td>0.826</td><td>0.179</td><td>0.220</td><td>0.059</td><td>0.820</td><td>0.024</td></tr><tr><td>C1 Suicidal ideation, communication and intent</td><td>0.512</td><td>0.328</td><td>0.696</td><td>0.903</td><td>0.778</td><td>0.674</td><td>0.897</td><td>0.036</td></tr><tr><td>C2 Hopelessness</td><td>0.581</td><td>0.412</td><td>0.750</td><td>0.392</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>C3 Psychological symptoms</td><td>0.650</td><td>0.486</td><td>0.815</td><td>0.114</td><td>0.452</td><td>0.178</td><td>1.149</td><td>0.095</td></tr><tr><td>C4 Treatment adherence</td><td>0.686</td><td>0.541</td><td>0.831</td><td>0.050</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>C5 Substance use</td><td>0.500</td><td>0.314</td><td>0.686</td><td>1.000</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>C6 Psychiatric admission and discharge</td><td>0.489</td><td>0.289</td><td>0.960</td><td>0.911</td><td>1.561</td><td>′0.089</td><td>27.253</td><td>0.760</td></tr><tr><td>C7 Psychosocial stress</td><td>0.709</td><td>0.534</td><td>0.884</td><td>0.028</td><td>0.254</td><td>0.073</td><td>0.882</td><td>0.031</td></tr><tr><td>C8 Problem solving deficits</td><td>0.682</td><td>0.513</td><td>0.852</td><td>0.055</td><td>0.349</td><td>0.125</td><td>0.974</td><td>0.045</td></tr><tr><td>F1 Access to preferred method of suicide</td><td>0.418</td><td>0.231</td><td>0.604</td><td>0.386</td><td>1.556</td><td>0.512</td><td>4.728</td><td>0.436</td></tr><tr><td>F2 Future service contact</td><td>0.686</td><td>0.513</td><td>0.859</td><td>0.050</td><td>0.407</td><td>0.167</td><td>0.990</td><td>0.047</td></tr><tr><td>F3 Future response to drug treatment</td><td>0.686</td><td>0.513</td><td>0.859</td><td>0.050</td><td>0.407</td><td>0.167</td><td>0.990</td><td>0.047</td></tr><tr><td>F4 Future response to psychological intervention</td><td>0.729</td><td>0.579</td><td>0.879</td><td>0.016</td><td>0.323</td><td>0.129</td><td>0.809</td><td>0.016</td></tr><tr><td>F5 Future Stress</td><td>0.520</td><td>0.328</td><td>0.712</td><td>0.831</td><td>0.803</td><td>0.264</td><td>2.444</td><td>0.699</td></tr></table> |
58e850c65ae7dad636eaafcab95bf5dba039b02bebe991d3faf54cc851041199.png | complex | <table><tr><td></td><td>50–64 yrs.(<i>N</i> = 1,021,648)n (%)</td><td>≥ 65 yrs.(<i>N</i> = 1,011,817)N (%)</td><td>ODDS RATIO(OR)OR 95%CI</td></tr><tr><td colspan="4">Immunocompromising conditions</td></tr><tr><td> Primary immunodeficiency</td><td>295 (<0.1)</td><td>294 (<0.1)</td><td>1.01 (0.85–1.19)</td></tr><tr><td> HIV infection</td><td>2825 (0.3)</td><td>449 (<0.1)</td><td>0.16 (0.14–0.18)</td></tr><tr><td> Nephrotic syndrome</td><td>577 (0.1)</td><td>903 (0.1)</td><td>1.58 (1.42–1.76)</td></tr><tr><td> Severe renal failure (GFR < 30)</td><td>1058 (0.1)</td><td>14,410 (1.4)</td><td>13.94 (13.04–14.84)</td></tr><tr><td> Bone marrow trasplantation</td><td>2415 (0.2)</td><td>2619 (0.3)</td><td>1.10 (1.04–1.16)</td></tr><tr><td> Recent cancer</td><td>30,339 (3.0)</td><td>73,609 (7.3)</td><td>2.56 (2.53–2.68)</td></tr><tr><td> Immunosuppressive medication/Radiotherapy</td><td>22,319 (2.2)</td><td>49,721 (4.9)</td><td>2.31 (2.28–2.35)</td></tr><tr><td colspan="4">Other high risk condition</td></tr><tr><td> Asplenia</td><td>186 (<0.1)</td><td>108 (<0.1)</td><td>0.59 (0.46–0.75)</td></tr><tr><td> Cochlear implant</td><td>23 (<0.1)</td><td>53 (<0.1)</td><td>2.33 (1.39–3.91)</td></tr><tr><td> CSF leaks</td><td>11 (<0.1)</td><td>30 (<0.1)</td><td>2.75 (1.33–5.83)</td></tr><tr><td>Chronic respiratory disease</td><td>67,987 (6.7)</td><td>144,268 (14.3)</td><td>2.33 (2.31–2.36)</td></tr><tr><td>Chronic heart disease</td><td>49,362 (4.8)</td><td>199,015 (19.7)</td><td>4.82 (4.77–4.87)</td></tr><tr><td>Liver disease</td><td>20,567 (2.0)</td><td>21,167 (2.1)</td><td>1.04 (1.02–1.06)</td></tr><tr><td>Diabetes mellitus</td><td>100,855 (9.9)</td><td>240,680 (23.8)</td><td>2.85 (2.83–2.87)</td></tr><tr><td>Alcoholism</td><td>36,808 (3.6)</td><td>21,973 (2.2)</td><td>0.59 (0.58–0.60)</td></tr><tr><td>Smoking</td><td>242,626 (23.7)</td><td>74,932 (7.4)</td><td>0.26 (0.25–0.27)</td></tr></table> |
29850512d4a092266975c8be534b586f5d12de81b21c3862467c265d5c1e08e5.png | complex | <table><tr><td colspan="2">Recurrence</td></tr><tr><td>Intrahepatic recurrence</td><td>222 (76.6%)</td></tr><tr><td>Extrahepatic recurrence</td><td>68 (23.4%)</td></tr><tr><td>Main treatment for recurrence</td><td> </td></tr><tr><td>Transplantation</td><td>10 (3.4%)</td></tr><tr><td>Repeat resection</td><td>29 (9.8%)</td></tr><tr><td>Local ablation therapy</td><td>29 (9.8%)</td></tr><tr><td>TACE</td><td>172 (58.1%)</td></tr><tr><td>Chemotherapy</td><td>26 (4.3%)</td></tr><tr><td>Radiation therapy</td><td>16 (5.4%)</td></tr><tr><td>Cause of death</td><td> </td></tr><tr><td>Recurrent HCC</td><td>182 (80.9%)</td></tr><tr><td>Complication of liver cirrhosis without recurrence</td><td>25 (11.1%)</td></tr><tr><td>Unrelated (including perioperative death)</td><td>18 (8.0%)</td></tr></table> |
308dfcbf85128d66f195045bfe07fa8f91cd76706ba80114eda998b5f0e8eca1.png | simple | <table><tr><td></td><td>Normoxic</td><td>Hypoxic</td><td>Hypoxic + CPP</td></tr><tr><td>Alkaline Phosphatase</td><td>179 <underline>+</underline> 20</td><td>195 <underline>+</underline> 31</td><td>176 <underline>+</underline> 16</td></tr><tr><td>ALT</td><td>25 <underline>+</underline> 4</td><td>30 <underline>+</underline> 10</td><td>33 <underline>+</underline> 6</td></tr><tr><td>AST</td><td>48 <underline>+</underline> 3</td><td>73 <underline>+</underline> 8 *</td><td>81 <underline>+</underline> 8 *</td></tr><tr><td>Creatine Kinase</td><td>163 <underline>+</underline> 46</td><td>236 <underline>+</underline> 90</td><td>225 <underline>+</underline> 38</td></tr><tr><td>GGT</td><td>2.0 <underline>+</underline> 0.0</td><td>3.0 <underline>+</underline> 0.0</td><td>2.4 <underline>+</underline> 0.6</td></tr><tr><td>Albumin</td><td>2.9 <underline>+</underline> 0.1</td><td>2.9 <underline>+</underline> 0.2</td><td>2.8 <underline>+</underline> 0.1</td></tr><tr><td>Total Protein</td><td>5.6 <underline>+</underline> 0.2</td><td>5.2 <underline>+</underline> 0.2</td><td>5.0 <underline>+</underline> 0.1</td></tr><tr><td>Total Bilirubin</td><td>0.1 <underline>+</underline> 0.0</td><td>0.1 <underline>+</underline> 0.0</td><td>0.1 <underline>+</underline> 0.0</td></tr><tr><td>Blood Urea Nitrogen</td><td>18.8 <underline>+</underline> 2.8</td><td>26.3 <underline>+</underline> 8.4</td><td>20.0 <underline>+</underline> 2.2</td></tr></table> |
1018d80e45c79acc6fe000a4cc17e8e194bbe6d1fecb9294eb240647945ada50.png | complex | <table><tr><td rowspan="3">Transient neurological symptoms</td><td colspan="8">Age (years)</td></tr><tr><td colspan="2">All</td><td colspan="2">65–74 (N=3657)</td><td colspan="2">75–84 (N=2618)</td><td colspan="2">85+ (N=473)</td></tr><tr><td>N</td><td>Per cent*</td><td>N</td><td>Per cent*</td><td>N</td><td>Per cent*</td><td>N</td><td>Per cent*</td></tr><tr><td>Loss of speech</td><td>149</td><td>2.1</td><td>55</td><td>1.5</td><td>84</td><td>3.3</td><td>10</td><td>2.0</td></tr><tr><td>Weakness</td><td>239</td><td>3.7</td><td>117</td><td>3.4</td><td>106</td><td>4.1</td><td>16</td><td>3.4</td></tr><tr><td>Loss of sight</td><td>410</td><td>6.3</td><td>214</td><td>6.3</td><td>170</td><td>6.6</td><td>26</td><td>4.5</td></tr><tr><td>At least one symptom</td><td>675</td><td>9.8</td><td>327</td><td>9.3</td><td>304</td><td>11.6</td><td>44</td><td>7.8</td></tr></table> |
b8179b6ea0e6066b1dd6587ac3d1ec86614c230aa6cd88c04fd5cee921445154.png | simple | <table><tr><td></td><td>Subjects with DLCO</td><td>Subjects without DLCO</td><td>p-value</td></tr><tr><td>Sample size</td><td>53</td><td>20</td><td>-</td></tr><tr><td>Age, years*</td><td>64 (1)</td><td>61 (2)</td><td>0.16</td></tr><tr><td>Sex, M/F</td><td>32/21</td><td>10/10</td><td>0.43</td></tr><tr><td>Pack years*</td><td>54 (3)</td><td>49 (5)</td><td>0.49</td></tr><tr><td>Current smokers (%)</td><td>15 (28)</td><td>4 (20)</td><td>0.48</td></tr><tr><td>ICS use (%)</td><td>24 (45)</td><td>12 (60)</td><td>0.27</td></tr><tr><td>SCS use (%)</td><td>3 (6)</td><td>2 (10)</td><td>0.52</td></tr><tr><td>% FEV<sub>1 </sub>*</td><td>51 (4)</td><td>51 (6)</td><td>0.97</td></tr><tr><td>FEV<sub>1</sub>/FVC*</td><td>45 (2)</td><td>46 (4)</td><td>0.89</td></tr></table> |
4abe8c6616be38fa8469156ff40049b4f7e1141805fbb181b558bc9fbfef1a52.png | simple | <table><tr><td></td><td>Targets</td><td><|P|></td><td><|N|></td><td>dDFIRE</td><td>OPUS_PSP</td><td>RWplus</td><td>GOAP</td><td>ROTAS</td></tr><tr><td>4state_reduced</td><td>7</td><td>195</td><td>468</td><td>0.86</td><td>0.80</td><td>0.81</td><td>0.91</td><td>0.92</td></tr><tr><td>fisa</td><td>2</td><td>47</td><td>453</td><td>0.79</td><td>0.60</td><td>0.79</td><td>0.79</td><td>0.77</td></tr><tr><td>lmds</td><td>2</td><td>60</td><td>439</td><td>0.74</td><td>0.64</td><td>0.66</td><td>0.61</td><td>0.56</td></tr><tr><td>fisa_casp3</td><td>2</td><td>20</td><td>1672</td><td>0.74</td><td>0.58</td><td>0.72</td><td>0.68</td><td>0.70</td></tr><tr><td>moulder</td><td>19</td><td>151</td><td>169</td><td>0.95</td><td>0.93</td><td>0.95</td><td>0.95</td><td>0.96</td></tr><tr><td>rosetta</td><td>27</td><td>50</td><td>50</td><td>0.71</td><td>0.66</td><td>0.74</td><td>0.75</td><td>0.77</td></tr><tr><td>I-TASSER</td><td>31</td><td>229</td><td>217</td><td>0.79</td><td>0.71</td><td>0.77</td><td>0.80</td><td>0.80</td></tr><tr><td>Amber99</td><td>41</td><td>219</td><td>821</td><td>0.87</td><td>0.79</td><td>0.83</td><td>0.93</td><td>0.93</td></tr><tr><td>CASP5-8</td><td>89</td><td>14</td><td>7</td><td>0.82</td><td>0.75</td><td>0.84</td><td>0.83</td><td>0.84</td></tr><tr><td>Total</td><td>220</td><td>105</td><td>245</td><td>0.82</td><td>0.75</td><td>0.82</td><td>0.84</td><td>0.85</td></tr><tr><td>p-value</td><td></td><td></td><td></td><td>1.02E-04</td><td>7.70E-27</td><td>1.30E-03</td><td>2.03E-06</td><td></td></tr></table> |
2fefab9152f7d70d23f3441ceedebc9bc063b81233ca2ec98e9dc273b49e608c.png | simple | <table><tr><td>#</td><td>Size</td><td>GO-ID</td><td>GO-Term</td><td><i>p</i>-value</td><td>N%</td></tr><tr><td>1</td><td>17</td><td>GO:0030880</td><td>RNA polymerase complex</td><td>3.30986E-39</td><td>100.0 %</td></tr><tr><td>2</td><td>8</td><td>GO:0044428</td><td>Nuclear part</td><td>3.70274E-05</td><td>100.0 %</td></tr><tr><td>3</td><td>7</td><td>GO:0030126</td><td>COPI vesicle coat</td><td>1.37069E-21</td><td>100.0 %</td></tr><tr><td>4</td><td>14</td><td>GO:0044428</td><td>Nuclear part</td><td>7.23152E-10</td><td>100.0 %</td></tr><tr><td>5</td><td>27</td><td>GO:0005739</td><td>Mitochondrion</td><td>9.82318E-22</td><td>100.0 %</td></tr><tr><td>7</td><td>18</td><td>GO:0000502</td><td>Proteasome complex</td><td>1.76807E-40</td><td>100.0 %</td></tr><tr><td>8</td><td>12</td><td>GO:0005634</td><td>Nucleus</td><td>3.90352E-06</td><td>100.0 %</td></tr><tr><td>9</td><td>7</td><td>GO:0030008</td><td>TRAPP complex</td><td>1.02802E-20</td><td>100.0 %</td></tr><tr><td>11</td><td>21</td><td>GO:0005634</td><td>Nucleus</td><td>2.04087E-10</td><td>100.0 %</td></tr><tr><td>12</td><td>10</td><td>GO:0044425</td><td>Membrane part</td><td>4.18992E-10</td><td>100.0 %</td></tr><tr><td>13</td><td>5</td><td>GO:0035097</td><td>Histone methyl–transferase complex</td><td>1.31389E-11</td><td>100.0 %</td></tr><tr><td>14</td><td>5</td><td>GO:0030126</td><td>COPI vesicle coat</td><td>1.18247E-14</td><td>100.0 %</td></tr><tr><td>15</td><td>9</td><td>GO:0016585</td><td>Chromatin remodeling complex</td><td>2.37606E-17</td><td>100.0 %</td></tr><tr><td>16</td><td>15</td><td>GO:0000502</td><td>Proteasome complex</td><td>2.20275E-33</td><td>100.0 %</td></tr><tr><td>17</td><td>13</td><td>GO:0043189</td><td>Histone acetyl–transferase complex</td><td>1.21627E-39</td><td>100.0 %</td></tr><tr><td>20</td><td>12</td><td>GO:0016514</td><td>SWI/SNF complex</td><td>4.98150E-37</td><td>100.0 %</td></tr><tr><td>21</td><td>60</td><td>GO:0005634</td><td>Nucleus</td><td>2.15384E-32</td><td>100.0 %</td></tr><tr><td>22</td><td>81</td><td>GO:0043227</td><td>Membrane-bound organelle</td><td>4.87516E-23</td><td>100.0 %</td></tr><tr><td>24</td><td>63</td><td>GO:0044464</td><td>Cell part</td><td>3.42642E-05</td><td>98.4 %</td></tr><tr><td>23</td><td>4</td><td>GO:0031011</td><td>INO80 complex</td><td>4.13601E-07</td><td>75.0 %</td></tr></table> |
754f539ca45e571e2fc3aa26360e07909c407541a5e8c30e6057674842cfa07a.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">ER-β</td><td colspan="3">PR</td></tr><tr><td>(+)</td><td>(-)</td><td><i>P</i></td><td>(+)</td><td>(-)</td><td><i>P</i></td></tr><tr><td>Age (years)</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td> ≥50</td><td>16</td><td>22</td><td>0.706</td><td>16</td><td>22</td><td>0.107</td></tr><tr><td> <50</td><td>52</td><td>62</td><td></td><td>32</td><td>82</td><td></td></tr><tr><td>Tumor size (cm)</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td> ≥5</td><td>48</td><td>58</td><td>0.837</td><td>38</td><td>68</td><td>0.086</td></tr><tr><td> <5</td><td>20</td><td>26</td><td></td><td>10</td><td>36</td><td></td></tr><tr><td>Laterality</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td> Bilateral</td><td>50</td><td>57</td><td>0.446</td><td>41</td><td>67</td><td>0.008</td></tr><tr><td> UnilateraI</td><td>18</td><td>27</td><td></td><td>7</td><td>37</td><td></td></tr><tr><td>Peritoneal metastasis</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td> No</td><td>57</td><td>44</td><td><0.001</td><td>40</td><td>61</td><td>0.003</td></tr><tr><td> Yes</td><td>11</td><td>40</td><td></td><td>8</td><td>43</td><td></td></tr><tr><td>Signet-ring cells</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td> Positive</td><td>26</td><td>46</td><td>0.042</td><td>21</td><td>51</td><td>0.544</td></tr><tr><td> Negative</td><td>42</td><td>38</td><td></td><td>27</td><td>53</td><td></td></tr><tr><td>Ascites</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td> No</td><td>30</td><td>23</td><td>0.031</td><td>19</td><td>34</td><td>0.407</td></tr><tr><td> Yes</td><td>38</td><td>61</td><td></td><td>29</td><td>70</td><td></td></tr><tr><td>Ovarian metastases</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td> Synchronous</td><td>41</td><td>52</td><td>0.839</td><td>28</td><td>65</td><td>0.624</td></tr><tr><td> Metachronous</td><td>27</td><td>32</td><td></td><td>20</td><td>39</td><td></td></tr><tr><td>Serum CEA (ng/mL)</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td> Normal</td><td>58</td><td>61</td><td>0.059</td><td>38</td><td>81</td><td>0.859</td></tr><tr><td> >5</td><td>10</td><td>23</td><td></td><td>10</td><td>23</td><td></td></tr><tr><td>Serum CA19-9 (U/mL)</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td> Normal</td><td>43</td><td>53</td><td>0.986</td><td>31</td><td>65</td><td>0.805</td></tr><tr><td> >39</td><td>25</td><td>31</td><td></td><td>17</td><td>39</td><td></td></tr><tr><td>Serum CA125 (U/mL)</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td> Normal</td><td>27</td><td>25</td><td>0.199</td><td>14</td><td>38</td><td>0.373</td></tr><tr><td> >35</td><td>41</td><td>59</td><td></td><td>34</td><td>66</td><td></td></tr></table> |
f61770437016849dc0c648e2db6d362731167b180ec03501736a77dd9d7a38ed.png | complex | <table><tr><td rowspan="2">Parameters</td><td colspan="2">Present study</td><td rowspan="2">Verkerk et al. [16]</td><td rowspan="2">Tüysüz et al. [15]</td></tr><tr><td>Ind IV:3</td><td>Ind IV:4</td></tr><tr><td>Gender</td><td>M</td><td>M</td><td>3F/2M</td><td>3F/1M</td></tr><tr><td>Age at last examination (y.)</td><td>14</td><td>12</td><td>1.5/21/22/23/24</td><td>2.5/10.5/11/17</td></tr><tr><td>Head circumference</td><td>−2SD</td><td>−2SD</td><td>−1 to −2.5 SD</td><td>−2 to −4 SD</td></tr><tr><td>Height (cm)</td><td>157</td><td>137</td><td>NA</td><td>NA</td></tr><tr><td>Intellectual disability</td><td>Severe</td><td>Severe</td><td>Severe in 5/5</td><td>Severe in 3/4</td></tr><tr><td>Seizures</td><td>+</td><td>-</td><td>-</td><td>+</td></tr><tr><td>Shy character</td><td>-</td><td>-</td><td>+</td><td>+</td></tr><tr><td>Aggressive behavior</td><td>+</td><td>+</td><td>-</td><td>-</td></tr><tr><td>Stereotype laughter</td><td>-</td><td>-</td><td>+</td><td>+</td></tr><tr><td>Severe speech disorder</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Infantile hypotonia</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Hypertonia</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Hyperreflexia</td><td>+</td><td>+</td><td>NA</td><td>NA</td></tr><tr><td>Babinski sign</td><td>+</td><td>+</td><td>+</td><td>NA</td></tr><tr><td>Spasticity</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Club feet</td><td>-</td><td>-</td><td>+</td><td>+</td></tr><tr><td>Independent walking (y.)</td><td>2</td><td>4</td><td>-</td><td>+/−</td></tr><tr><td>Ambulation</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>Craniofacial features</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Facial hypotonia</td><td>-</td><td>-</td><td>NA</td><td>+</td></tr><tr><td>Bitemporal narrowing</td><td>-</td><td>-</td><td>NA</td><td>+</td></tr><tr><td>Broad nasal bridge</td><td>-</td><td>-</td><td>NA</td><td>+</td></tr><tr><td>Bulbous nose</td><td>-</td><td>+</td><td>NA</td><td>+</td></tr><tr><td>Short philtrum</td><td>+</td><td>+</td><td>NA</td><td>+</td></tr><tr><td><i>Brain MR imaging</i></td><td>Yes</td><td>No</td><td>3/5</td><td>4/4</td></tr><tr><td>Widened lateral ventricles</td><td>+</td><td></td><td>+</td><td>+</td></tr><tr><td>Thin splenium of the CC</td><td>+</td><td></td><td>+</td><td>+</td></tr><tr><td>Cerebellar hypoplasia/atrophy</td><td>+</td><td></td><td>2/3</td><td>-</td></tr></table> |
2a12d0ca480fc6fa2cfba15fdfd8982dac222b8cf0ecc4b6ed444dc24ee61aa7.png | simple | <table><tr><td>Characteristic</td><td>Value</td><td>%</td></tr><tr><td>Age (years)</td><td></td><td></td></tr><tr><td>Range</td><td>30–87</td><td></td></tr><tr><td>Mean ± SD (range)</td><td>60.3±15.9</td><td></td></tr><tr><td>Gender, n</td><td></td><td></td></tr><tr><td>Male</td><td>62</td><td>51.2</td></tr><tr><td>Female</td><td>59</td><td>48.8</td></tr><tr><td>Diagnosis method, n</td><td></td><td></td></tr><tr><td>Histological diagnosis</td><td>78</td><td>64.5</td></tr><tr><td>Imaging and medical history diagnosis</td><td>43</td><td>35.5</td></tr><tr><td>Tumor type, n</td><td></td><td></td></tr><tr><td>Colorectal cancer</td><td>52</td><td>43.0</td></tr><tr><td>Lung cancer</td><td>19</td><td>15.7</td></tr><tr><td>Breast cancer</td><td>14</td><td>11.6</td></tr><tr><td>Renal cancer</td><td>7</td><td>5.8</td></tr><tr><td>Gastric cancer</td><td>5</td><td>4.1</td></tr><tr><td>Other</td><td>24</td><td>19.8</td></tr><tr><td>Tumor loading, n</td><td></td><td></td></tr><tr><td>With</td><td>72</td><td>59.5</td></tr><tr><td>Without</td><td>49</td><td>40.5</td></tr><tr><td>Adjuvant radiotherapy and/or chemotherapy, n</td><td></td><td></td></tr><tr><td>With</td><td>71</td><td>58.7</td></tr><tr><td>Without</td><td>50</td><td>41.3</td></tr></table> |
027fe55be37f5b45a9d9694e9dfcec248db0f73d1aa948aca70acc54767ed126.png | complex | <table><tr><td>Investigator</td><td>Patient</td><td>Total fibres</td><td>% COX positive</td><td>% Intermediate positive</td><td>% Intermediate negative</td><td>% COX negative</td></tr><tr><td rowspan="8">1</td><td>DYSF 1</td><td>1491</td><td>98.2%</td><td>1.8%</td><td>0.0%</td><td>0.0%</td></tr><tr><td>DYSF 2</td><td>577</td><td>75.4%</td><td>18.4%</td><td>6.1%</td><td>0.1%</td></tr><tr><td>DYSF 3</td><td>963</td><td>65.5%</td><td>21.9%</td><td>11.9%</td><td>0.6%</td></tr><tr><td>DYSF 4</td><td>1774</td><td>97.7%</td><td>5.0%</td><td>0.1%</td><td>0.0%</td></tr><tr><td>DYSF 5</td><td>397</td><td>86.9%</td><td>12.8%</td><td>0.3%</td><td>0.0%</td></tr><tr><td>DYSF 6</td><td>563</td><td>80.8%</td><td>17.9%</td><td>0.9%</td><td>0.4%</td></tr><tr><td>DYSF 7</td><td>132</td><td>69.7%</td><td>30.3%</td><td>0.0%</td><td>0.0%</td></tr><tr><td>DYSF 8</td><td>453</td><td>92.5%</td><td>4.9%</td><td>2.0%</td><td>0.7%</td></tr><tr><td rowspan="8">2</td><td>DYSF 1</td><td>1357</td><td>83.6%</td><td>16.3%</td><td>0.07%</td><td>0.0%</td></tr><tr><td>DYSF 2</td><td>382</td><td>71.7%</td><td>26.9%</td><td>1.5%</td><td>0.0%</td></tr><tr><td>DYSF 3</td><td>328</td><td>65.9%</td><td>30.4%</td><td>3.7%</td><td>0.0%</td></tr><tr><td>DYSF 4</td><td>1131</td><td>97.1%</td><td>2.6%</td><td>0.2%</td><td>0.1%</td></tr><tr><td>DYSF 5</td><td>395</td><td>77.7%</td><td>22.0%</td><td>0.3%</td><td>0.0%</td></tr><tr><td>DYSF 6</td><td>726</td><td>70.4%</td><td>27.1%</td><td>1.9%</td><td>0.6%</td></tr><tr><td>DYSF 7</td><td>135</td><td>58.5%</td><td>31.1%</td><td>10.4%</td><td>0.0%</td></tr><tr><td>DYSF 8</td><td>463</td><td>78.2%</td><td>20.3%</td><td>1.2%</td><td>0.4%</td></tr></table> |
b568ef25b154685f9682b62cf39aabdc6b849d4e08f47fc25ab30013930588dc.png | simple | <table><tr><td>Metagenome source</td><td>Sample</td><td>Metagenome type</td><td>Categories observed<sup>N</sup></td><td>Shannon diversity Index (H’)</td><td>Evenness (E)</td></tr><tr><td>This study</td><td>Cow 2202<sup>C</sup></td><td>Virome</td><td>20</td><td>2.192</td><td>0.732</td></tr><tr><td> </td><td>Cow 657</td><td>Virome</td><td>21</td><td>2.162</td><td>0.710</td></tr><tr><td> </td><td>Cow 1995</td><td>Virome</td><td>22</td><td>2.299</td><td>0.744</td></tr><tr><td> </td><td>Cow 2028</td><td>Virome</td><td>20</td><td>2.052</td><td>0.685</td></tr><tr><td> </td><td>Cow 2042</td><td>Virome</td><td>17</td><td>2.011</td><td>0.710</td></tr><tr><td> </td><td>Cow 2165</td><td>Virome</td><td>16</td><td>1.911</td><td>0.689</td></tr><tr><td> </td><td>Cow 3060</td><td>Virome</td><td>16</td><td>2.150</td><td>0.775</td></tr><tr><td> </td><td>Cow 4570</td><td>Virome</td><td>15</td><td>2.023</td><td>0.747</td></tr><tr><td> </td><td>Cow 5679</td><td>Virome</td><td>18</td><td>2.184</td><td>0.756</td></tr><tr><td> </td><td>Cow 6833</td><td>Virome</td><td>19</td><td>2.125</td><td>0.722</td></tr><tr><td> </td><td>Cow 6857</td><td>Virome</td><td>18</td><td>2.142</td><td>0.741</td></tr><tr><td> </td><td>Cow 6870</td><td>Virome</td><td>16</td><td>1.756</td><td>0.633</td></tr><tr><td> </td><td>Cow 7939</td><td>Virome</td><td>21</td><td>2.200</td><td>0.722</td></tr><tr><td> </td><td>Average*</td><td>Virome</td><td>18.4</td><td>2.093</td><td>0.720</td></tr><tr><td>Other Studies</td><td>Cow 6993 [8]</td><td>Virome</td><td>36</td><td>2.425</td><td>0.677</td></tr><tr><td> </td><td>Cow 766 [8]</td><td>Virome</td><td>34</td><td>2.553</td><td>0.724</td></tr><tr><td> </td><td>Cow 7887 [8]</td><td>Virome</td><td>35</td><td>2.580</td><td>0.726</td></tr><tr><td> </td><td>Swine Faeces [18]<sup>+</sup></td><td>Virome</td><td>33</td><td>2.398</td><td>0.686</td></tr><tr><td> </td><td>Human Saliva [19]<sup>+</sup></td><td>Virome</td><td>36</td><td>2.221</td><td>0.620</td></tr><tr><td> </td><td>Pond [20]<sup>+</sup></td><td>Virome</td><td>31</td><td>2.537</td><td>0.739</td></tr><tr><td> </td><td>Cow 2202<sup>C</sup>[6]</td><td>Microbial</td><td>27</td><td>2.731</td><td>0.829</td></tr><tr><td> </td><td>Cow 3063<sup>C</sup>[6]</td><td>Microbial</td><td>30</td><td>2.794</td><td>0.822</td></tr><tr><td> </td><td>Cow 6803<sup>C</sup>[6]</td><td>Microbial</td><td>30</td><td>2.778</td><td>0.817</td></tr><tr><td> </td><td>Cow 6852<sup>C</sup>[6]</td><td>Microbial</td><td>29</td><td>2.809</td><td>0.834</td></tr><tr><td> </td><td>Cow 6859<sup>C</sup>[6]</td><td>Microbial</td><td>29</td><td>2.860</td><td>0.849</td></tr><tr><td> </td><td>Cow 6882<sup>C</sup>[6]</td><td>Microbial</td><td>24</td><td>2.752</td><td>0.866</td></tr><tr><td> </td><td>Cow 7920<sup>C</sup>[6]</td><td>Microbial</td><td>28</td><td>2.762</td><td>0.829</td></tr></table> |
c208ddb354482909cfadb9f6cdf9b046f88ab56744ea76356f525cbeb5b8b696.png | complex | <table><tr><td> </td><td colspan="4">Group 1</td><td colspan="2">Group 2</td><td colspan="2">Group 3</td></tr><tr><td> </td><td>Relapsing- remitting MS</td><td>Primary progressive MS</td><td>Secondary progressive MS</td><td>Healthy controls</td><td>Pediatric onset MS</td><td>Pediatric healthy controls</td><td>Pre- relapse patients</td><td>Relapse patients</td></tr><tr><td>N</td><td>20</td><td>13</td><td>12</td><td>48</td><td>12</td><td>10</td><td>18</td><td>11</td></tr><tr><td>Males N (%)</td><td>3 (15.0)</td><td>6 (46.2)</td><td>1 (8.3)</td><td>14 (29.2)</td><td>4 (33.3)</td><td>3 (30.0)</td><td>3 (16.7)</td><td>2 (18.2)</td></tr><tr><td>Age Mean (SD)</td><td>43.0 (8.9)</td><td>56.9 (7.7)</td><td>53.6 (12.5)</td><td>45.1 (13.1)</td><td>13.9 (2.3)</td><td>11.4 (3.3)</td><td>40.7 (11.3)</td><td>36.4 (10.9)</td></tr><tr><td>Hispanic N (%)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>1 (8.3)</td><td>1 (10.0)</td><td>1 (5.6)</td><td>0 (0)</td></tr><tr><td>White N (%)</td><td>18 (90.0)</td><td>13 (100)</td><td>12 (100)</td><td>44 (91.7)</td><td>10 (83.3)</td><td>8 (80.0)</td><td>17 (94.4)</td><td>9 (81.8)</td></tr><tr><td>BMI Mean (SD)</td><td>27.7 (5.0)</td><td>30.1 (5.4)</td><td>30.7 (7.9)</td><td>26.0 (6.2)</td><td>26.9 (9.2)</td><td>21.4 (3.7)</td><td>26.2 (4.4)</td><td>29.5 (6.3)</td></tr><tr><td>EDSS Median (Range)</td><td>2 (0–4.5)</td><td>6 (1.5-7)</td><td>5.0 (2.5-8.0)</td><td> </td><td>1.75 (0–2)</td><td> </td><td>1.75 (0–6)</td><td>2 (0–3.5)</td></tr><tr><td>Disease Duration Mean (SD)</td><td>11.3 (9.3)</td><td>14.5 (7.6)</td><td>19.9 (9.6)</td><td> </td><td>1.75 (2.1)</td><td> </td><td>8.1 (6.6)</td><td>8.2 (5.5)</td></tr><tr><td>Leptin (pg/ml) Mean (SD)</td><td>23,462.3 (27,708.9)</td><td>17,924.6 (14,009.8)</td><td>40,412.6 (27,951.8)</td><td>13,840.5 (18,447.6)</td><td>27,357.3 (20,207.4)</td><td>11,177.0 (11,484.7)</td><td>24,381.6 (20,350.1)</td><td>37,587.1 (26,465.4)</td></tr><tr><td>A-FABP (ng/ml) Mean (SD)</td><td>21.2 (14.6)</td><td>34.9 (18.9)</td><td>38.8 (15.5)</td><td>18.4 (18.8)</td><td>26.7 (18.0)</td><td>14.7 (7.6)</td><td>17.5 (10.5)</td><td>27.7 (13.1)</td></tr></table> |
4a7a5575f1752f0d63e7f3721da56b5b63bd49487e88e14a42bd284717fe2ef7.png | simple | <table><tr><td>Code</td><td>Test</td><td>Supported draft</td></tr><tr><td>INV_1_24</td><td>FISH/int</td><td>UMD (85%)</td></tr><tr><td>INV_1_53.3</td><td>FISH/int</td><td>UMD (94%)</td></tr><tr><td>INV_4_7.2</td><td>FISH/int</td><td>UMD (90%)</td></tr><tr><td>INV_7_103.2</td><td>FISH/int</td><td>UMD (96%)</td></tr><tr><td>INV_10_59.3</td><td>FISH/int</td><td>UMD (95%)</td></tr><tr><td>INV_14_32</td><td>FISH/int</td><td>UMD (73%)</td></tr><tr><td>INV_20_0</td><td>FISH/int</td><td>UMD (98%)</td></tr><tr><td>INV_23_0</td><td>FISH/met.</td><td>UMD</td></tr><tr><td>INV_26_18.8</td><td>FISH/int</td><td>UMD (75%)</td></tr><tr><td>INV_27_42.3</td><td>FISH/int</td><td>UMD (90%)</td></tr><tr><td>MDP_4_16.2</td><td>FISH/int</td><td>Btau (98%)</td></tr><tr><td>MDP_5_9.6</td><td>FISH/met.</td><td>UMD</td></tr><tr><td>MDP_7_7.6</td><td>PCR</td><td>UMD</td></tr><tr><td>MDP_7_43.1</td><td>PCR</td><td>-</td></tr><tr><td>MDP_28_0.7</td><td>PCR</td><td>UMD</td></tr><tr><td>DCM_2-11</td><td>FISH/met</td><td>UMD</td></tr><tr><td>DCM_3-13</td><td>FISH/met</td><td>Btau</td></tr><tr><td>DCM_3-2</td><td>FISH/met</td><td>UMD</td></tr><tr><td>DCM_3-22</td><td>FISH/met</td><td>UMD</td></tr><tr><td>DCM_7-X</td><td>FISH/met</td><td>UMD</td></tr><tr><td>DCM_10-1</td><td>FISH/met</td><td>UMD</td></tr><tr><td>DCM_10-4</td><td>FISH/met</td><td>UMD</td></tr><tr><td>DCM_15-X</td><td>FISH/met</td><td>UMD</td></tr><tr><td>DCM_27-21</td><td>FISH/met</td><td>Btau</td></tr></table> |
1210d5e5869a551e7a44c611a8c2022d4480327bedae7e2108a8b24fdb14602a.png | simple | <table><tr><td></td><td></td><td>Allpaths-LG/</td><td>Allpaths-LG/</td></tr><tr><td>Scaffold sequences</td><td>Allpaths-LG</td><td>Sspace/GapClose</td><td>Sspace/GapClose/Reapr</td></tr><tr><td>Number</td><td>57 815</td><td>16 090</td><td>13 206</td></tr><tr><td>Total size, without gaps, bp</td><td>469 049 393</td><td>565 959 143</td><td>476 867 120</td></tr><tr><td>Total size, with gaps, bp</td><td>614 626 609</td><td>586 542 612</td><td>503 314 177</td></tr><tr><td>Number > 10 Kbp</td><td>10 029</td><td>8602</td><td>8348</td></tr><tr><td>Number > 20 Kbp</td><td>6920</td><td>6791</td><td>6647</td></tr><tr><td>Number > 100 Kbp</td><td>1100</td><td>1709</td><td>1304</td></tr><tr><td>Number > 1 Mbp</td><td>2</td><td>0</td><td>0</td></tr><tr><td>Longest sequence, bp</td><td>1 844 569</td><td>979 053</td><td>558 523</td></tr><tr><td>Average size, bp</td><td>10 631</td><td>36 454</td><td>38 112</td></tr><tr><td>N50 length, bp</td><td>57 726</td><td>97 266</td><td>80 946</td></tr><tr><td>L50 count</td><td>2595</td><td>1792</td><td>1906</td></tr><tr><td>GC %</td><td>33.63</td><td>33.57</td><td>33.62</td></tr></table> |
2a9ea923d66daf7a6c18ed94c09841e8e9a1e07a1950ed934ed23bab7eb534b6.png | simple | <table><tr><td>Process Type</td><td>processes</td><td>instances</td><td>Time</td><td>Total ($)</td></tr><tr><td>Blast</td><td>21945</td><td>100</td><td>40 hours 0 mins</td><td>$ 3,680</td></tr><tr><td>Ortholog Estimation</td><td>281160</td><td>100</td><td>28 hours 21 mins</td><td>$ 2,622</td></tr></table> |
17c62f4dc82e17268fe2fef5fc2091beb1cec2a00e5815160adfeac6b5adac52.png | complex | <table><tr><td></td><td>Odds ratio</td><td>95% Confidence interval</td><td><i>P</i> value</td></tr><tr><td colspan="4">Predictors of AKI</td></tr><tr><td>Log angiopoietin-2</td><td>4.41</td><td>2.02–9.63</td><td><0.0001</td></tr><tr><td>Log osteoprotegerin</td><td>1.98</td><td>1.02–3.82</td><td>0.043</td></tr><tr><td>Age<sup>a</sup></td><td>1.07</td><td>1.04–1.10</td><td><0.0001</td></tr><tr><td colspan="4">Predictor of severe malaria</td></tr><tr><td>Log angiopoietin-2</td><td>5.35</td><td>2.01–14.25</td><td>0.001</td></tr><tr><td>Log osteoprotegerin</td><td>2.66</td><td>1.15–6.14</td><td>0.022</td></tr><tr><td>Log parasite count</td><td>1.47</td><td>1.15–1.89</td><td>0.002</td></tr></table> |
5edb160ecf0f7e083502f59dfe6efa37ae269216eeef924398c01d8c050a42ec.png | simple | <table><tr><td>Treatment</td><td>N</td><td>Median</td><td>IQR</td><td>RR</td><td>95% CI</td><td>z value</td><td>p value</td></tr><tr><td>No insecticide</td><td>1054</td><td>47.0</td><td>22.0 – 110.3</td><td>45.0</td><td>[23.1, 87.8]</td><td>11.168</td><td>NA</td></tr><tr><td>Transfluthrin coils</td><td>737</td><td>71.0</td><td>28.0 – 92.5</td><td>41.1</td><td>[33.6, 50.2]</td><td>-0.897</td><td>0.369</td></tr><tr><td>Metofluthrin coils</td><td>877</td><td>67.0</td><td>39.8 – 103.0</td><td>51.1</td><td>[42.0, 62.3]</td><td>1.273</td><td>0.203</td></tr><tr><td>DDT 2gm<sup>2</sup></td><td>821</td><td>42.5</td><td>37.5 – 72.3</td><td>44.9</td><td>[36.8, 54.8]</td><td>-0.014</td><td>0.989</td></tr></table> |
72ffd32955bd080bdcb669989612c9193c57af1e5bd482f300495c0df4b26fa9.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Any enteric pathogen</td><td colspan="2"><i>Campylobacter</i> spp.</td><td colspan="2"><i>Giardia</i> spp.</td><td colspan="2">Pathogenic <i>Escherichia coli</i>†</td></tr><tr><td>PR (95% CI)</td><td><i>P</i> value</td><td>PR (95% CI)</td><td><i>P</i> value</td><td>PR (95% CI)</td><td><i>P</i> value</td><td>PR (95% CI)</td><td><i>P</i> value</td></tr><tr><td>Neighborhood: Old Town</td><td>1.32 (0.50, 3.49)</td><td>0.57</td><td>1.91 (0.71, 5.14)</td><td>0.18</td><td>1.56 (0.48, 6.46)</td><td>0.45</td><td>0.73 (0.14, 3.78)</td><td>0.64</td></tr><tr><td>Poor hygiene</td><td>1.97 (0.75, 5.62)</td><td>0.17</td><td>3.42 (1.30, 12.3)</td><td>0.02</td><td>1.69, (0.53, 7.27)</td><td>0.39</td><td>0.55 (0.07, 3.37)</td><td>0.34</td></tr><tr><td>Neighborhood: Old Town</td><td>1.37 (0.51, 3.72)</td><td>0.53</td><td>2.15 (0.80, 5.97)</td><td>0.13</td><td>1.60 (0.49, 6.78)</td><td>0.47</td><td>0.70 (0.11, 5.02)</td><td>0.56</td></tr><tr><td>Poor hygiene</td><td>2.01 (0.76, 5.77)</td><td>0.16</td><td>3.61 (1.37, 11.4)†</td><td>0.01</td><td>1.72 (0.54, 7.57)</td><td>0.54</td><td>0.53 (0.09, 4.10)</td><td>0.31</td></tr></table> |
cffe1cc850c2df600000995df6fbcaa58a4b1e13391b8ba60123565267ebe373.png | simple | <table><tr><td>Pathway</td><td>TF</td><td>miRNA</td></tr><tr><td>Activin</td><td>TP53</td><td>miR-143</td></tr><tr><td>AKT</td><td>MYC</td><td>miR-145</td></tr><tr><td>ALK</td><td>GATA4</td><td>miR-187</td></tr><tr><td>ATM</td><td>SMAD1</td><td>miR-296</td></tr><tr><td>BMI1</td><td>ESRRB</td><td>miR-301</td></tr><tr><td>BMP</td><td>SOX2</td><td>miR-21</td></tr><tr><td>Cell cycle</td><td>NANOG</td><td>let-7a</td></tr><tr><td>EGF/EGFR</td><td>KLF4</td><td>miR-371</td></tr><tr><td>ERBB2</td><td>MYB</td><td>miR-372</td></tr><tr><td>ERK</td><td>MYCN</td><td>miR-373</td></tr><tr><td>FGF</td><td>ZFX</td><td>miR-367</td></tr><tr><td>Glycolysis</td><td>STAT3</td><td>miR-302a</td></tr><tr><td>Hippo</td><td>ZIC3</td><td>miR-302a*</td></tr><tr><td>IGF</td><td>ZFP42</td><td>miR-302b</td></tr><tr><td>JAK/STAT</td><td>SALL4</td><td>miR-302b*</td></tr><tr><td>c-KIT</td><td>REST</td><td>miR-302c</td></tr><tr><td>Lefty</td><td>TCF3</td><td>miR-302c*</td></tr><tr><td>LIF</td><td>HOXB1</td><td>miR-302d</td></tr><tr><td>MAPK</td><td>HAND1</td><td>miR-200c</td></tr><tr><td>MEK/ERK</td><td>POU5F1</td><td>miR-222</td></tr><tr><td>NF-κB</td><td>SRY</td><td></td></tr><tr><td>NHEJ/HR <sup>a</sup></td><td>TBX5</td><td></td></tr><tr><td>Nodal</td><td>E2F4</td><td></td></tr><tr><td>Notch</td><td>GATA6</td><td></td></tr><tr><td>p53</td><td>PAX6</td><td></td></tr><tr><td>PRC2</td><td>TCF4</td><td></td></tr><tr><td>PDGF</td><td>FOXD3</td><td></td></tr><tr><td>PI3K</td><td>CNOT3</td><td></td></tr><tr><td>PTEN</td><td>ZEB2</td><td></td></tr><tr><td>RAS</td><td>ESX1L</td><td></td></tr><tr><td>RTK</td><td></td><td></td></tr><tr><td>Hedgehog (SHH)</td><td></td><td></td></tr><tr><td>Smad</td><td></td><td></td></tr><tr><td>Stat3</td><td></td><td></td></tr><tr><td>Telomerase</td><td></td><td></td></tr><tr><td>TGFβ</td><td></td><td></td></tr><tr><td>VEGF</td><td></td><td></td></tr><tr><td>WNT</td><td></td><td></td></tr></table> |
1a5d6246c41a28bf747f5774fabd6d04440284310b3c81d90635e22cc8934db8.png | simple | <table><tr><td>Variable</td><td>Dextrose75 g</td><td>Dextrose150 g</td><td>Lipid33 g</td><td>Lipid66 g</td></tr><tr><td>Kilocalories</td><td>2023 ± 237</td><td>2354 ± 242</td><td>1983 ± 206</td><td>1789 ± 181</td></tr><tr><td>Protein (g)</td><td>92 ± 11</td><td>102 ± 9</td><td>95 ± 13</td><td>88 ± 16</td></tr><tr><td>Carbohydrate (g)</td><td>261 ± 39</td><td>315 ± 41</td><td>248 ± 31</td><td>247 ± 33</td></tr><tr><td>Fat (g)</td><td>72 ± 11</td><td>81 ± 12</td><td>72 ± 13</td><td>57 ± 9</td></tr><tr><td>Vitamin C (mg)</td><td>64 ± 26</td><td>47 ± 11</td><td>40 ± 7</td><td>51 ± 13</td></tr><tr><td>Vitamin E (mg)</td><td>4 ± 2</td><td>4 ± 1</td><td>3 ± 1</td><td>3 ± 1</td></tr><tr><td>Vitamin A (RE)</td><td>267 ± 82</td><td>374 ± 110</td><td>228 ± 113</td><td>236 ± 102</td></tr></table> |
406632cca340e9288ce0f546c0d09ea97e6e3df0fcdaf6344d4f3a2c179d6075.png | complex | <table><tr><td rowspan="2">Parameter</td><td rowspan="2">Shams</td><td colspan="2">Exposure to AO nanowhiskers for:</td></tr><tr><td>2 wks</td><td>4 wks</td></tr><tr><td>Total cells/mouse, n x 10<sup>3</sup></td><td>74.0 ± 7.9</td><td>171.6 ± 19.7 **</td><td>440.3 ± 33.6 ***</td></tr><tr><td>Total protein, μg/mL</td><td>107.7 ± 4.7</td><td>108.0 ± 1.5</td><td>101.2 ± 2.7</td></tr><tr><td>LDH activity, U/L</td><td>180 ± 18</td><td>146 ± 17</td><td>191 ± 10</td></tr></table> |
9d475d7c44f58bc41576169965a0c5ff5c1cd9e9fc49f68a24c154bd2b8be5f5.png | complex | <table><tr><td rowspan="2">Variables</td><td colspan="2">Cases</td><td colspan="2">Controls</td><td rowspan="2">P value</td></tr><tr><td>N = 357</td><td>%</td><td>N = 1,428</td><td>%</td></tr><tr><td>Age at DM</td><td colspan="4"> </td><td>0.483</td></tr><tr><td>30-60</td><td>69</td><td>15.90</td><td>300</td><td>17.28</td><td rowspan="2"> </td></tr><tr><td>≥60</td><td>288</td><td>66.36</td><td>1,128</td><td>64.98</td></tr><tr><td>Sex</td><td colspan="4"> </td><td>1.000</td></tr><tr><td>Male</td><td>215</td><td>49.54</td><td>568</td><td>32.72</td><td rowspan="2"> </td></tr><tr><td>Female</td><td>142</td><td>32.72</td><td>860</td><td>49.54</td></tr><tr><td>Peptic ulcer history</td><td>172</td><td>39.63</td><td>334</td><td>19.24</td><td><0.001</td></tr><tr><td>Ulcer bleeding history</td><td>61</td><td>14.06</td><td>156</td><td>8.99</td><td><0.001</td></tr><tr><td>HP eradication rate</td><td>33</td><td>7.60</td><td>139</td><td>8.01</td><td>0.779</td></tr><tr><td>Comorbidities</td><td colspan="5"> </td></tr><tr><td>CAD</td><td>120</td><td>27.65</td><td>603</td><td>34.74</td><td>0.003</td></tr><tr><td>CVD</td><td>84</td><td>19.35</td><td>466</td><td>26.84</td><td><0.001</td></tr><tr><td>CLD</td><td>78</td><td>17.97</td><td>337</td><td>19.41</td><td>0.484</td></tr><tr><td>COPD</td><td>98</td><td>22.58</td><td>465</td><td>26.79</td><td>0.063</td></tr><tr><td>CKD</td><td>77</td><td>17.74</td><td>431</td><td>24.83</td><td>0.001</td></tr><tr><td>GERD or EE</td><td>21</td><td>4.84</td><td>91</td><td>5.24</td><td>0.733</td></tr><tr><td>Medications</td><td colspan="5"> </td></tr><tr><td>Pioglitazone</td><td>25</td><td>5.76</td><td>154</td><td>8.87</td><td>0.033</td></tr><tr><td>Rosiglitazone</td><td>34</td><td>7.83</td><td>211</td><td>12.15</td><td>0.010</td></tr><tr><td>Metformin</td><td>236</td><td>54.38</td><td>990</td><td>57.03</td><td>0.241</td></tr><tr><td>Sulfonylurea</td><td>256</td><td>58.99</td><td>1,022</td><td>58.87</td><td>0.958</td></tr><tr><td>Glucosidase inhibitors</td><td>36</td><td>8.29</td><td>293</td><td>16.88</td><td><0.001</td></tr><tr><td>Meglitinides (Glinides)</td><td>35</td><td>8.06</td><td>241</td><td>13.88</td><td><0.001</td></tr><tr><td>DPP-4 inhibitors</td><td>1</td><td>0.23</td><td>85</td><td>4.90</td><td><0.001</td></tr><tr><td>Insulin</td><td>37</td><td>8.53</td><td>265</td><td>15.26</td><td><0.001</td></tr><tr><td>Statins</td><td>86</td><td>19.82</td><td>531</td><td>30.59</td><td><0.001</td></tr><tr><td>ARBs</td><td>88</td><td>20.28</td><td>534</td><td>30.76</td><td><0.001</td></tr><tr><td>ACE inhibitors</td><td>126</td><td>29.03</td><td>560</td><td>32.26</td><td>0.173</td></tr><tr><td>Aspirin</td><td>118</td><td>27.19</td><td>610</td><td>35.14</td><td><0.001</td></tr><tr><td>COX-2 inhibitors</td><td>27</td><td>6.22</td><td>189</td><td>10.89</td><td>0.003</td></tr><tr><td>NSAIDs</td><td>74</td><td>17.05</td><td>432</td><td>24.88</td><td><0.001</td></tr></table> |
a3af96cadc1036c5101ee8a450aefd142a40593c93ffc0a8d7a54aa32af807d8.png | complex | <table><tr><td>Gram</td><td>Bacterial strain</td><td colspan="5">Concentration of SS-capped AgNPs (mM)</td><td>MIC (mM)</td></tr><tr><td> </td><td> </td><td>0.001</td><td>0.004</td><td>0.008</td><td>0.017</td><td>0.034</td><td> </td></tr><tr><td>+</td><td>MRSA</td><td>T</td><td>T/C</td><td>C</td><td>C</td><td>C</td><td>0.008</td></tr><tr><td>+</td><td><i>S. aureus</i></td><td>T</td><td>T/C</td><td>C</td><td>C</td><td>C</td><td>0.008</td></tr><tr><td>+</td><td><i>B. subtilis</i></td><td>T</td><td>T/C</td><td>C</td><td>C</td><td>C</td><td>0.008</td></tr><tr><td>−</td><td><i>P. aeruginosa</i></td><td>T</td><td>C</td><td>C</td><td>C</td><td>C</td><td>0.004</td></tr><tr><td>−</td><td><i>A. baumannii</i></td><td>C</td><td>C</td><td>C</td><td>C</td><td>C</td><td>0.001</td></tr><tr><td>−</td><td><i>E. coli</i></td><td>T</td><td>C</td><td>C</td><td>C</td><td>C</td><td>0.004</td></tr></table> |
776e7ec3a076a5406fe18663991eb3a94ab5c591da9b2aa0ff67c909b2ee9c10.png | complex | <table><tr><td>ACE genotype</td><td colspan="2">II</td><td colspan="2">D carriers</td></tr><tr><td>Percent body fat category</td><td>Normal fat(n = 30)</td><td>Overfat(n = 15)</td><td>Normal fat(n = 62)</td><td>Overfat(n = 45)</td></tr><tr><td>SBP (mmHg)</td><td>103.2 (1.3)*</td><td>105.7 (1.9)</td><td>102.6 (0.9)#</td><td>108.1 (1.1)*#</td></tr><tr><td>DBP (mmHg)</td><td>68.6 (1.1)</td><td>70.2 (1.6)</td><td>69.5 (0.8)</td><td>71.4 (1.0)</td></tr></table> |
9b854aff9d81ee45dcb53625cab4c511db5ff782adb1ae0f964ad460dccafa15.png | complex | <table><tr><td></td><td>TCPC (n = 6)</td><td>TCPC + AVR (n = 4)</td></tr><tr><td colspan="3">Morphology of AV valve</td></tr><tr><td> SAVV (morphologically tricuspid valve)</td><td>5 (83 %)</td><td>0</td></tr><tr><td> CAAV</td><td>1 (17 %) early death</td><td>4 (100 %)</td></tr><tr><td colspan="3">Degree of AV valve regurgitation</td></tr><tr><td> Slight</td><td>3 (50 %)</td><td>0</td></tr><tr><td> Mild</td><td>3 (50 %)</td><td>0</td></tr><tr><td> Moderate</td><td>0</td><td>2 (50 %)</td></tr><tr><td> Severe</td><td>0</td><td>2 (50 %)</td></tr><tr><td>Early mortality</td><td>1</td><td>0</td></tr></table> |
2481b02a8aef0eae67a907b2dbd10e9689beefc7d35c161f62a1c6e859d7d951.png | simple | <table><tr><td>Patient</td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td>Age at onset (y)</td><td>6</td><td>1</td><td>0.8</td><td>2</td></tr><tr><td>Age at diagnosis* (y)</td><td>10</td><td>6</td><td>11</td><td>5</td></tr><tr><td>Present age (y)</td><td>13</td><td>8</td><td>15</td><td>Died at 8 Y</td></tr><tr><td>Family history</td><td>+</td><td>+</td><td>-</td><td>-</td></tr><tr><td>First symptom</td><td>Septicemia</td><td>Otitis media</td><td>Otitis media</td><td>Otitis media</td></tr><tr><td>Otitis media</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Sinusitis</td><td>+</td><td>-</td><td>+</td><td>-</td></tr><tr><td>Pneumonia</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Bronchiectasis</td><td>+</td><td>-</td><td>+</td><td>-</td></tr><tr><td>Arthritis</td><td>+</td><td>-</td><td>-</td><td>+</td></tr><tr><td>Skin infection</td><td>+</td><td>+</td><td>-</td><td>-</td></tr><tr><td>Septicemia</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Meningitis/encephalitis</td><td>+</td><td>-</td><td>+</td><td>-</td></tr><tr><td>Recurrent diarrhea</td><td>-</td><td>-</td><td>-</td><td>+</td></tr><tr><td>Tonsils</td><td>Absent</td><td>Hypoplastic</td><td>Absent</td><td>Hypoplastic</td></tr><tr><td>Duration of IVIG treatment (m)</td><td>25</td><td>17</td><td>33</td><td>12</td></tr></table> |
675d2091e54e8c98bed94062018d9e4ac5f153254633539bf93195f05905c4a5.png | simple | <table><tr><td>Gene Set</td><td>Number of Genes</td><td>Categorized Genes</td><td><i>p</i>-Value</td></tr><tr><td>Galactose metabolism</td><td>16</td><td>Gck</td><td><0.0001</td></tr><tr><td>Cysteine metabolism</td><td>16</td><td>Sult1c2</td><td>0.003</td></tr><tr><td>Aminoacyl-tRNA biosynthesis</td><td>16</td><td>Vars2</td><td>0.009</td></tr><tr><td>Wnt signaling pathway</td><td>112</td><td>Sox17Dkk2 <sup>*</sup></td><td>0.014</td></tr><tr><td>Taste transduction</td><td>29</td><td>Gnat3 <sup>*</sup>Tas2r114</td><td>0.046</td></tr><tr><td>C21-Steroid hormone metabolism</td><td>10</td><td>Cyp21a1</td><td>0.1250</td></tr><tr><td>Chondroitin sulfate biosynthesis</td><td>14</td><td>B3gat2Chst12</td><td>0.1260</td></tr><tr><td>Antigen processing and presentation</td><td>58</td><td>RT1-Aw2</td><td>0.163</td></tr></table> |
4cf7fe0232d3be583721f6bf38b3ef4b1db3479a431c367cfa4a1b10b5511c83.png | simple | <table><tr><td>Primer</td><td>Forward</td><td>Reverse</td></tr><tr><td>IFN-γ</td><td>GGTCAACAACCCACAGGTCC</td><td>CGACTCCTTTTCCGCTTCC</td></tr><tr><td>IL-4</td><td>TCTCGAATGTACCAGGAGCCATATC</td><td>AGCACCTTGGAAGCCCTACAGA</td></tr><tr><td>IL-10</td><td>GCTCCTAGAGCTGCGGACT</td><td>TGTTGTCCAGCTGGTCCTTT</td></tr><tr><td>IL-17A</td><td>AGGACGCGCAAACATGAGTC</td><td>TTGGACACGCTGAGCTTTGAG</td></tr><tr><td>TGF-β</td><td>CTGGATACCAACTACTGCTTCAG</td><td>TTGGTTGTAGAGGGCAAGGACCT</td></tr><tr><td>Foxp3</td><td>ACACCCAGGAAAGACAGCAAC</td><td>CTCGAAGACCTTCTCACAACCAG</td></tr><tr><td>GAPDH</td><td>CAACTTTGGCATTGTGGAAGG</td><td>ACACATTGGGGGTAGGAACAC</td></tr></table> |
7f0a137f90e8c490a9ae37b7f08fb8e43d42235484bf1d36d3053427c2b99d84.png | simple | <table><tr><td>Aspects</td><td>Score/question</td></tr><tr><td>1. Risk factors associated with obstetric fistula</td><td>1</td></tr><tr><td> - Early pregnancy</td><td>0.125</td></tr><tr><td> - Home delivery</td><td>0.125</td></tr><tr><td> - Female Genital Mutilation</td><td>0.125</td></tr><tr><td> - Evil spirits</td><td>0.125</td></tr><tr><td> - Breach of a prohibited act</td><td>0.125</td></tr><tr><td> - Prolonged labour</td><td>0.125</td></tr><tr><td> - Bad luck</td><td>0.125</td></tr><tr><td> - Malnutrition of the mother</td><td>0.125</td></tr><tr><td>2. Symptoms of obstetric fistula</td><td>1</td></tr><tr><td> - Urinary incontinence</td><td>0.2</td></tr><tr><td> - Faecal incontinence</td><td>0.2</td></tr><tr><td> - Continuous sleeping</td><td>0.2</td></tr><tr><td> - Stomach ache</td><td>0.2</td></tr><tr><td> - Vulva irritation</td><td>0.2</td></tr><tr><td>3. Duration of normal labour</td><td>1</td></tr><tr><td>4. Source of emergency obstetric care</td><td>1</td></tr><tr><td>Total</td><td>4</td></tr></table> |
a712e534ee76d10a4bda9a440eb79816f343ef7240635a76838ee3557ab33569.png | simple | <table><tr><td>Standard Deviation (change)</td><td>Treatment Change</td><td>N per group</td><td>N total</td></tr><tr><td>18</td><td>20</td><td>14</td><td>28</td></tr><tr><td></td><td>28</td><td>8</td><td>16</td></tr><tr><td></td><td>30</td><td>7</td><td>14</td></tr><tr><td>20</td><td>20</td><td>17</td><td>34</td></tr><tr><td></td><td>28</td><td>9</td><td>18</td></tr><tr><td></td><td>30</td><td>8</td><td>16</td></tr><tr><td>22</td><td>20</td><td>20</td><td>40</td></tr><tr><td></td><td>28</td><td>11</td><td>22</td></tr><tr><td></td><td>30</td><td>10</td><td>20</td></tr><tr><td>25</td><td>20</td><td>26</td><td>52</td></tr><tr><td></td><td>28</td><td>14</td><td>28</td></tr><tr><td></td><td>30</td><td>12</td><td>24</td></tr></table> |
7921fa15f991ea7d8b11237280dd485db9764a7b9c6d18a0a2f255b1dd3db29a.png | complex | <table><tr><td rowspan="2" colspan="2"><i>Patients’ characteristics</i></td><td>ADC</td><td>NAET</td><td>Whole sample</td><td rowspan="2">Chi square (<i>p</i>-value)</td></tr><tr><td>Number (%)</td><td>Number (%)</td><td>Number (%)</td></tr><tr><td rowspan="3"><i>Industrial sector</i></td><td><i>Wood</i></td><td>16 (50)</td><td>5 (24)</td><td>21 (40)</td><td rowspan="3">14.60 (0.001)</td></tr><tr><td><i>Leather</i></td><td>11 (34)</td><td>2 (10)</td><td>13 (25)</td></tr><tr><td><i>Other</i></td><td>5 (16)</td><td>14 (67)</td><td>19 (36)</td></tr><tr><td rowspan="3"><i>Age (years)</i></td><td><i>≤59</i></td><td>8 (25)</td><td>10 (48)</td><td>18 (34)</td><td rowspan="3">4.17 (0.125)</td></tr><tr><td><i>60–74</i></td><td>8 (25)</td><td>6 (29)</td><td>14 (26)</td></tr><tr><td>>74</td><td>16 (50)</td><td>5 (23)</td><td>21 (40)</td></tr><tr><td rowspan="3"><i>Smoking (pack-years)</i></td><td><i>0</i></td><td>17 (53)</td><td>14 (67)</td><td>31 (58)</td><td rowspan="3">2.67 (0.263)</td></tr><tr><td><i>≤18</i></td><td>6 (19)</td><td>5 (24)</td><td>11 (21)</td></tr><tr><td><i>>18</i></td><td>9 (29)</td><td>2 (9)</td><td>11 (21)</td></tr><tr><td rowspan="2"><i>Sex</i></td><td><i>M</i></td><td>26 (81)</td><td>14 (67)</td><td>40 (75)</td><td rowspan="2">1.46 (0.227)</td></tr><tr><td><i>W</i></td><td>6 (19)</td><td>7 (33)</td><td>13 (25)</td></tr><tr><td rowspan="2"><i>Chronic Sinusitis</i></td><td><i>Yes</i></td><td>6 (19)</td><td>4 (19)</td><td>10 (19)</td><td rowspan="2">0.001 (0.978)</td></tr><tr><td><i>No</i></td><td>26 (81)</td><td>17 (81)</td><td>43 (81)</td></tr><tr><td rowspan="2"><i>Allergies</i></td><td><i>Yes</i></td><td>4 (13)</td><td>2 (10)</td><td>6 (11)</td><td rowspan="2">0.11 (0.738)</td></tr><tr><td><i>No</i></td><td>28 (87)</td><td>19 (90)</td><td>47 (89)</td></tr><tr><td rowspan="3"><i>Site of onset</i></td><td><i>Ethmoid</i></td><td>32 (100)</td><td>6 (29)</td><td>38 (72)</td><td rowspan="3"></td></tr><tr><td><i>Maxillary</i></td><td>0</td><td>8 (38)</td><td>8 (15)</td></tr><tr><td><i>Septum</i></td><td>0</td><td>7 (33)</td><td>7 (13)</td></tr><tr><td rowspan="2"><i>ADC subtype</i></td><td><i>ITAC</i><sup><i>a</i></sup></td><td>30 (94)</td><td>-</td><td>-</td><td rowspan="2"></td></tr><tr><td><i>Non-ITAC</i></td><td>2 (6)</td><td>-</td><td>-</td></tr></table> |
e06c362d47ab1fc02d0e12eb06e7b847e80985fc5883a1744c083e4faf271d4a.png | simple | <table><tr><td></td><td>sense</td><td>antisense</td></tr><tr><td>#1</td><td>GTATCTGCACTCTCAATCAGGAGC</td><td>AAACTGTAACCCCTATCTCTACTCAC</td></tr><tr><td>#2</td><td>CCTGGGTTTCCACCATATGCTTTC</td><td>AGTTCCTTGCACTCCTGTTAACAA</td></tr><tr><td>#3</td><td>CCTGGGTTTCCACCATATGCTTTC</td><td>GGTCGCCTAGTGTCATGACCA</td></tr><tr><td>#4</td><td>GACCACATCCCAACCGAATC</td><td>CACAGGCCAGACTGACACCC</td></tr><tr><td>#5</td><td>GACCACATCCCAACCGAATC</td><td>CTGACACCCAGTAGTGAAGG</td></tr><tr><td>#6</td><td>GATAGCAGCCGCAGAAGAGC</td><td>CCACCTGGGTTTCCACCATA</td></tr></table> |
68c3f597e94cfde36aeced7a7412f0e72ec19bc4df5404124667f18ffd0c8b5b.png | simple | <table><tr><td>Commercial laboratory variable</td><td>Mean change younger cohort</td><td>Mean change older cohort</td><td>p-value</td></tr><tr><td>CD3%</td><td>−2.75</td><td>2.33</td><td>0.036</td></tr><tr><td>CD4%</td><td>−2.50</td><td>1.67</td><td>0.028</td></tr><tr><td>WBC</td><td>2.13</td><td>−0.70</td><td>0.031</td></tr><tr><td>IgA</td><td>4.25</td><td>−13.17</td><td>0.059</td></tr><tr><td>Zinc/Copper Ratio</td><td>−0.08</td><td>0.13</td><td>0.061</td></tr></table> |
fbc64a7c9f2bff4414f3218e926e0259df79e3911762d5caef8b03b434c1c674.png | simple | <table><tr><td>Strain</td><td>Source</td><td>Accession no.</td><td>Genome size (bp)</td><td><i>N</i><sub>50</sub> (bp)</td><td>No. of scaffolds (>300 bp)</td><td>G+C content (%)</td></tr><tr><td><i>Arcobacter</i> sp. AF1028</td><td>Human feces</td><td>JART00000000</td><td>2,414,790</td><td>148,259</td><td>46</td><td>27.24</td></tr><tr><td><i>Arcobacter</i> sp. AF1078</td><td>Human feces</td><td>JARS00000000</td><td>2,496,885</td><td>127,252</td><td>53</td><td>27.18</td></tr></table> |
1dc0ec8422e38e342fc512fa1b1107801017099a55faafe06e17e70fa585662f.png | complex | <table><tr><td></td><td>All articles (n=168)</td><td>Including <i>NEJM</i> protocols (n=61)</td></tr><tr><td>Characteristics</td><td>n (%)</td><td>n (%)</td></tr><tr><td colspan="3">Journal</td></tr><tr><td> <i>NEJM</i></td><td>61 (36)</td><td>61</td></tr><tr><td> <i>Lancet</i></td><td>64 (38)</td><td></td></tr><tr><td> <i>JAMA</i></td><td>19 (11)</td><td></td></tr><tr><td> <i>BMJ</i></td><td>8 (5)</td><td></td></tr><tr><td> <i>Annals of Internal Medicine</i></td><td>5 (2)</td><td></td></tr><tr><td> <i>PLoS Medicine</i></td><td>7 (4)</td><td></td></tr><tr><td> <i>Archives of Internal Medicine</i></td><td>2 (1)</td><td></td></tr><tr><td> <i>JAMA of Internal Medicine</i></td><td>2 (1)</td><td></td></tr><tr><td colspan="3">Year of publication</td></tr><tr><td> 2010</td><td>26 (15)</td><td>9 (15)</td></tr><tr><td> 2011</td><td>27 (16)</td><td>9 (15)</td></tr><tr><td> 2012</td><td>29 (17)</td><td>8 (13)</td></tr><tr><td> 2013</td><td>39 (23)</td><td>19 (31)</td></tr><tr><td> 2014</td><td>27 (16)</td><td>10 (16)</td></tr><tr><td> 2015</td><td>20 (12)</td><td>6 (10)</td></tr><tr><td colspan="3">Type of intervention</td></tr><tr><td> Drug</td><td>112 (67)</td><td>44 (72)</td></tr><tr><td> Surgery</td><td>22 (13)</td><td>7 (11)</td></tr><tr><td> Other</td><td>34 (20)</td><td>10 (16)</td></tr><tr><td colspan="3">Randomisation</td></tr><tr><td> Patient</td><td>163 (97)</td><td>59 (97)</td></tr><tr><td> Cluster</td><td>5 (3)</td><td>2 (3)</td></tr><tr><td colspan="3">Power</td></tr><tr><td> 80%</td><td>6 (36)</td><td>19 (31)</td></tr><tr><td> 85%</td><td>11 (7)</td><td>5 (8)</td></tr><tr><td> 90%</td><td>65 (39)</td><td>26 (43)</td></tr><tr><td> 71–99% (excluding the above)</td><td>21 (12)</td><td>11 (18)</td></tr><tr><td> Not reported/unclear</td><td>10 (6)</td><td>0</td></tr><tr><td colspan="3">Composite outcome</td></tr><tr><td> Yes</td><td>78 (46)</td><td>37 (61)</td></tr><tr><td> No</td><td>90 (54)</td><td>24 (39)</td></tr><tr><td colspan="3">Disease</td></tr><tr><td> Heart disease</td><td>30 (18)</td><td>13 (21)</td></tr><tr><td> Blood disorder</td><td>19 (11)</td><td>6 (10)</td></tr><tr><td> Cancer</td><td>16 (10)</td><td>8 (13)</td></tr><tr><td> Diabetes</td><td>11 (7)</td><td>2 (3)</td></tr><tr><td> Thromboembolism</td><td>6 (4)</td><td>6 (10)</td></tr><tr><td> Skin infection (non-contagious)</td><td>3 (2)</td><td>2 (3)</td></tr><tr><td> Urinary tract infection</td><td>3 (2)</td><td>0</td></tr><tr><td> Arthritis</td><td>3 (2)</td><td>1 (2)</td></tr><tr><td> Opthomology</td><td>3 (2)</td><td>1 (2)</td></tr><tr><td> Pneumonia</td><td>3 (2)</td><td>1 (2)</td></tr><tr><td> Complications in pregnancy</td><td>3 (2)</td><td>0</td></tr><tr><td> Stroke</td><td>3 (2)</td><td>2 (3)</td></tr><tr><td> Testing method</td><td>3 (2)</td><td>1 (2)</td></tr><tr><td> Appendicitis</td><td>2 (1)</td><td>1 (2)</td></tr><tr><td> Depression</td><td>2 (1)</td><td>0</td></tr><tr><td> Other non-infectious disease</td><td>18 (11)</td><td>7 (11)</td></tr><tr><td> HIV</td><td>18 (11)</td><td>2 (3)</td></tr><tr><td> Tuberculosis</td><td>6 (4)</td><td>4 (7)</td></tr><tr><td> Malaria</td><td>4 (2)</td><td>1 (2)</td></tr><tr><td> Skin infection (contagious)</td><td>2 (1)</td><td>0</td></tr><tr><td> Hepatitis C</td><td>2 (1)</td><td>2 (3)</td></tr><tr><td> Other infectious disease</td><td>8 (5)</td><td>1 (2)</td></tr></table> |
2e9cdfa979466c8a94ff33a0e25b96d96c0bf7f1d0f051cbac8fa3c7c2a9df4d.png | simple | <table><tr><td>Author</td><td>Study design</td><td>Oral health criteria</td><td>Study population</td><td>Results</td></tr><tr><td>Bundgaard et al. (85)</td><td>Case-control</td><td>Missing teeth</td><td>161 patients and 400 controls (Denmark)</td><td>Significantly increased risk of developing oral SCCA for patients with fewer than 15 teeth</td></tr><tr><td>Rezende et al. (86)</td><td>Case-control</td><td>CPITN<sup>a</sup> and DMFT<sup>b</sup></td><td>50 patients and 50 controls (Cuba)</td><td>76% of subjects in cancer group showed greater than 6 mm pockets compared to 10% of control group</td></tr><tr><td>Garrote et al. (87)</td><td>Case-control</td><td>Missing teeth</td><td>200 patients and controls (Cuba)</td><td>Significantly increased risk of oral cancer for patients missing 16 or more teeth</td></tr><tr><td>Hiraki et al. (88)</td><td>Case-control</td><td>Missing teeth</td><td>429 patients and 10,480 controls (Japan)</td><td>Significantly increased risk of head and neck cancer with decreased number remaining teeth</td></tr><tr><td>Marshall et al. (89)</td><td>Case-control</td><td>Missing teeth</td><td>290 patients and controls (United States)</td><td>Significantly increased risk of oral cancer with loss of 11 or more teeth</td></tr><tr><td>Michaud et al. (90)</td><td>Cohort</td><td>Self-reported history of periodontal disease (confirmed by radiographs and missing teeth)</td><td>118 patients (United States)</td><td>No significant increase in risk for oropharyngeal cancer with history of periodontal disease or increased number of tooth loss</td></tr><tr><td>Rosenquist et al. (91)</td><td>Case-control</td><td>Missing teeth</td><td>132 patients and 320 controls (Sweden)</td><td>Significantly increased risk of oral and oropharyngeal cancer for missing over 20 teeth</td></tr><tr><td>Tezal et al. (92)</td><td>Cohort</td><td>Clinical attachment loss (CAL)</td><td>131 oral tumors and 323 oral pre-cancerous lesions (United States)</td><td>Significantly increased risk of oral tumor and pre-cancerous lesion with >1.5 mm clinical attachment loss</td></tr><tr><td>Tezal et al. (81)</td><td>Case-control</td><td>Alveolar bone loss</td><td>51 cases and 54 controls (United States)</td><td>Significantly increased risk of tongue cancer with increased alveolar bone loss</td></tr><tr><td>Tezal et al. (82)</td><td>Case-control</td><td>Alveolar bone loss</td><td>266 patients and 207 controls (United States)</td><td>Significantly increased risk of oral cavity SCC with periodontitis</td></tr><tr><td>Tezal et al. (93)</td><td>Case-control</td><td>Alveolar bone loss</td><td>124 head and neck SCC patients (United States)</td><td>Periodontitis is associated with tumor HPV status</td></tr><tr><td>Wen et al. (94)</td><td>Cohort</td><td>Medical records from insurance claims</td><td>96,375 gingivitis and 51,791 periodontitis cases (Taiwan)</td><td>Significantly increased risk of oral cancer with the history of periodontitis</td></tr><tr><td>Zheng et al. (95)</td><td>Case-control</td><td>Missing teeth</td><td>404 subjects and controls (United States)</td><td>Significantly increased risk of oral cancer with increased missing teeth</td></tr></table> |
767d51dd80a1c15d4605fa6ab857d4e548ca4591a62e543408dc10094c498e97.png | simple | <table><tr><td>Injure</td><td>1-4 y</td><td>5-9 y</td><td>10-14 y</td></tr><tr><td>Transport accidents</td><td>21(47.7)</td><td>23(39.7)</td><td>45(51.7)</td></tr><tr><td>Accidental drowning and submersion</td><td>2(4.5)</td><td>17(29.3)</td><td>28(32.2)</td></tr><tr><td>Falls</td><td>7(15.9)</td><td>5(8.6)</td><td>5(5.7)</td></tr><tr><td>Suicide</td><td>0(0)</td><td>1(1.7)</td><td>4(4.6)</td></tr><tr><td>Suffocation</td><td>4(9.0)</td><td>3(5.2)</td><td>2(2.3)</td></tr><tr><td>Other</td><td>14(31.8)</td><td>11(19)</td><td>3(3.4)</td></tr></table> |
e969908397908803b6ec9a75912b2e67fa66276893b274cbec4bd8e646510c50.png | simple | <table><tr><td>Characteristic</td><td>Patients (n= 19)(%)</td></tr><tr><td>Sex (males/females)</td><td>12/7</td></tr><tr><td>Age, years, median (range)</td><td>54 (30–75)</td></tr><tr><td>Underlying liver disease</td><td> </td></tr><tr><td>Hepatitis B virus</td><td>11 (57.89)</td></tr><tr><td>Alcoholic</td><td>3 (15.79)</td></tr><tr><td>Autoimmune hepatitis</td><td>1 (5.26)</td></tr><tr><td>Hybrid cause</td><td>4 (21.05)</td></tr><tr><td>Basic underlying disease</td><td> </td></tr><tr><td>Cardiovascular disease</td><td>4 (21.05)</td></tr><tr><td>Diabetes mellitus type 2</td><td>2 (10.53)</td></tr><tr><td>Chronic lung diseases</td><td>2 (10.53)</td></tr><tr><td>Complications</td><td> </td></tr><tr><td>Hepatic encephalopathy</td><td>8 (42.10)</td></tr><tr><td>Hepatic renal syndrome</td><td>4 (21.05)</td></tr><tr><td>Upper gastric bleeding</td><td>4 (21.05)</td></tr><tr><td>Ascites</td><td>16 (84.21)</td></tr><tr><td>Hydrothorax</td><td>10 (52.63)</td></tr><tr><td>Hepatic carcinoma</td><td>2 (10.53)</td></tr><tr><td>CTP scores (mean ± SD)</td><td>11 ± 2</td></tr><tr><td>Child B</td><td>6 (31.58)</td></tr><tr><td>Child C</td><td>13 (68.42)</td></tr><tr><td>MELD (mean ± SD)</td><td>22 ± 7</td></tr><tr><td>Neutropenia</td><td>2 (10.53)</td></tr><tr><td>Broad-spectrum antibiotics usage</td><td>18 (94.74)</td></tr><tr><td>One antibiotic</td><td>9 (47.37)</td></tr><tr><td>Two antibiotics</td><td>4 (21.05)</td></tr><tr><td>Three antibiotics</td><td>5 (26.32)</td></tr><tr><td>Steroids exposure(longer than 1 week)</td><td>11 (57.89)</td></tr><tr><td>Survival rate</td><td> </td></tr><tr><td>1 month</td><td>5/19</td></tr><tr><td>3 month</td><td>4/19</td></tr></table> |
b52fd66d697a58595277f3390f9e6c1fad26e4b8ad0d1de266ae8f1001afcd88.png | complex | <table><tr><td></td><td>Mean</td><td>Median</td><td>Min</td><td>Max</td></tr><tr><td colspan="5">% of Patients Who Should Receive DES, 1st Year Following Approval</td></tr><tr><td>Bare metal stent patients</td><td>42.8%</td><td>30.0%</td><td>5.1%</td><td>100.0%</td></tr><tr><td>CABG patients</td><td>16.8%</td><td>10.0%</td><td>5.0%</td><td>50.0%</td></tr><tr><td colspan="5">% of Patients Who Should Receive DES, 2nd Year Following Approval</td></tr><tr><td>Bare metal stent patients</td><td>56.0%</td><td>50.0%</td><td>10.2%</td><td>100.0%</td></tr><tr><td>CABG patients</td><td>25.5%</td><td>20.0%</td><td>5.0%</td><td>80.0%</td></tr><tr><td colspan="5">% of Patients Who Should Receive DES, 3rd Year Following Approval</td></tr><tr><td>Bare metal stent patients</td><td>70.1%</td><td>90.0%</td><td>30.0%</td><td>100.0%</td></tr><tr><td>CABG patients</td><td>31.4%</td><td>30.0%</td><td>5.0%</td><td>90.0%</td></tr><tr><td colspan="5">% of Patients Who Should Receive DES, 4th Year Following Approval</td></tr><tr><td>Bare metal stent patients</td><td>79.7%</td><td>90.0%</td><td>40.6%</td><td>100.0%</td></tr><tr><td>CABG patients</td><td>37.8%</td><td>35.0%</td><td>5.0%</td><td>90.0%</td></tr><tr><td colspan="5">% of Patients Who Should Receive DES, 5th Year Following Approval</td></tr><tr><td>Bare metal stent patients</td><td>86.8%</td><td>90.0%</td><td>60.8%</td><td>100.0%</td></tr><tr><td>CABG patients</td><td>43.7%</td><td>40.0%</td><td>5.0%</td><td>90.0%</td></tr></table> |
c9a08fda830b3880a99294e628853f07f53769feb818b3fc7d38c9038f9c07bb.png | complex | <table><tr><td rowspan="3">Job satisfaction domains</td><td colspan="2">Level of satisfaction</td></tr><tr><td>Satisfied</td><td>Dissatisfied</td></tr><tr><td>N (%)</td><td>N (%)</td></tr><tr><td>Leadership and planning</td><td>175 (43.2)</td><td>230 (56.8)</td></tr><tr><td>Culture and communications</td><td>180 (44.6)</td><td>225 (55.4)</td></tr><tr><td>Employee’s role</td><td>211 (52.1)</td><td>194 (47.9)</td></tr><tr><td>Work environment</td><td>178 (43.9)</td><td>227 (56.1)</td></tr><tr><td>Relationship with supervisor</td><td>163 (40.2)</td><td>242 (59.8)</td></tr><tr><td>Training and development</td><td>165 (41.4)</td><td>237 (58.6)</td></tr><tr><td>Pay and benefits</td><td>148 (36.5)</td><td>257 (63.5)</td></tr><tr><td>Coworker relation ship</td><td>209 (51.6)</td><td>196 (48.4)</td></tr><tr><td>Overall satisfaction</td><td>179 (44.2)</td><td>226 (55.8)</td></tr></table> |
af658c110b7145ee1b0b49c8aa859214fda0dc1cad278331bc63f1d34baf5c3a.png | simple | <table><tr><td></td><td>Overweight*</td><td>Body fat (%)<sup>+</sup></td><td>Lean body mass (kg)<sup>+</sup></td></tr><tr><td>Birth weight (z)</td><td>1.18 (1.02 to 1.35)</td><td>0.02 (−0.39 to 0.43)</td><td>1.54 (1.15 to 1.93)</td></tr><tr><td> <i>P </i>for trend</td><td>0.02</td><td>0.9</td><td><0.001</td></tr><tr><td>Ponderal index (z)</td><td>1.15 (1.00 to 1.32)</td><td>0.28 (−0.14 to 0.69)</td><td>0.41 (0.01 to 0.82)</td></tr><tr><td> <i>P </i>for trend</td><td>0.05</td><td>0.2</td><td>0.04</td></tr><tr><td>Placental weight (z)</td><td>1.06 (0.93 to 1.22)</td><td>0.15 (−0.26 to 0.56)</td><td>0.90 (0.51 to 1.29)</td></tr><tr><td> <i>P </i>for trend</td><td>0.4</td><td>0.5</td><td><0.001</td></tr><tr><td>Max placental diam (z)</td><td>1.02 (0.89 to 1.16)</td><td>−0.02 (−0.43 to 0.38)</td><td>0.45 (0.06 to 0.84)</td></tr><tr><td> <i>P </i>for trend</td><td>0.8</td><td>0.9</td><td>0.02</td></tr><tr><td>Lesser placental diam (z)</td><td>0.99 (0.86 to 1.13)</td><td>−0.21 (−0.61 to 0.20)</td><td>0.48 (0.09 to 0.88)</td></tr><tr><td> <i>P </i>for trend</td><td>0.9</td><td>0.3</td><td>0.02</td></tr><tr><td>Placental area (z)</td><td>0.98 (0.86 to 1.13)</td><td>−0.14 (−0.55 to 0.27)</td><td>0.47 (0.08 to 0.87)</td></tr><tr><td> <i>P </i>for trend</td><td>0.8</td><td>0.5</td><td>0.02</td></tr><tr><td>Tall mothers(HEIGHT > 160 cm)</td><td></td><td></td><td></td></tr><tr><td>Birth weight (z)</td><td>1.11 (0.94 to 1.31)</td><td>0.21 (−0.29 to 0.71)</td><td>1.46 (0.95 to 1.97)</td></tr><tr><td> <i>P </i>for trend</td><td>0.2</td><td>0.4</td><td><0.001</td></tr><tr><td>Ponderal index (z)</td><td>1.12 (0.96 to 1.32)</td><td>0.44 (−0.01 to 0.90)</td><td>0.47 (0.00 to 0.95)</td></tr><tr><td> <i>P </i>for trend</td><td>0.2</td><td>0.06</td><td>0.05</td></tr><tr><td>Placental weight (z)</td><td>1.06 (0.90 to 1.24)</td><td>0.01 (−0.47 to 0.49)</td><td>0.83 (0.33 to 1.32)</td></tr><tr><td> <i>P </i>for trend</td><td>0.5</td><td>1.0</td><td>0.001</td></tr><tr><td>Max placental diam (z)</td><td>1.06 (0.89 to 1.25)</td><td>0.12 (−0.39 to 0.62)</td><td>0.75 (0.23 to 1.28)</td></tr><tr><td> <i>P </i>for trend</td><td>0.5</td><td>0.6</td><td>0.005</td></tr><tr><td>Lesser placental diam (z)</td><td>1.18 (1.00 to 1.38)</td><td>0.58 (0.10 to 1.07)</td><td>0.65 (0.14 to 1.15)</td></tr><tr><td> <i>P </i>for trend</td><td>0.05</td><td>0.02</td><td>0.01</td></tr><tr><td>Placental area (z)</td><td>1.12 (0.95 to 1.32)</td><td>0.40 (−0.10 to 0.89)</td><td>0.71 (0.21 to 1.23)</td></tr><tr><td> <i>P </i>for trend</td><td>0.2</td><td>0.1</td><td>0.006</td></tr></table> |
c42739bf0afc4d7a89a7176c422d00464d6003d2edd1363612aa2d20ffbc9901.png | complex | <table><tr><td>Surgical Margins</td><td colspan="3">Pathological Stage</td><td>P</td></tr><tr><td>(Group 1)</td><td>pT2</td><td>pT3</td><td>Total</td><td></td></tr><tr><td>Negative</td><td>44 (95.7%)</td><td>02 (4.3%)</td><td>46 (100%)</td><td>0.027<sub>F</sub></td></tr><tr><td>Positive</td><td>06 (66.7%)</td><td>03 (33.3%)</td><td>09 (100%)</td><td></td></tr><tr><td>Total</td><td>50 (90.9%)</td><td>05 (9.1%)</td><td>55 (100%)</td><td></td></tr><tr><td>(Group 2)</td><td>pT2</td><td>pT3</td><td>Total</td><td></td></tr><tr><td>Negative</td><td>44 (95.7%)</td><td>02 (4.3%)</td><td>46 (100%)</td><td><0.001<sub>F</sub></td></tr><tr><td>Positive</td><td>02 (20.0%)</td><td>08 (80.0%)</td><td>10 (100%)</td><td></td></tr><tr><td>Total</td><td>46 (82.1%)</td><td>10 (17.9%)</td><td>56 (100%)</td><td></td></tr></table> |
16a0c73f1137f362bdafc6287065dac32074d6736b00208db5f3caf61b1bc603.png | complex | <table><tr><td rowspan="2">Activity and Level</td><td rowspan="2">No.</td><td colspan="2">Model 1<sup>a</sup></td><td colspan="2">Model 2<sup>b</sup></td><td colspan="2">Model 3<sup>c</sup></td></tr><tr><td>B</td><td>95% CI</td><td>B</td><td>95% CI</td><td>B</td><td>95% CI</td></tr><tr><td>Attendance at sports/PA clubs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Low</td><td>2,333</td><td>0</td><td>Referent</td><td>0</td><td>Referent</td><td>0</td><td>Referent</td></tr><tr><td> Medium</td><td>2,299</td><td>2.0</td><td>1.5, 2.6</td><td>0.6</td><td>0.1, 1.1</td><td>0.3</td><td>−0.2, 0.8</td></tr><tr><td> High</td><td>3,830</td><td>3.4</td><td>2.9, 3.9</td><td>1.2</td><td>0.7, 1.6</td><td>0.6</td><td>0.2, 1.1</td></tr><tr><td>Sports/PA with siblings</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Low</td><td>945</td><td>0</td><td>Referent</td><td>0</td><td>Referent</td><td>0</td><td>Referent</td></tr><tr><td> Medium</td><td>1,887</td><td>0.8</td><td>0.1, 1.6</td><td>−0.1</td><td>0.6, 0.8</td><td>−0.1</td><td>−0.8, 0.6</td></tr><tr><td> High</td><td>5,630</td><td>−0.4</td><td>−1.0, 0.3</td><td>−0.7</td><td>−1.3, −0.1</td><td>−0.6</td><td>−1.2, 0.0</td></tr><tr><td>Sports/PA with parents</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Low</td><td>1,824</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Medium</td><td>3,090</td><td>1.1</td><td>0.6, 1.7</td><td>0.5</td><td>0.0, 1.0</td><td>0.4</td><td>−0.2, 0.9</td></tr><tr><td> High</td><td>3,548</td><td>0.4</td><td>−0.1, 1.0</td><td>0.1</td><td>−0.4, 0.6</td><td>0.2</td><td>−0.3, 0.6</td></tr><tr><td>Park/playground visits</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Low</td><td>1,513</td><td>0</td><td>Referent</td><td>0</td><td>Referent</td><td>0</td><td>Referent</td></tr><tr><td> Medium</td><td>2,690</td><td>0.7</td><td>0.1, 1.3</td><td>0.2</td><td>−0.4, 0.7</td><td>0.2</td><td>−0.4, 0.7</td></tr><tr><td> High</td><td>4,259</td><td>−0.5</td><td>0.1, 1.0</td><td>0.3</td><td>−0.2, 0.8</td><td>0.3</td><td>−0.2, 0.8</td></tr></table> |
4a25ed4904dd1766f4ab575126f658bd3613b04e41b671fe6e1daadc7ef0f29b.png | complex | <table><tr><td rowspan="2">Cy-3-G (μmol/L)</td><td colspan="2">P<sub>app</sub> (×10<sup>−7</sup> cm/s)</td><td rowspan="2">Efflux Ratio</td><td rowspan="2">Transport Efficiency (%)</td></tr><tr><td>B → A</td><td>A → B</td></tr><tr><td>10</td><td>10.57 ± 1.12</td><td>14.96 ± 1.88</td><td>0.71</td><td>2.41</td></tr><tr><td>20</td><td>6.45 ± 0.46</td><td>8.98 ± 1.12</td><td>0.72</td><td>1.45</td></tr><tr><td>40</td><td>3.58 ± 0.37</td><td>4.75 ± 0.51</td><td>0.75</td><td>0.76</td></tr></table> |
8b140c2d3ea53e7ac559d2d4f0b763e8cc0d68c178a76760db6f7335bc34acf9.png | simple | <table><tr><td>Variable</td><td>Neonatal mortality rate (NMR)</td><td>Infant mortality rate (IMR)</td><td>Under-5 mortality rate (U5MR)</td></tr><tr><td>Behvarz density</td><td>-0.108 (-2.09 – 1.87)</td><td>-0.021 (-0.13 – 0.08)</td><td>-0.012 (-0.11 – 0.09)</td></tr><tr><td>Effect of rural family physician program and social protection scheme</td><td>-0.906 (-1.94 – 0.13)</td><td>0.002 (-0.05 – 0.06)</td><td>0.006 (-0.04 – 0.06)</td></tr><tr><td>Annual incremental effect of rural family physician program and social protection scheme</td><td>-0.341* (-0.57 – -0.11)</td><td>-0.016* (-0.03 – -0.01)</td><td>-0.003 (-0.01 – 0.01)</td></tr><tr><td>Time effect</td><td>-0.231* (-0.39 – -0.07)</td><td>-0.034** (-0.04 – -0.03)</td><td>-0.040** (-0.05 – -0.03)</td></tr><tr><td>Years of schooling</td><td>0.237 (0.35 – 0.82)</td><td>0.024 (-0.01 – 0.06)</td><td>0.020 (-0.01 – 0.05)</td></tr><tr><td>Wealth index</td><td>-0.889* (-1.43 – -0.35)</td><td>-0.052** (-0.08 – -0.02)</td><td>-0.055** (-0.08 – -0.03)</td></tr><tr><td>Sex ratio</td><td>2.051 (-33.44 – 37.54)</td><td>0.904 (-0.99 – 2.80)</td><td>1.312 (-0.49 – 3.11)</td></tr><tr><td>Logarithmic scale of rural population size</td><td>-0.918 (-4.05 – 2.21)</td><td>-0.223* (-0.39 – 0.06)</td><td>-0.219* (-0.38 – -0.06)</td></tr></table> |
295bbd109e7d96cf15e0b6302128512d3b7d74926138dde7682dba46e8f9a4f5.png | simple | <table><tr><td>Outcomes</td><td>Support (N = 105)</td><td>Control (N = 107)</td><td>RR (95%CI)</td><td>p value</td></tr><tr><td>Apgar score at 1 minute < 7</td><td>20</td><td>21</td><td>0.97 (0.56–1.68)</td><td>0.915</td></tr><tr><td>Apgar score at 5 minutes < 7</td><td>3</td><td>2</td><td>1.53 (0.26–8.96)</td><td>0.681*</td></tr><tr><td>Birthweight (g) (mean ± SD 95%)</td><td>3.197 (2.360–4.245)</td><td>3.246 (2.410–4.145)</td><td>-</td><td>0.370<sup>¶</sup></td></tr><tr><td>Admission to NICU</td><td>5</td><td>6</td><td>0.91 (0.47–1.77)</td><td>0.781</td></tr><tr><td>Immediate contact mother/newborn</td><td>52</td><td>41</td><td>1.29 (0.95–1.76)</td><td>0.100</td></tr><tr><td>Time of contact mother/newborn (min) (mean ± 95% SD)</td><td>25.1 (10–55)</td><td>22.7 (10–40)</td><td>-</td><td>0.360<sup>†</sup></td></tr><tr><td>Takes breast/suckles in delivery room</td><td>12</td><td>7</td><td>1.75 (0.72–4.26)</td><td>0.213</td></tr><tr><td>Takes breast/suckles (12 h following birth)</td><td>99</td><td>100</td><td>1.08 (0.59–1.97)</td><td>0.801</td></tr><tr><td>Breast fissure</td><td>7</td><td>6</td><td>1.19 (0.41–3.42)</td><td>0.747</td></tr><tr><td>Number of breast-feeds 12 hours following birth (mean)</td><td>4.3 (0–12)</td><td>4.4 (0–10)</td><td>-</td><td>0.589<sup>†</sup></td></tr></table> |
6b35df04f345cf45302e0129bd3bee1e8fb359a3e00f2b3508c59fc1d4b49af6.png | simple | <table><tr><td>Method</td><td>Precision (%)</td><td>Recall (%)</td><td>F-score (%)</td></tr><tr><td>hHMM</td><td>98.5 ± 0.4</td><td>93.5 ± 1.9</td><td>95.9 ± 0.9</td></tr><tr><td>eDTW</td><td>94 ± 1.2</td><td>93.5 ± 0.8</td><td>93.8 ± 0.5</td></tr><tr><td>Peak detection</td><td>87.4 ± 1.2</td><td>95.9 ± 1.8</td><td>91.5 ± 0.4</td></tr><tr><td>pDTW</td><td>91.8 ± 2.1</td><td>90.1 ± 2.2</td><td>90.9 ± 1.4</td></tr></table> |
23bf7f5fc7a6ef2ed3478e88a65f92b74bbda798ef82dd145015a2544c73d134.png | simple | <table><tr><td>UNIPROT KEY</td><td>DESCRIPTION</td><td>MW (kDa)</td><td>Mascot score</td><td>A/C ratio</td><td>A/C std. dev. </td><td>A/C <i>p</i> value</td><td>At/C ratio</td><td>At/C std. dev.</td><td>At/C <i>p</i> value</td></tr><tr><td>Q9JI91</td><td>Alpha-actinin-2</td><td>103.8</td><td>353.78</td><td>2.875</td><td>0.825</td><td>1.84E-03</td><td>3.030</td><td>0.865</td><td>1.72E-03</td></tr><tr><td>P26231</td><td>Catenin alpha-1</td><td>100.1</td><td>100</td><td>2.212</td><td>0.193</td><td>5.04E-04</td><td>2.230</td><td>0.226</td><td>5.03E-04</td></tr><tr><td>P63260</td><td>Actin, cytoplasmic 2</td><td>41.8</td><td>5740.2</td><td>1.422</td><td>0.265</td><td>1.49E-02</td><td>2.386</td><td>0.305</td><td>1.10E-04</td></tr><tr><td>P60710</td><td>Actin, cytoplasmic 1</td><td>41.7</td><td>5483.9</td><td>1.483</td><td>0.163</td><td>4.84E-05</td><td>1.785</td><td>0.184</td><td>1.80E-06</td></tr><tr><td>Q68FF6</td><td>ARF GTPase-activating protein GIT1</td><td>85.2</td><td>62.49</td><td>1.590</td><td>0.610</td><td>6.57E-02</td><td>1.308</td><td>0.369</td><td>8.19E-02</td></tr><tr><td>Q60737</td><td>Casein kinase II subunit alpha</td><td>36.5</td><td>45.1</td><td>1.532</td><td>0.485</td><td>8.67E-02</td><td>1.267</td><td>0.274</td><td>5.76E-02</td></tr><tr><td>Q61739</td><td>Integrin alpha-6</td><td>97.3</td><td>122.1</td><td>1.499</td><td>0.175</td><td>1.12E-03</td><td>1.022</td><td>0.066</td><td>2.41E-01</td></tr><tr><td>Q3V3R4</td><td>Integrin alpha-1</td><td>130.7</td><td>236.53</td><td>1.325</td><td>0.065</td><td>3.38E-09</td><td>0.598</td><td>0.0308</td><td>3.26E-08</td></tr><tr><td>P62835</td><td>Ras-related protein Rap-1A</td><td>21.0</td><td>444.1</td><td>1.063</td><td>0.235</td><td>4.03E-01</td><td>0.747</td><td>0.156</td><td>8.04E-02</td></tr><tr><td>Q04736</td><td>Tyrosine-protein kinase Yes</td><td>92.38</td><td>60.6</td><td>1.008</td><td>0.090</td><td>5.49E-01</td><td>0.706</td><td>0.066</td><td>8.97E-05</td></tr><tr><td>Q9QUI0</td><td>Transforming protein RhoA</td><td>21.8</td><td>242.8</td><td>1.018</td><td>0.114</td><td>7.23E-01</td><td>0.741</td><td>0.083</td><td>1.42E-02</td></tr><tr><td>Q9QZQ1</td><td>Afadin</td><td>202.0</td><td>206.4</td><td>0.996</td><td>0.129</td><td>1.84E-03</td><td>0.559</td><td>0.051</td><td>2.40E-06</td></tr><tr><td>P09055</td><td>Integrin beta-1</td><td>88.2</td><td>333.2</td><td>0.989</td><td>0.048</td><td>5.76E-01</td><td>0.575</td><td>0.021</td><td>5.21E-11</td></tr><tr><td>Q02248</td><td>Catenin beta-1</td><td>85.4</td><td>2060.4</td><td>0.973</td><td>0.514</td><td>9.08E-01</td><td>0.740</td><td>0.255</td><td>1.97E-01</td></tr><tr><td>P27601</td><td>Guanine nucleotide-binding protein subunit alpha-13</td><td>44.0</td><td>108.65</td><td>0.938</td><td>0.252</td><td>6.44E-01</td><td>0.550</td><td>0.230</td><td>3.39E-02</td></tr><tr><td>Q7TPR4</td><td>Alpha-actinin-1</td><td>103.0</td><td>1300.8</td><td>0.940</td><td>0.229</td><td>3.63E-02</td><td>1.029</td><td>0.190</td><td>3.50E-02</td></tr><tr><td>P63001</td><td>Ras-related C3 botulinum toxin substrate 1</td><td>21.4</td><td>111.49</td><td>0.932</td><td>0.057</td><td>2.94E-01</td><td>0.611</td><td>0.052</td><td>2.37E-06</td></tr><tr><td>P26041</td><td>Moesin</td><td>67.7</td><td>1657.9</td><td>0.913</td><td>0.024</td><td>2.01E-02</td><td>0.605</td><td>0.017</td><td>9.9E-20</td></tr><tr><td>P26040</td><td>Ezrin</td><td>69.4</td><td>594.85</td><td>0.904</td><td>0.068</td><td>3.22E-03</td><td>0.732</td><td>0.062</td><td>4.39E-04</td></tr><tr><td>P26043</td><td>Radixin</td><td>68.5</td><td>691.5</td><td>0.871</td><td>0.106</td><td>3.00E-01</td><td>0.694</td><td>0.053</td><td>3.37E-05</td></tr><tr><td>Q62470</td><td>Integrin alpha-3</td><td>116.7</td><td>178.09</td><td>0.846</td><td>0.049</td><td>2.24E-02</td><td>0.543</td><td>0.0373</td><td>5.97E-09</td></tr><tr><td>Q61879</td><td>Myosin-10</td><td>228.9</td><td>3486.6</td><td>0.843</td><td>0.028</td><td>2.04E-08</td><td>0.778</td><td>0.019</td><td>9.9E-20</td></tr><tr><td>A2ARA8</td><td>Integrin alpha-8</td><td>117.5</td><td>69.83</td><td>0.803</td><td>0.232</td><td>2.51E-01</td><td>0.537</td><td>0.108</td><td>1.11E-02</td></tr><tr><td>P62141</td><td>Serine/threonine-protein phosphatase PP1-beta catalytic subunit</td><td>37.2</td><td>61.83</td><td>0.779</td><td>0.124</td><td>5.84E-02</td><td>0.598</td><td>0.103</td><td>1.50E-02</td></tr><tr><td>Q8VDD5</td><td>Myosin-9</td><td>226.2</td><td>7387</td><td>0.741</td><td>0.089</td><td>4.55E-03</td><td>0.742</td><td>0.056</td><td>2.71E-03</td></tr><tr><td>Q64727</td><td>Vinculin</td><td>16.6</td><td>2596.1</td><td>0.755</td><td>0.315</td><td>2.53E-01</td><td>0.685</td><td>0.301</td><td>1.69E-01</td></tr><tr><td>P26039</td><td>Talin-1</td><td>269.7</td><td>3143</td><td>0.728</td><td>0.022</td><td>5.00E-10</td><td>0.684</td><td>0.020</td><td>2.19E-12</td></tr><tr><td>Q9JKF1</td><td>RasGTPase-activating-like protein IQGAP1</td><td>188.7</td><td>188.6</td><td>0.696</td><td>0.186</td><td>6.47E-02</td><td>0.699</td><td>0.193</td><td>6.48E-02</td></tr><tr><td>O55222</td><td>Integrin-linked protein kinase</td><td>51.3</td><td>330.25</td><td>0.668</td><td>0.060</td><td>9.41E-05</td><td>0.704</td><td>0.045</td><td>1.05E-03</td></tr></table> |
0b49c7b6a19457bc5dbbd21ac8bda1cda7aead91205b80845b6b6c8308659769.png | simple | <table><tr><td> Variables</td><td> Persistently Active (n=45)</td><td> Persistently Sedentary (n=10)</td><td><i>p-</i>value</td></tr><tr><td></td><td> Median (IR)</td><td> Median (IR)</td><td></td></tr><tr><td> M/F</td><td>29 / 16</td><td>4 / 6</td><td></td></tr><tr><td> Age (years)</td><td>38.3 (6.9)</td><td>43.8 (13)</td><td>0.121</td></tr><tr><td> Body weight (Kg)</td><td>77.3 (17)</td><td>74.8 (17.5)</td><td>0.639</td></tr><tr><td> Height (cm)</td><td>174.1 (12.8)</td><td>166.3 (18.5)</td><td>0.015</td></tr><tr><td> BMI (Kg/m<sup>2</sup>)</td><td>24.3 (4.8)</td><td>26.1 (9.4)</td><td>0.190</td></tr><tr><td> WC (cm)</td><td>80.5 (13.2)</td><td>88.5 (21.5)</td><td>0.210</td></tr><tr><td> Body fat (%)</td><td>24.1 (10.5)</td><td>40.2 (17.6)</td><td>0.001</td></tr><tr><td> Trunk fat (%)</td><td>31.3 (8.2)</td><td>47.9 (14.6)</td><td>0.001</td></tr><tr><td> Glucose (mg/dL)</td><td>89.3 (9.1)</td><td>91.1 (11.5)</td><td>0.413</td></tr><tr><td> Triglycerides (mg/dL)</td><td>76.2 (46.9)</td><td>127.7 (36.8)</td><td>0.002</td></tr><tr><td> Total cholesterol (mg/dL)</td><td>190.1 (47.8)</td><td>225.4 (54.2)</td><td>0.036</td></tr><tr><td> HDL-C (mg/dL)</td><td>52.5 (12.3)</td><td>50.1 (19.9)</td><td>0.793</td></tr><tr><td> LDL-C (mg/dL)</td><td>123.2 (40.2)</td><td>132.3 (38.2)</td><td>0.385</td></tr><tr><td> LDL-C/HDL-C (mg/dL)</td><td>2.3 (1.2)</td><td>2.7 (1.3)</td><td>0.789</td></tr><tr><td> VLDL-C (mg/dL)</td><td>15.2 (9.3)</td><td>25.5 (7.4)</td><td>0.001</td></tr><tr><td> HbA<sub>1c</sub> (mmol/mol)</td><td>5.3 (0.5)</td><td>5.3 (0.8)</td><td>0.637</td></tr><tr><td> CIT (mm)</td><td>0.60 (0.11)</td><td>0.78 (0.11)</td><td>0.001</td></tr><tr><td> FIT (mm)</td><td>0.49 (0.08)</td><td>0.53 (0.12)</td><td>0.287</td></tr><tr><td> Steps/day</td><td>9,476.1 (3148)</td><td>6,848.8 (4474)</td><td>0.001</td></tr><tr><td> SBP (mmHg)</td><td>110 (20)</td><td>105 (30)</td><td>0.920</td></tr><tr><td> DBP (mmHg)</td><td>80 (10)</td><td>75 (20)</td><td>0.885</td></tr></table> |
e1699bebb2144df18c7ba21a3eac3d4ae035c5cb524cc50599ae8694826d9baf.png | simple | <table><tr><td>Risk factor</td><td>Intervention options if risk factor identified</td></tr><tr><td>History of falls/falls injuries</td><td>Referral to GPAppropriate acute management if injury recent</td></tr><tr><td>Medications (number)</td><td>Refer to GP for medication review</td></tr><tr><td>Medications (associated with increased falls risk)</td><td>Refer to GP/specialist for medication review</td></tr><tr><td>Medical conditions (associated with increased falls risk)</td><td>Refer to GP/specialist for review</td></tr><tr><td>Sensory loss: vision</td><td>Brochure on lighting and home safetyRefer to optometristRefer to Ophthalmologist via GPRefer to Vision Australia (includes mobility training and aids for visually impaired)Refer to OT for home assessmentRefer to GP</td></tr><tr><td>Sensory loss: hearing</td><td>Refer to audiologist</td></tr><tr><td>Sensory loss: somatosensory</td><td>Refer to podiatristRefer to GP</td></tr><tr><td>Feet and footwear</td><td>Refer to podiatristProvide information about good footwear and falls prevention</td></tr><tr><td>Cognitive status</td><td>Refer to GPMemory Clinic referral in consultation with GP if memory problems have not been investigatedReferral to OT for strategies to facilitate memory and/or home assessment</td></tr><tr><td>Continence</td><td>Refer to GPContinence clinic referralRefer to physiotherapistRefer for OT home assessment/functional assessment, including need for commode</td></tr><tr><td>Nutritional status</td><td>Provide brochure on nutritionRefer to dieticianGP referral</td></tr><tr><td>Environment</td><td>Provide with information pamphlet on safety in the homeRefer for OT home assessment/functional assessment and training</td></tr><tr><td>Function</td><td>Refer to OT for home assessment/functional assessment and trainingRefer to Physiotherapist for assessment and exercise to improve functionReferral for support services</td></tr><tr><td>Functional behaviour</td><td>Refer to physiotherapist, OT, GP</td></tr><tr><td>Balance</td><td>Home exercise programReferral to PhysiotherapistReferral for OT for a home assessmentReferral to GP for further investigation</td></tr><tr><td>Gait and physical activity</td><td>Home exercise programReferral to PhysiotherapistReferral for OT home assessment/functional assessment and trainingBrochure on tips for walking</td></tr><tr><td>Osteoporosis risk</td><td>Refer to GP for consideration of calcium and/or vitamin D supplementsRefer to dieticianHip protectors</td></tr><tr><td>Additional options for preventing falls injury</td><td>Hip protectorsPersonal alarm</td></tr></table> |
b7ff5d4719cfefa710119170ffc6eee5af57e171ccf8780895891cccfe7bc879.png | simple | <table><tr><td>Patient #</td><td>Sex</td><td>Age(year)</td><td>Injected activity (MBq)</td><td>Diagnosis</td></tr><tr><td>1</td><td>M</td><td>2</td><td>320</td><td>Mediastinum 7-cm diameter NET</td></tr><tr><td>2</td><td>F</td><td>7</td><td>450</td><td></td></tr><tr><td>3</td><td>M</td><td>11</td><td>490</td><td>Right adrenal pheochromocytoma (only shown in SPECT/CT image)</td></tr><tr><td>4-A<sup>a</sup></td><td>F</td><td>12</td><td>500</td><td></td></tr><tr><td>5</td><td>F</td><td>12</td><td>600</td><td></td></tr><tr><td>4-B<sup>a</sup></td><td>F</td><td>13</td><td>450</td><td></td></tr><tr><td>6</td><td>F</td><td>13</td><td>480</td><td>Appendix NET, area of accumulation above the uterus</td></tr><tr><td>7</td><td>F</td><td>14</td><td>600</td><td>MEN-1, head of the pancreas NET and lymph node accumulation on the left side</td></tr><tr><td>8</td><td>M</td><td>14</td><td>940</td><td></td></tr><tr><td>9</td><td>F</td><td>16</td><td>500</td><td></td></tr><tr><td>10</td><td>F</td><td>16</td><td>600</td><td></td></tr><tr><td>11</td><td>M</td><td>17</td><td>720</td><td>MEN-1, head of the pancreas insulinoma</td></tr></table> |
9b0f5b9a698f7684fc212338979893c1f68f000267586ee6de1c380f83c8cb52.png | simple | <table><tr><td>Positive-to-Negative Ratio</td><td>Accuracy</td><td>F-Measure</td><td>MCC</td><td>Recall</td><td>Precision</td></tr><tr><td>1:1</td><td>0.6800</td><td>0.6667</td><td>0.3612</td><td>0.6400</td><td>0.6957</td></tr><tr><td>1:2</td><td>0.6667</td><td>0.5098</td><td>0.2638</td><td>0.5652</td><td>0.4643</td></tr><tr><td>1:3</td><td>0.6832</td><td>0.3043</td><td>0.0992</td><td>0.3043</td><td>0.3043</td></tr></table> |
172fc78ca69c1bdd24e83c20f7f6f62b0dc6f50e40cc0e5d8e609213e9c01ea4.png | simple | <table><tr><td>Cell line</td><td>Media</td><td>Comment</td></tr><tr><td>1. 293</td><td>DMEM</td><td>Embryonic kidney</td></tr><tr><td>2. A549</td><td>DMEM</td><td>Adenocarcinomic alveolar basal epithelial</td></tr><tr><td>3. C33a</td><td>DMEM</td><td>Cervical carcinoma</td></tr><tr><td>4. DUT145</td><td>DMEM</td><td>Prostate cancer</td></tr><tr><td>5. H1229</td><td>RPMI</td><td>Lung carcinoma</td></tr><tr><td>6. HaCAT</td><td>RPMI</td><td>Immortalized, non-tumorigenic keratinocyte</td></tr><tr><td>7. HCT116</td><td>McCoy 5A</td><td>Colorectal carcinoma</td></tr><tr><td>8. HeLa</td><td>Joklik</td><td>Cervical carcinoma</td></tr><tr><td>9. hESC2</td><td>DMEM</td><td>Human embryonic stem cells</td></tr><tr><td>10. HFF</td><td>DMEM</td><td>Human foreskin fibroblasts</td></tr><tr><td>11. HL60</td><td>IMM</td><td>Promyelocytic leukemia cells</td></tr><tr><td>13. Huh7.0</td><td>DMEM</td><td>Hepatocarcinoma</td></tr><tr><td>14. Huh7.5</td><td>DMEM</td><td>Hepatocarcinoma (RIG-I-deficient)</td></tr><tr><td>14. MCF7</td><td>DMEM</td><td>Breast carcinoma</td></tr><tr><td>15. MDaMB231</td><td>L15</td><td>Breast carcinoma</td></tr><tr><td>16. Mdm13</td><td>DMEM</td><td>Monocyte-derived macrophages</td></tr><tr><td>17. NB4</td><td>RPMI</td><td>Acute promyelocytic cell line</td></tr><tr><td>18. PANC1</td><td>DMEM</td><td>Pancreatic carcinoma, epithelial-like</td></tr><tr><td>19. PC3</td><td>DMEM</td><td>Prostate cancer</td></tr><tr><td>20. SAOS</td><td>McCoy 5A</td><td>Epithelial-like osteosarcoma cell line</td></tr><tr><td>21. SW480</td><td>L15</td><td>Colon adenocarcinoma</td></tr><tr><td>22. U2OS</td><td>DMEM</td><td>Osteosarcoma</td></tr><tr><td>23. U251</td><td>DMEM</td><td>Glioblastoma</td></tr><tr><td>24. U937</td><td>RPMI</td><td>Leukemic monocyte lymphoma</td></tr></table> |
5f69c08d5af0fc9393cfdcdf53309e3958b81a4aaffa689840e5c6314d9f8a2d.png | complex | <table><tr><td>Gene abbreviationa</td><td>Gene symbola</td><td>Accession no.b</td><td>Gene description</td><td>Gene group</td><td><i>Z</i>-Testc</td><td>Ratiod</td><td>95% CIe</td></tr><tr><td colspan="8">Up-regulated gene expression</td></tr><tr><td> <i>TECK</i>/<i>CCL25</i></td><td><i>Scya25</i></td><td>NM_009138</td><td>small inducible cytokine A25</td><td>Chemokine</td><td>1.5 × 10<sup>–14</sup></td><td>4.2</td><td>6.2–2.9</td></tr><tr><td> <i>Mdk</i></td><td><i>Mdk</i></td><td>NM_010784</td><td>midkine</td><td>Neurotrophic group</td><td>2.9 × 10<sup>–7</sup></td><td>3.0</td><td>4.7–1.9</td></tr><tr><td> <i>IL-5</i></td><td><i>Il5</i></td><td>NM_010558</td><td>interleukin 5</td><td>Interleukin</td><td>9.5 × 10<sup>–4</sup></td><td>1.9</td><td>2.9–1.3</td></tr><tr><td> <i>VEGF-A</i></td><td><i>Vegf</i></td><td>NM_009505</td><td>vascular endothelial growth factor</td><td>Angiogenic factor</td><td>2.5 × 10<sup>–5</sup></td><td>1.8</td><td>2.2–1.4</td></tr><tr><td colspan="8">Down-regulated gene expression</td></tr><tr><td> <i>EphA3</i></td><td><i>Epha3</i></td><td>M68513</td><td>eph-related receptor tyrosine kinase (Mek4)</td><td>Eph family</td><td>4.0 × 10<sup>–8</sup></td><td>0.5</td><td>0.6–0.4</td></tr><tr><td> <i>CCR-4</i></td><td><i>Cmkbr4</i></td><td>NM_009916</td><td>chemokine (C-C) receptor 4</td><td>Chemokine receptor</td><td>1.8 × 10<sup>–5</sup></td><td>0.6</td><td>0.8–0.5</td></tr><tr><td> <i>LIF</i></td><td><i>Lif</i></td><td>NM_008501</td><td>leukemia inhibitory factor</td><td>Cytokine and receptors</td><td>3.0 × 10<sup>–5</sup></td><td>0.6</td><td>0.8–0.4</td></tr><tr><td> <i>GDF-7</i></td><td><i>Gdf7</i></td><td>U08339</td><td>BALB/c putative growth factor GDF7 (Gdf7) gene</td><td>TGF-beta superfamily</td><td>2.4 × 10<sup>–4</sup></td><td>0.5</td><td>0.7–0.3</td></tr><tr><td> <i>EBF</i></td><td><i>Ebf</i></td><td>NM_007897</td><td>early B-cell factor</td><td>Signal transduction</td><td>3.7 × 10<sup>–4</sup></td><td>0.5</td><td>0.7–0.4</td></tr><tr><td> <i>CD27/TNFRSF7</i></td><td><i>Tnfrsf7</i></td><td>L24495</td><td>CD27 antigen</td><td>TNF superfamily</td><td>6.4 × 10<sup>–4</sup></td><td>0.6</td><td>0.8–0.4</td></tr><tr><td> <i>SLIT-3</i></td><td><i>Slit3</i></td><td>AF088902</td><td>SLIT1 protein</td><td>Developmental factor</td><td>9.2 × 10<sup>–4</sup></td><td>0.7</td><td>0.8–0.5</td></tr><tr><td> <i>CX3CL</i>1</td><td><i>Scyd1</i></td><td>NM_009142</td><td>small inducible cytokine subfamily D, 1</td><td>Chemokine</td><td>1.2 × 10<sup>–3</sup></td><td>0.4</td><td>0.7–0.2</td></tr><tr><td> <i>SMAD1</i></td><td><i>Madh1</i></td><td>NM_008539</td><td>MAD homolog 1 (<i>Drosophila</i>)</td><td>Signal transduction</td><td>1.3 × 10<sup>–3</sup></td><td>0.6</td><td>0.8–0.5</td></tr><tr><td> <i>A1</i></td><td><i>Bcl2a1a</i></td><td>L16462</td><td>hemopoietic-specific early response protein</td><td>Apoptosis related</td><td>1.5 × 10<sup>–3</sup></td><td>0.6</td><td>0.8–0.4</td></tr></table> |
7f32dd2734a9883634d2d37379596910304d391dad00be26259e25b6208246c7.png | simple | <table><tr><td>Variables</td><td>Single-Pollutant Model</td><td>Model Adjusting PM<sub>2.5</sub></td><td><i>Z</i> Value *</td><td><i>p</i> Value *</td></tr><tr><td>NO<sub>2</sub></td><td></td><td></td><td></td><td></td></tr><tr><td>Lag0</td><td>0.40 (0.02 to 0.78)</td><td>0.72 (0.12 to 1.31)</td><td>−0.870</td><td>0.385</td></tr><tr><td>Lag1</td><td>−0.13 (−0.46 to 0.20)</td><td>−0.23 (−0.60 to 0.14)</td><td>0.407</td><td>0.684</td></tr><tr><td>Lag2</td><td>−0.08 (−0.38 to 0.23)</td><td>−0.38 (−0.69 to −0.06)</td><td>0.232</td><td>0.816</td></tr><tr><td>3 days average</td><td>−0.37 (−0.84 to 0.10)</td><td>−0.65 (−1.23 to −0.07)</td><td>0.738</td><td>0.460</td></tr><tr><td>SO<sub>2</sub></td><td></td><td></td><td></td><td></td></tr><tr><td>Lag0</td><td>0.67 (0.35 to 1.00)</td><td>0.76 (0.39 to 1.12)</td><td>−0.336</td><td>0.737</td></tr><tr><td>Lag1</td><td>0.34 (0.04 to 0.64)</td><td>0.39 (0.05 to 0.74)</td><td>−0.224</td><td>0.823</td></tr><tr><td>Lag2</td><td>0.22 (−0.05 to 0.49)</td><td>0.03 (−0.26 to 0.33)</td><td>0.913</td><td>0.361</td></tr><tr><td>3 days average</td><td>0.36 (−0.10 to 0.82)</td><td>0.38 (−0.12 to 0.89)</td><td>−0.072</td><td>0.943</td></tr><tr><td>CO</td><td></td><td></td><td></td><td></td></tr><tr><td>Lag0</td><td>2.07 (1.20 to 2.95)</td><td>4.13 (2.79 to 5.49)</td><td>−2.520</td><td>0.012</td></tr><tr><td>Lag1</td><td>0.78 (0.04 to 1.52)</td><td>0.69 (−0.11 to 1.51)</td><td>0.146</td><td>0.884</td></tr><tr><td>Lag2</td><td>−0.25 (−0.94 to 0.45)</td><td>−0.62 (−1.33 to 0.10)</td><td>0.736</td><td>0.461</td></tr><tr><td>3 days average</td><td>0.56 (−0.50 to 1.64)</td><td>0.77 (−0.50 to 2.05)</td><td>−0.242</td><td>0.809</td></tr><tr><td>Ozone</td><td></td><td></td><td></td><td></td></tr><tr><td>Lag0</td><td>−2.06 (−2.39 to −1.73)</td><td>−2.23 (−2.57 to −1.90)</td><td>0.732</td><td>0.464</td></tr><tr><td>Lag1</td><td>−1.48 (−1.78 to −1.18)</td><td>−1.54 (−1.85 to −1.22)</td><td>0.265</td><td>0.791</td></tr><tr><td>Lag2</td><td>−1.44 (−1.73 to −1.15)</td><td>−1.32 (−1.63 to −1.02)</td><td>−0.547</td><td>0.584</td></tr><tr><td>3 days average</td><td>−1.90 (−2.35 to −1.45)</td><td>−2.12 (−2.58 to −1.65)</td><td>0.652</td><td>0.514</td></tr></table> |
2246def6ec7866d01cf316d24279f3811aff45c08551dd799a5445e2c1735cc7.png | simple | <table><tr><td>Features<sup>$</sup></td><td>Starter Group</td><td>Experimental Group</td><td>P Value</td></tr><tr><td>P1 max</td><td>0.080 ± 0.080</td><td>0.044 ± 0.044</td><td>0.011 *</td></tr><tr><td>P1 mean</td><td>0.050 ± 0.049</td><td>0.030 ± 0.030</td><td>0.017 *</td></tr><tr><td>P2 max</td><td>0.114 ± 0.118</td><td>0.068 ± 0.072</td><td>0.024 *</td></tr><tr><td>P2 mean</td><td>0.082 ± 0.082</td><td>0.051 ± 0.055</td><td>0.029 *</td></tr><tr><td>P3 max</td><td>0.136 ± 0.129</td><td>0.070 ± 0.055</td><td>0.003 **</td></tr><tr><td>P3 mean</td><td>0.088 ± 0.083</td><td>0.058 ± 0.061</td><td>0.029 *</td></tr><tr><td>Total max</td><td>0.138 ± 0.128</td><td>0.075 ± 0.061</td><td>0.003 **</td></tr><tr><td>Total mean</td><td>0.075 ± 0.068</td><td>0.048 ± 0.050</td><td>0.015 *</td></tr><tr><td>L_level %</td><td>53 ± 27</td><td>80 ± 30</td><td>0.025 *</td></tr><tr><td>M_level %</td><td>32 ± 21</td><td>15 ± 23</td><td>0.055 *</td></tr><tr><td>H_level %</td><td>15 ± 19</td><td>5 ± 10</td><td>0.077</td></tr></table> |
fd77e6861201c0d9c780940fec6f4ac9e2ff07a264e967da81f90c549476b2ec.png | simple | <table><tr><td>Organization</td><td>Country</td><td>Title</td><td>Year</td></tr><tr><td>National Institute of Health Care and Excellence</td><td>United Kingdom</td><td>Recognition, referral, diagnosis, and management of adults with autism</td><td>2012</td></tr><tr><td>Australian Psychological Association</td><td>Australia</td><td>Clinical Assessment Resource: An overview of best practice tools and approaches to conducting biopsychosocial and developmental assessment of child, young people, and adults with a disability who display behaviors of concern</td><td>2011</td></tr><tr><td>Canadian Association of Occupational Therapists (CAOT)</td><td>Canada</td><td>Position Statement on Autism Spectrum Disorders and Occupational Therapy</td><td>2015</td></tr><tr><td>American Occupational Therapy Association (AOTA)</td><td>United States</td><td>Scope of Occupational Therapy Services for Individuals with ASD across the Life Course</td><td>2015</td></tr><tr><td>College of Occupational Therapy</td><td>United Kingdom</td><td>Occupational Therapy and Learning Disabilities</td><td>2012</td></tr></table> |
e5009c0a5da12599a5feedbc349aea0b6fe3bb2f96ca7f71fd69743103da1537.png | complex | <table><tr><td>Coefficients of variation (CVs)</td><td colspan="2">Children groups</td><td colspan="3">ANOVA</td></tr><tr><td></td><td>Spastic CP (n =10)</td><td>TD (n =10)</td><td><i>F</i><sub><i>1,18</i></sub></td><td><i>p </i>value</td><td>Effect size <i>d</i></td></tr><tr><td>Utterance duration</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Mono-syllable task</td><td>17.87 ± 11.87</td><td>5.23 ± 2.33</td><td>10.923</td><td>0.004*</td><td>0.615</td></tr><tr><td> Poly-syllable task</td><td>24.30 ± 17.90</td><td>7.57 ± 4.11</td><td>8.299</td><td>0.010</td><td>0.562</td></tr><tr><td>Peak vertical oral opening displacement</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Mono-syllable task</td><td>24.34 ± 13.53</td><td>34.14 ± 26.16</td><td>1.108</td><td>0.307</td><td>0.241</td></tr><tr><td> Poly-syllable task</td><td>18.30 ± 15.82</td><td>29.42 ± 20.20</td><td>1.880</td><td>0.187</td><td>0.308</td></tr><tr><td>Peak vertical oral opening velocity</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Mono-syllable task</td><td>17.21 ± 14.97</td><td>24.69 ± 13.50</td><td>1.376</td><td>0.256</td><td>0.266</td></tr><tr><td> Poly-syllable task</td><td>15.63 ± 17.09</td><td>15.16 ± 18.78</td><td>0.003</td><td>0.954</td><td>0.014</td></tr></table> |
bff30c1665095de1bdef7485a9a892f54793aa272d8fc307c66f7bd7a76b228c.png | simple | <table><tr><td></td><td>Blastn (WGS <i>An. gambiae</i>)</td><td>Blastx (Nr)</td><td>Blastn (Nr)</td><td>Blastn (dbEST)</td><td>Unannotated</td><td>Total</td></tr><tr><td>3 Positive Controls</td><td>No Significant Hit</td><td>3</td><td></td><td></td><td></td><td>3</td></tr><tr><td>403 Unique Transcripts</td><td>403</td><td>240</td><td>8</td><td>112</td><td>43</td><td>403</td></tr><tr><td>Early Genes</td><td>144</td><td>77</td><td>2</td><td>45</td><td>20</td><td>144</td></tr><tr><td>Middle Genes</td><td>130</td><td>78</td><td>6</td><td>36</td><td>10</td><td>130</td></tr><tr><td>Late Genes</td><td>139</td><td>93</td><td>2</td><td>31</td><td>13</td><td>139</td></tr><tr><td>Total</td><td>413</td><td>248</td><td>10</td><td>112</td><td>43</td><td>413</td></tr></table> |
945ee74b6ea15b51df9bcfd1958807dd088bc654551fbebb156cf02086f2215b.png | simple | <table><tr><td>Study</td><td>Bacterial strain</td><td>Preparation</td><td>Patient population</td><td>Intervention</td><td>Results</td></tr><tr><td> </td><td> </td><td> </td><td>Cell or animal type</td><td> </td><td> </td></tr><tr><td><i>In vitro</i> experiments</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Strunk et al.,<sup>78</sup> 2012</td><td>SE 1457</td><td>Heat-killed</td><td>GA<30wk, 31-33 wk, 37-41 wk</td><td>6 h</td><td>IL-1β, IL-6, IL-8, TNF-α↑with GA</td></tr><tr><td> </td><td> </td><td>10<sup>8</sup>cfu/ml</td><td>Cord & adult peripheral MNCs</td><td> </td><td>Adult level TLR2 expression & phagocytosis</td></tr><tr><td> Mohamed et al.,<sup>79</sup> 2007</td><td>SE PT 9657</td><td>Heat-killed</td><td>Healthy term infants</td><td>4 h</td><td>IL-1β, IL-6, IL-8, TNF-α↑with time</td></tr><tr><td> </td><td> </td><td>10<sup>3</sup>cfu/ml</td><td>Cord & adult peripheral WBC</td><td> </td><td>Pro-inflammatory effect: SE <<i>E.coli</i> & GBS</td></tr><tr><td> Tatad et al.,<sup>80</sup> 2008</td><td>Clinical isolate</td><td>Heat-killed</td><td>Healthy term & preterm infants</td><td> 18 h</td><td>IL-6, IL-8, IL-10, IL-12↑ similar to adult</td></tr><tr><td> </td><td> </td><td>10<sup>4</sup>cfu/ml</td><td>Cord & adult peripheral WBC</td><td> </td><td>Inflammatory response: preterm > term</td></tr><tr><td> Härtel et al.,<sup>81</sup> 2007</td><td>ATCC 12228</td><td>Live bacteria</td><td>Term & preterm infants</td><td>24 h</td><td>IL-6, TNF-α↑with GA</td></tr><tr><td> </td><td>Strain 94B080</td><td>1cfu:1 WBC &</td><td>Neonatal peripheral WBC</td><td> </td><td>Pro-inflammatory effect: BF<sup>+</sup> strain<BF<sup>-</sup> strain</td></tr><tr><td> </td><td>Strain 94B575</td><td>10 cfu:1 WBC</td><td> </td><td> </td><td>IL-10, TGF-β expression independent of GA</td></tr><tr><td> Peoples et al.,<sup>82</sup> 2009</td><td>Clinical isolate</td><td>Heat-killed</td><td>Healthy term & preterm infants</td><td>18 h</td><td>IL-6, IL-10↑> adult</td></tr><tr><td> </td><td> </td><td>10<sup>4</sup> cfu/ml</td><td>Cord & adult peripheral WBC</td><td> </td><td>IL-8, IL-12, INF-NK, INF-T↑ similar to adult</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>Inflammatory response: preterm=term</td></tr><tr><td> Haase et al.,<sup>83</sup> 2011</td><td>ATCC 12228</td><td>Live bacteria</td><td>Healthy term & preterm infants</td><td>1 h</td><td>TNF-α, IL-6, IL-8↑</td></tr><tr><td> </td><td>Strain 94B080</td><td>1cfu:1 WBC</td><td>Cord WBC</td><td> </td><td>Pro-inflammatory effect: BF<sup>+</sup> strain>BF<sup>-</sup> strain</td></tr><tr><td> </td><td>Strain 94B575</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Björkqvist et al.,<sup>77</sup> 2004</td><td>Clinical isolate</td><td>Live bacteria</td><td>Healthy term & preterm infants</td><td>30 min</td><td>Oxidative burst intensity: preterm < term</td></tr><tr><td> </td><td> </td><td>10 cfu:1 PMNL</td><td>Neonatal peripheral PMNLs</td><td> </td><td>SE similar to GBS</td></tr><tr><td> Ivarsson et al.,<sup>104</sup> 2013</td><td>Clinical isolate</td><td>Live bacteria</td><td>Vascular endothelial cells</td><td>18 h</td><td>IL-8, ICAM-1 ↑</td></tr><tr><td> </td><td> </td><td>10<sup>4</sup>cfu/ml</td><td>Small airway epithelial cells</td><td> </td><td>Pro-inflammatory effect: SE > SA</td></tr><tr><td> Hussain et al.,<sup>105</sup> 2013</td><td>Strain 94B080</td><td>Live bacteria</td><td>Bronchial epithelial cells</td><td>36 h</td><td>TNF-α, IL-6, IL-8 and iNOS↑ with time</td></tr><tr><td> </td><td> </td><td>10<sup>4</sup>cfu/ml</td><td> </td><td> </td><td>Expression of ENaC and CFTR↑</td></tr><tr><td><i>In vivo</i> experiments</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Kronforst et al.,<sup>87</sup> 2012</td><td>SE 1457</td><td>Live bacteria</td><td>C57BL/6 WT mice</td><td>48 h</td><td>At 2 h:</td></tr><tr><td> </td><td> </td><td>up to 2×10<sup>9</sup> cfu/ml</td><td>< 24 h old</td><td> </td><td>IL-1β, IL-6, TNF-α, TLR2↑ with inoculum</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>At 24 h & 48 h:</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>Inoculum-dependent neonatal weight loss</td></tr><tr><td> Bi et al.,<sup>86</sup> 2015</td><td>SE 1457</td><td>Live bacteria</td><td>C57BL/6J WT mice</td><td>72 h</td><td>At 6 h:</td></tr><tr><td> </td><td> </td><td>1×10<sup>8</sup>cfu/ml</td><td>< 24 h old</td><td> </td><td>IL-6, CCL2, CXCL1, IL-12↑ in blood & brain</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>Caspase-3 & TLR2 mRNA ↑ in the brain</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>At 24 h:</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>PMNLs↑ in blood & cerebral spinal fluid</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>White and grey matter impairment</td></tr></table> |
f7493e4a79f93769ff7ce7b2a11591396534704fa6fb47b4fad14968c912ea42.png | complex | <table><tr><td>Characteristic</td><td>S‐HFpEF (n=83)</td><td>AD‐HFpEF (n=78)</td><td>Overall (n=161)</td><td><i>P</i> Value</td></tr><tr><td colspan="5">Demographics</td></tr><tr><td>Age, years: n, median (25th–75th)</td><td>83, 72 (65–79)</td><td>78, 73 (65–79)</td><td>161, 72 (65–79)</td><td>0.970</td></tr><tr><td>Male sex</td><td>43/83 (51.8%)</td><td>39/78 (50.0%)</td><td>82/161 (50.9%)</td><td>0.819</td></tr><tr><td>Race (% white)</td><td>74/83 (89.2%)</td><td>62/78 (79.5%)</td><td>136/161 (84.5%)</td><td>0.091</td></tr><tr><td>Weight, kg (median, 25th–75th)</td><td>93.2 (80.5–103.6)</td><td>95.0 (79.1–112.3)</td><td>93.2 (80.5–108.2)</td><td>0.535</td></tr><tr><td>Body mass index, (median, 25th–75th)</td><td>32.3 (27.4–37.1)</td><td>33.6 (28.5–37.9)</td><td>32.9 (27.9–37.5)</td><td>0.163</td></tr><tr><td>Ejection fraction: n, median (25th–75th)</td><td>83, 62.0 (58.0–66.0)</td><td>78, 55.0 (55.0–61.0)</td><td>161, 60.0 (55.0–65.0)</td><td><0.001</td></tr><tr><td>Systolic blood pressure, mm Hg: n, median (25th–75th)</td><td>83, 122 (113–137)</td><td>78, 119 (107–131)</td><td>161, 122 (112–135)</td><td>0.029</td></tr><tr><td>Heart rate, beats/min: n, median (25th–75th)</td><td>83, 69 (62–80)</td><td>78, 72 (65–84)</td><td>161, 72 (62–80)</td><td>0.073</td></tr><tr><td>JVP≥8 cm</td><td>36/80 (45.0%)</td><td>68/72 (94.4%)</td><td>104/152 (68.4%)</td><td><0.001</td></tr><tr><td>Edema≥2</td><td>12/83 (14.5%)</td><td>53/76 (69.7%)</td><td>65/159 (40.9%)</td><td><0.001</td></tr><tr><td colspan="5">Comorbidities</td></tr><tr><td>Hospitalization for heart failure in past year</td><td>29/83 (34.9%)</td><td>47/76 (61.8%)</td><td>76/159 (47.8%)</td><td><0.001</td></tr><tr><td>Hypertension</td><td>65/83 (78.3%)</td><td>69/78 (88.5%)</td><td>134/161 (83.2%)</td><td>0.085</td></tr><tr><td>Ischemia as cause of HF</td><td>33/83 (39.8%)</td><td>37/78 (47.4%)</td><td>70/161 (43.5%)</td><td>0.326</td></tr><tr><td>Atrial fibrillation/flutter</td><td>42/83 (50.6%)</td><td>55/78 (70.5%)</td><td>97/161 (60.2%)</td><td>0.010</td></tr><tr><td>Diabetes mellitus</td><td>29/83 (34.9%)</td><td>48/78 (61.5%)</td><td>77/161 (47.8%)</td><td><0.001</td></tr><tr><td>Orthopnea</td><td>45/78 (57.7%)</td><td>63/74 (85.1%)</td><td>108/152 (71.1%)</td><td><0.001</td></tr><tr><td>COPD</td><td>16/83 (19.3%)</td><td>27/78 (34.6%)</td><td>43/161 (26.7%)</td><td>0.028</td></tr><tr><td>NYHA class</td><td></td><td></td><td></td><td><0.001</td></tr><tr><td>II</td><td>40/83 (48.2%)</td><td>4/69 (5.8%)</td><td>44/152 (28.9%)</td><td></td></tr><tr><td>III</td><td>43/83 (51.8%)</td><td>50/69 (72.5%)</td><td>93/152 (61.2%)</td><td></td></tr><tr><td>IV</td><td>0/83 (0.0%)</td><td>15/69 (21.7%)</td><td>15/152 (9.9%)</td><td></td></tr><tr><td>Baseline anemia</td><td>25/83 (30.1%)</td><td>56/78 (71.8%)</td><td>81/161 (50.3%)</td><td><0.001</td></tr><tr><td colspan="5">Medications at enrollment</td></tr><tr><td>ACE inhibitor or ARB</td><td>53/83 (63.9%)</td><td>30/78 (38.5%)</td><td>83/161 (51.6%)</td><td>0.001</td></tr><tr><td>Beta blockers</td><td>61/83 (73.5%)</td><td>64/78 (82.1%)</td><td>125/161 (77.6%)</td><td>0.193</td></tr><tr><td>Aldosterone antagonist</td><td>5/83 (6.0%)</td><td>20/78 (25.6%)</td><td>25/161 (15.5%)</td><td><0.001</td></tr><tr><td>Any diuretic</td><td>70/83 (84.3%)</td><td>76/78 (97.4%)</td><td>146/161 (90.7%)</td><td>0.004</td></tr><tr><td>Loop diuretic</td><td>64/83 (77.1%)</td><td>76/78 (97.4%)</td><td>140/161 (87.0%)</td><td><0.001</td></tr><tr><td>Calcium channel blocker</td><td>26/83 (31.3%)</td><td>25/78 (32.1%)</td><td>51/161 (31.7%)</td><td>0.921</td></tr><tr><td>Statin</td><td>54/83 (65.1%)</td><td>49/78 (62.8%)</td><td>103/161 (64.0%)</td><td>0.767</td></tr><tr><td colspan="5">Laboratory values</td></tr><tr><td>Sodium, mg/L: n, median (25th–75th)</td><td>75, 140 (138–142)</td><td>78, 139 (137–142)</td><td>153, 140 (137–142)</td><td>0.127</td></tr><tr><td>Blood urea nitrogen, mg/dL: n, median (25th–75th)</td><td>68, 25.1 (18.7–35.0)</td><td>78, 33.5 (26.0–49.0)</td><td>146, 30.0 (22.0–44.0)</td><td><0.001</td></tr><tr><td>Creatinine, mg/dL: n, median (25th–75th)</td><td>83, 1.2 (0.9–1.5)</td><td>78, 1.6 (1.3–1.9)</td><td>161, 1.4 (1.1–1.8)</td><td><0.001</td></tr><tr><td>NT‐pro BNP, pg/mL: n, Median (25th–75th)</td><td>83, 648.1 (352.9–1334)</td><td>78, 3146 (1583–5747)</td><td>161, 1482 (596.0–3172)</td><td><0.001</td></tr><tr><td>eGFR, mL/min; n, median (25th–75th)</td><td>83, 53.5 (39.0–71.4)</td><td>78, 40.0 (30.0–48.9)</td><td>161, 45.6 (34.5–57.7)</td><td><0.001</td></tr><tr><td>Baseline core lab cystatin C value (mg/L): n, median (25th–75th)</td><td>83, 1.4 (1.0–1.8)</td><td>78, 1.7 (1.4–2.1)</td><td>161, 1.6 (1.2–2.0)</td><td><0.001</td></tr></table> |
d7fd17285b9b614e1273d81bd476bac81094693a940bf49a6303f6032542f944.png | simple | <table><tr><td></td><td>2005</td><td>2006</td><td>2007</td><td>2008</td><td>2009</td><td>2010</td><td>TOTAL</td></tr><tr><td>Horses</td><td>783</td><td>822</td><td>1,506</td><td>2,002</td><td>3,220</td><td>7,296</td><td>15,629</td></tr></table> |
9d394a4d5043d39968ae3478c3affe2424a3dedbb710f0d6ff07feb7132dbeb0.png | complex | <table><tr><td>LNR group</td><td>Ratio/Node quota</td><td>N</td><td>Differentiation grade (well/med./poor)</td><td>N-status (N1/N2)</td><td colspan="2">Lymph nodes (median)</td><td>Chemotherapy eligibility (yes/no)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Assessed</td><td>Positive</td><td></td></tr><tr><td>1</td><td>0–0.15</td><td>46</td><td>4/36/6</td><td>46/0</td><td>10 (1–19)</td><td>1 (0–3)</td><td>27/19</td></tr><tr><td>2</td><td>0.16–0.65</td><td>45</td><td>3/30/12</td><td>15/30</td><td>10 (4–21)</td><td>4 (1–11)</td><td>23/22</td></tr><tr><td>3</td><td>0.66–1</td><td>45</td><td>0/14/31</td><td>6/39</td><td>9 (2–32)</td><td>8 (2–26)</td><td>27/18</td></tr><tr><td>Total</td><td>0–1</td><td>136</td><td>7/80/49</td><td>67/69</td><td>10 (1–32)</td><td>4 (0–26)</td><td>77/59</td></tr></table> |
c5ea052a29d88258211cd8c57694e5d7cc643c2220b3a4d067224df55cb80e37.png | complex | <table><tr><td>Drug’s name</td><td>Dose</td><td>Comments</td></tr><tr><td>Vasodilator drugs (hypotensives)</td><td></td><td></td></tr><tr><td>Propofol</td><td>2 - 2.5 mg/kg load, 25 - 75 μg/kg/min maintain</td><td>Local irritation, propofol infusion syndrome</td></tr><tr><td>Remifentanil</td><td>1 μg/kg load, 0.05 μg/kg/min maintain</td><td>Respiratory depression, hyperalgesia, vomiting</td></tr><tr><td>Dexmetedomidine</td><td>1 mg/kg load, 0.7 mg/kg/h maintain</td><td>Sedative effects</td></tr><tr><td>Nitroprusside</td><td>1 - 2 μg/kg/min</td><td>Severe hypotension, cyanide toxicity</td></tr><tr><td>Nitroglycerine</td><td>25 - 250 μg/min</td><td>Reflex tachycardia, methemoglobinemia</td></tr><tr><td>Nicardipine</td><td>5 mg/h</td><td>Braycardia, severe hypotension, cardiac blocks</td></tr><tr><td>Esmolol</td><td>5 - 10 mg/3 - 5 min bolus</td><td rowspan="2">AV block, bronchial hyperactivity</td></tr><tr><td>Labetalol</td><td>5 - 10 mg bolus</td></tr><tr><td>Urapidil</td><td>10 - 15 mg/h</td><td>Severe hypotension</td></tr><tr><td>Clonidine</td><td>0.1 - 1.2 mg</td><td>Rebound hypertension, dry mouth</td></tr><tr><td>Magnesium sulfate</td><td>1 - 8 mg load, 1 - 4 mg/h maintain</td><td>Potentiates muscle relaxants</td></tr><tr><td>Vasoconstrictor drugs (hypertensives)</td><td></td><td></td></tr><tr><td>Epinephrine</td><td>1 - 20 μg/min</td><td>Tachycardia</td></tr><tr><td>Norepinephrine</td><td>1 - 30 μg/min</td><td>Reflective bradycardia</td></tr><tr><td>Dopamine</td><td>5 - 10 μg/min</td><td>Tachycardia, arrhythmias</td></tr><tr><td>Phenilephrine</td><td>10 - 100 μg/min</td><td>Reflective bradycardia</td></tr><tr><td>Vasopressin</td><td>0.1 - 0.4 units/min</td><td>Myocardial infarction</td></tr><tr><td>Ephedrine</td><td>5 - 10 mg</td><td>None</td></tr></table> |
3ac73b3b3175342232519dd0da70c25131e6fe5cd62be66156b13d79e0fb86b1.png | simple | <table><tr><td>Mean (SD)</td><td>Non-atopic asthma n = 37</td><td>Atopic asthma n = 137</td><td><i>p value</i></td></tr><tr><td>HAD-Anxiety</td><td>8.43 (4.35)</td><td>7.98 (4.45)</td><td><i>0.607</i></td></tr><tr><td>HAD-Depression</td><td>7.57 (4.52)</td><td>6.85 (4.43)</td><td><i>0.277</i></td></tr><tr><td>HAD- Total</td><td>16.00 (7.51)</td><td>14.82 (8.10)</td><td><i>0.302</i></td></tr><tr><td>ACT</td><td>17.97 (4.89)</td><td>18.42 (5.18)</td><td><i>0.486</i></td></tr><tr><td>AQLQ-Total</td><td>4.45 (1.24)</td><td>4.29 (1.24)</td><td><i>0.683</i></td></tr><tr><td>AQLQ-Symptom</td><td>4.90 (1.34)</td><td>4.72 (1.39)</td><td><i>0.550</i></td></tr><tr><td>AQLQ-Activity</td><td>4.10 (1.35)</td><td>4.02 (1.25)</td><td><i>0.855</i></td></tr><tr><td>AQLQ-Emotional</td><td>4.63 (1.49)</td><td>4.47 (1.59)</td><td><i>0.771</i></td></tr></table> |
609d713dc3f57dd89d2fd4f943bd3dfacc4d9d14b7f050ead288de7347e0f93a.png | simple | <table><tr><td>Intervention</td><td>At Risk Target Population</td><td>Numbers at Risk Reached</td><td>% of Identified at Risk Reached by the RED Strategy</td><td>General Target Population in RED Catchment Areas</td><td>% of Additional Population Reached through the RED Strategy</td></tr><tr><td>Additional immunized children</td><td>489</td><td>477</td><td>97.55</td><td>3126 (children 1-15)</td><td>15% of the target children for immunization</td></tr><tr><td>Additional registered populations at Family Group Practices clinics</td><td>2598</td><td>2485</td><td>95.65</td><td>8708(Total Population in RED Area)</td><td>28.5% of total registered population at the family clinics</td></tr><tr><td>Additional ANC care contacts</td><td>515</td><td>508</td><td>98.64</td><td>5616(Total ANC Contacts in RED Area)</td><td>9% of all ANC Contacts</td></tr><tr><td>Additional family planning contacts</td><td>1047</td><td>1047</td><td>100.00</td><td>96560(Total Family Planning Contacts in RED Area)</td><td>1.08% of all family planning contacts</td></tr><tr><td>Additional emergency food provision</td><td>Not yet fully assessed</td><td>515</td><td>Not yet fully assessed</td><td>8708(Total Population in RED Area)</td><td>5.9% of Target population</td></tr></table> |
dd09189e36cd7c766a96b7d4c21c7c891dcd7335c7e11a935838b8a192c26a0e.png | complex | <table><tr><td></td><td>Total</td><td>Previously incarcerated N(%)</td><td>First incarceration N(%)</td><td>Crude odds ratio (95% CI)</td><td>Adjusted odds ratio (95% CI), <i>P</i></td></tr><tr><td><i>Age</i> in years Mean [SD]</td><td>707</td><td>32 [10.5]</td><td>28.1 [10.3]</td><td>1 (0.99–1.02)</td><td>1.04(1.02–1.06), <i>P</i> < 0.001</td></tr><tr><td colspan="6"><i>Sex</i></td></tr><tr><td> Male Female</td><td>64760</td><td>333(96.8)11(3.2)</td><td>314 86.5)49(13.5)</td><td>4.7(2.4–9.2)</td><td>4.3 (2–9.1), <i>P</i> < 0.001</td></tr><tr><td colspan="6"><i>Antisocial disorder</i></td></tr><tr><td> Yes No</td><td>245462</td><td>162(47.1)182 (52.8)</td><td>83 (22.9)280(77.1)</td><td>3 (2.2–4.1)</td><td>2.6 (1.8–3.7), <i>P</i> < 0.001</td></tr><tr><td><i>Generalized anxiety disorder</i></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Yes No</td><td>182525</td><td>92(26.7)252(73.3)</td><td>90(24.8)273(75.2)</td><td>1.1 (0.8–1.5)</td><td>0.8 (0.5–1.3), <i>P</i> = 0.4</td></tr><tr><td colspan="6"><i>Psychosis</i></td></tr><tr><td> Yes No</td><td>51656</td><td>37(10.7)307(89.3)</td><td>14(3.9)349(96.1)</td><td>3 (1.6–5.7)</td><td>1.4 (0.7–2.9), <i>P</i> = 0.01</td></tr><tr><td colspan="6"><i>Substance addiction</i></td></tr><tr><td> Yes No</td><td>235472</td><td>153(44.5)191 (55.52)</td><td>82(22.6)281(77.4)</td><td>2.7(2–3.8)</td><td>1.9 (1.3–2.7), <i>P</i> = 0.001</td></tr><tr><td colspan="6"><i>Alcohol addiction</i></td></tr><tr><td> Yes No</td><td>124583</td><td>88(25.6)256(74.4)</td><td>36(9.9)327(90.1)</td><td>3.1 (2–4.7)</td><td>1.7 (1.1–2.8), <i>P</i> = 0.02</td></tr><tr><td colspan="6"><i>PTSD</i></td></tr><tr><td> Yes No</td><td>107600</td><td>64(18.6)280(81.4)</td><td>43(11.9)320(88.1)</td><td>1.7(1.1–2.6)</td><td>1.3 (0.8–2.2), <i>P</i> = 0.3</td></tr><tr><td colspan="6"><i>Social phobia</i></td></tr><tr><td> Yes No</td><td>63644</td><td>34(9.9)310(90.1)</td><td>29(8)334(92)</td><td>1.2 (0.74–2.1)</td><td>1.2 (0.6–2.3), <i>P</i> = 0.6</td></tr><tr><td colspan="6"><i>Agoraphobia</i></td></tr><tr><td> Yes No</td><td>76631</td><td>46(13.4)298(86.4)</td><td>30(8.2)333(91.8)</td><td>1.7 (1.05–2.8)</td><td>1.1 (0.6–2.1), <i>P</i> = 0.6</td></tr><tr><td colspan="6"><i>Panic attacks</i></td></tr><tr><td> Yes No</td><td>48659</td><td>27(7.9)317(92.1)</td><td>21(5.8)342(94.2)</td><td>1.4 (0.7–2.5)</td><td>0.8 (0.4–1.6), <i>P</i> = 0.5</td></tr><tr><td colspan="6"><i>Manic</i></td></tr><tr><td> Yes No</td><td>26681</td><td>18(5.2)326(94.8)</td><td>8(2.2)355(97.8)</td><td>2.56 (1.05–5.7)</td><td>1.3 (0.5–3.6), <i>P</i> = 0.5</td></tr><tr><td colspan="6"><i>Mood disorders</i></td></tr><tr><td> Yes No</td><td>38669</td><td>19(5.5)325(94.5)</td><td>19(5.2)344(94.8)</td><td>1.1 (0.5–2)</td><td>0.5 (0.2–1.2), <i>P</i> = 0.13</td></tr><tr><td colspan="6"><i>Suicidality</i></td></tr><tr><td> Yes No</td><td>93614</td><td>54(15.7)290(84.3)</td><td>39(10.7)324(89.3)</td><td>1.5 (0.99–2.4)</td><td>1.2 (0.7–2), <i>P</i> = 0.6</td></tr><tr><td colspan="6"><i>Depression</i></td></tr><tr><td> Yes No</td><td>101606</td><td>63 (18.3)281(81.7)</td><td>38 (10.53)325(89.5)</td><td>1.9 (1.2–3)</td><td>1.7 (0.96–3), <i>P</i> = 0.06</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.